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 Colorectal cancer (CRC) is the third most prevalent cancer in men and women with 
almost 150,000 new cases diagnosed per year, and almost 50,000 deaths. Inflammation is 
recognized as a strong risk factor for CRC. The relationship between inflammation potentiating 
cancer remains unsettled although a common explanation for the role of inflammation involves 
the formation of reactive oxygen and nitrogen species (RONS). RONS can directly, through 
oxidation of DNA bases, or indirectly, through the formation of lipid peroxidation products, 
generate DNA lesions that in turn can lead to increased mutations that activate oncogenes and/or 
block the function of tumor suppressor genes. To address this fundamental question, C57Bl/6 
(B6) WT and TCRβ null mice were treated with a DNA damaging agent (azoxymethane, AOM) 
and/or an inflammatory agent (dextran sulfate sodium, DSS) to mimic an inflammation model of 
CRC. The carcinogenic and mutagenic effect of the treatments was examined by pathological 
evaluation of the mouse colons and by measuring the somatic stem cell mutation frequency (MF) 
in the colon. The results of the carcinogenicity studies show that WT mice are more prone to 
development of CRC than the TCRβ-/- mice when a low concentration of DSS is used. The 
mutagenesis results find that DSS, which causes a strong inflammatory response, does NOT 
result in stem cell mutations in the colon of WT or TCRβ-/- mice. Therefore, inflammation does 
not potentiate cancer development by increasing the mutation rate. In contrast, AOM causes a 
significant increase in the colon stem cell MF in both strains but the MF is 50% lower in the 
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TCRβ-/- vs. WT mice. Accordingly, we propose that the oncogenic mutations observed in CRC 
produced by the combination of a genotoxin with an inflammatory agent arise due to the 
transient creation of a mutator phenotype where stem cells with DNA damage are “forced” to 
bypass cell cycle arrest and apoptosis because of T-cell supported wound repair and tissue 
regeneration. We also propose that the effect of DSS treatments after AOM mutagenesis 
potentiates cancer development by dysregulation of intracellular levels of β-catenin, thereby 
enhancing the oncogenic effects of AOM mutated β-catenin.    
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1.0  INTRODUCTION 
1.1 SCOPE AND SYNOPSIS 
The purpose of this chapter is to introduce and familiarize the reader with the general knowledge 
and background material related to our studies. The material covered in this chapter provides 
significant and extensive details of the colon morphology and the animal model of colon cancer 
induction used for this work. More specific introductions to each experiment and the results are 
provided at the beginning of each experimental study chapters 2 and 3.Chapter 1 begins with 
relevant statistics for colon cancer incidence and mortality, and then reviews colon function and 
the layers that comprise the colon, with an explanation that the epithelium is the origin of colon 
adenomas and adenocarcinomas. The chapter then details the types and functions of the cells that 
comprise the colon and small intestine. Also, the argument is presented that colonic stem cells 
can fix a mutation and propagate a population of cells that could become the first cancer cells. 
Chapter 1 then introduces the two-stage colon cancer induction model of a mutagen, 
azoxymethane (AOM), and an inflammatory agent, dextran sulfate sodium (DSS), and how there 
action reflects colon cancer development in humans.  Chapter 1 details the morphological 
disruption of the colon architecture and the immune response generated by DSS treatment, with 
an emphasis on the effects of reactive oxygen and nitrogen species (RONS). Chapter 1 concludes 
with a review of the strain differences of mice to the induction of colon cancer.  
 1 
1.2 COLON CANCER FACTS AND STATISITICS 
The American Cancer Society estimates that 136,830 cases of colorectal cancer (CRC) will occur 
in the United States during 2014.(1) 96,380 cases will be colon cancers and 40,000 rectal 
cancers.(1) Colon cancer is the third most common cancer diagnosed in both men and women.(1) 
The previous statement, which excludes skin cancers, ranks colon cancer incidence behind lung 
cancer and cancers of sex-related organs, i.e., prostate, breast.(1)(2) The World Cancer Research 
Fund International (WCRF International) reported that 1.4 million cases of CRC were diagnosed 
worldwide in 2012,(3) and it is predicted that there will be 2.4 million cases diagnosed per year 
by 2035.(3)  
The American Cancer Society also estimates that 50,310 deaths will occur as a result of 
colon cancer morbidity in the USA during 2014.(1) CRC has the third highest incidence of 
mortality among both men and women. CRC results in the second highest yearly mortality 
among cancer related deaths for both men and women combined.(1)  
The American Cancer Society (ACS) predicts that the lifetime risk of a person 
developing colorectal cancer is one in twenty.(1) Risk factors for developing CRCs can greatly 
enhance the probability of an individual developing CRC. ACS categorizes risk factors as; “Risk 
factors you cannot change”, “Lifestyle related factors”, and “Factors with uncertain, 
controversial, or unproven effects on CRC”.(1) “Personal history of inflammatory bowel disease” 
is cited as a risk factor that is not controlled by the individual.(1) Individuals with inflammatory 
bowel disease (IBD) have a six times greater risk of developing CRC.(386) The onset of an 
inflammatory bowel disease (IBD) may lead to earlier detection and treatment of CRC, as 
patients diagnosed with an IBD will begin screening for CRC at an earlier time than patients 
without an IBD.(1) Obesity also increases the risk of an individual developing colon cancer and is 
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a lifestyle related factor.(1)(388) Obesity is likely related to diet which is another lifestyle related 
factor.(1)(388) 
1.3 FUNCTION AND ARCHITECTURE OF THE LOWER INTESTINE 
The large or lower intestine is comprised of several regions; the cecum, colon, rectum, and anal 
canal (Figure 1). The cecum is located at the lower right side of the abdominal cavity and forms 
a dilated pouch-like structure that links the ileum of the small intestine to the large intestine 
through the ileocecal sphincter.(4) The ascending colon starts at the cecum and extends upwards 
toward the thoracic cavity along the right side of the abdominal cavity.(4) The colon then turns to 
the left and runs the length of the abdominal cavity just below the liver and stomach,(4) and this 
region is called the transverse colon. The colon then moves down the left side of the abdominal 
cavity and this region is termed the descending colon.(4) The descending colon then takes on a 
slight S-shape and is called the sigmoidal colon.(4) The final portion of the colon is the rectum 
that lies above the sacrum and ends at the anal canal.(4) The entire organ is approximately 1.5 
meters long.(4) It is anchored in the abdominal cavity by the peritoneum and rests on the skeletal 
muscle.(4) 
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Figure 1.  The Human Lower Intestine 
(adopted from reference 4) 
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1.3.1 Tissue Layers of the Colon and Colorectal Cancer  
The wall of the colon is comprised of several different layers (Figure 2). The innermost layer 
bordering the lumen is called the mucosal layer. The mucosal epithelial layer is the source of 
colonic adenomas and adenocarcinomas(5)(Figure 2). This layer is comprised of three regions; a 
single sheet of columnar epithelial cells, the lamina propria, and muscularis mucosae.(4)(5) The 
epithelium forms long finger-like invaginations which are termed crypts. Colonic crypts extend 
into the lumen and are defined as columnar due to the fact that they are straight and 
unbranched(13)(Figure 4).  
The crypt architecture is a critical component of the colon’s ability to mediate its 
functions. The shape of the crypts creates a greater surface area than would otherwise be possible 
if the epithelium was a smooth flat cell layer.(4)(13) This creates a more extensive contact with the 
feces as the waste is slowly moved by the reflexive action of the smooth muscle, essentially 
creating a churning effect.(4) The crypt shape also ensures that dead epithelial cells are removed 
and normal turnover of the epithelial cells can be maintained(10)(section 1.2.2), as removing dead 
cells requires frictional interactions with the semi-solid waste to shed the dead cell layer. The 
different cell types that comprise the epithelial layer are thoroughly discussed in section 1.2.2.  
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Figure 2. Colonic Epithelial Layers and Cancer Progression 
(adopted from reference 5) 
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 Underlying the colonic epithelial layer is the lamina propria. This is a layer of connective tissue 
that is highly vascularized and heavily populated with immune cells.(4)(13) The vascularization is 
necessary for the survival of the epithelial cells, and the immune cells help maintain surveillance 
and natural tolerance. The lamina propria is a very distinct region under histological 
examination.(13) The muscularis mucosae is an innervated smooth muscle that functions in the 
local movement of the mucosal and aids in the recovery of nutrients.(4)(13) The enteric nervous 
system is comprised of at least three different types of neurons.(379)(380) Efferent neurons (motor 
neurons) carry signals from the central nervous system (CNS) to muscles and glands 
(effectors).(379)(380)(381)(382) Afferent neurons (sensory neurons) relay signals from the mucosa and 
muscle to nerve centers.(379)(380)(381)(382) Interneurons connect and integrate information from 
sensory neurons to motor neurons.(379)(380)(381)(382) The muscularis mucosae also acts as a 
scaffolding for the mucosal layer.(4)(13)  
An adenocarcinoma is a cancer that originates from a glandular cell (Figure 2). In the 
colon these are the mucus secreting epithelial cells. The progression of a colonic adenocarcinoma 
is defined by stages.(5) Each stage describes the degree of invasion of the adenocarcinoma into 
the layers of colon. For example; Stage I describes a cancer invading through the submucosa and 
reaching the muscular externa. In Stage IV colon cancer, cancer cells have metastasized via the 
lymphatic system to other organs.(5) 
The submucosa is a layer of connective tissue between the mucosa and muscularis 
externa(4)(13)(Figure 2). The submucosa is comprised of coarse collagen fibers, large blood and 
lymphatic vessels, lymph nodes, and autonomic nerve plexi and ganglia.(4)(13) The submucosa 
also contains various tissue resident immune cells.(4)(13) The muscularis externa in the colon is a 
 7 
smooth muscle.(4)(13) Smooth muscle is controlled by the autonomic visceral nervous system4)(13) 
The primary function of the colonic muscularis externa is to move solid waste through the 
abdominal cavity.(4)(13) The final layer is the serosa, which is comprised of a thin connective 
layer called the adventitia and the mesothelium layer which secrets serous fluid. Serous fluid is 
enriched with proteins and moistens internal organs in the body cavity.(4)(13) 
Adenocarcinomas are able to invade the mucosal and submucosal layers of the colon. 
However, in the muscularis externa, adenocarcinomas can continue to advance through the 
muscle and serosa (Stage II) before spreading to other organs (Stage IV).(5) Adenocarcinomas do 
not always penetrate through the muscularis externa (Stage III), but can spread by recruiting the 
vasculature and metastasize to adjacent lymph nodes (Stage IV).(5) 
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1.3.2 Cell Types, Functions, and Structure of the Colonic Epithelium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Colonic Epithelial Cells and Lineage Differentiation 
      (adopted from reference 6) 
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 Figure 4. Colonic Epithelial Cell Migration and Differentiation 
(adopted from reference 10) 
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The colonic epithelium is comprised of five distinct cell types (Figure 3). Four of which 
arise from the lineage differentiation of colonic stem cell progeny (Figure 3). The location of the 
cells in the columnar shape of the colonic epithelial crypt define the degree of lineage 
differentiation that the epithelial cells have undergone(6)(10)(Figure 4). Stem cells remain fixed in 
the base of the crypts but the stem cell progeny will migrate out of the stem cell niche and begin 
lineage differentiation in the transit-amplifying compartment(6)(10)(Figure 4). Colonic epithelial 
cells move in an assembly line fashion from the base of the crypt, progressing thorough lineage 
differentiation, to the luminal border of the crypt where they are shed(7)(8)(Figure 4). The cells at 
the luminal border undergo apoptosis to avoid accumulating and disrupting the steady-state 
turnover of the colonic epithelial cells.(7)(9)(10) Under normal conditions, the introduction of new 
cells and the loss of existing cells establish an equilibrium.(7)(9)(10) Tissue damage and 
inflammatory responses disrupt the normal rate of stem cell division and fully differentiated cell 
loss,(11)(12) requiring stem cells to divide at a faster rate to compensate for the sudden depletion of 
the differentiated cells. 
1.3.2.1 Absorptive Cells  
Absorptive cells (enterocytes) are abundant in the colonic epithelium lining the lumen. 
Enterocytes have an apical border on the lumen side of their plasma membrane called the brush 
border(13)(Figure 3).  The apical border extrudes microvilli that increase the surface area of the 
cells.(13) This facilitates the recovery of nutrients which enterocytes export through their basal 
membrane into the lamina propria.(13) Enterocytes are likely exposed to many agents that 
generate promutagenic DNA lesions due to the influx of molecules reabsorbed from the 
undigested wastes. Enterocytes are also susceptible to acquiring mutagenic DNA damage 
generated by reactive oxygen and nitrogen species (RONS) during immune responses. However, 
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fully differentiated enterocytes do not undergo cell division under homeostatic conditions. Cell 
division is a requirement for mutagenesis since DNA must undergo replication for a DNA lesion 
to cause incorrect nucleobases to be fixed into a cell’s genome. Enterocytes are normally 
retained for a week or less and are then induced to undergo apoptosis.(8)(10) The lack of cell 
division and their short life span make enterocytes unlikely candidates to become cancer cells. 
1.3.2.2  Goblet Cells 
Goblet cells are also abundant in the colonic epithelium. They appear to exceed the 
absorptive cells in some areas of the colon. Goblet cells have an apical border on the lumenal 
side of their plasma membrane(13)(Figure 3). They secrete mucus that assists in moving solid 
waste, protects the mucosal epithelial cells, and balances the pH of the colonic lumen.(4)(13) While 
goblet cells are not at risk from absorbing DNA damaging molecules, they would be susceptible 
to acquiring mutagenic DNA damage generated by RONS during immune responses. Goblet 
cells are not dividing under homeostatic conditions, and therefore highly unlikely to fix a lesion 
into a mutation. Goblet cells are normally retained for less than a week and are then induced to 
undergo apoptosis.(8)(10) As with the enterocytes, the lack of cell division and a short life span 
make goblet cells unlikely candidates to become cancer cells. 
1.3.2.3  Enteroendocrine Cells 
Enteroendocrine cells comprise the largest endocrine system of body.(14) The 
enteroendocrine cells comprise only one percent of the entire gut epithelium,(8) yet express a high 
degree of diversity as fifteen different cell types have been identified.  The colonic epithelial 
enteroendocrine cells lack the diversity of the enteroendocrine cells of the small intestine, 
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primarily having only three different cell types: enterochromaffin (EC) cells, D cells, and L 
cells,(15) although other subsets may exist as well.(8)   
Enteroendocrine cells display a longer retention time in the colon than enterocytes and 
goblet cells. Enteroendocrine cells can be retained for up to three weeks vs. a week or less for 
enterocytes and goblet cells.(8) Enteroendocrince cells increase their retention time by dissolving 
their tight cell-cell junctional connections to adjacent cells.(8) This essentially releases 
enteroendocrine cells from the assembly line, and allows them to retain a predetermined position 
within the crypt.  
Enteroendocrine cells are secretory and not at risk from absorbing DNA damaging 
molecules, but are at risk from immune response derived RONS. It is likely enteroendocrine cells 
have an atypical apoptotic induction signaling pathway vs. enterocytes and goblet cells, due to 
their long retention time and their dissociation from the typical crypt architecture. 
Enteroendocrine cells are not dividing under homeostatic conditions, and therefore highly 
unlikely to fix a lesion into a mutation. However, during severe wound distress fully 
differentiated cells may undergo cell division to compensate for the loss of tissue integrity.(14) To 
fix a mutation in its genome, an enteroendocrine cell would need to divide with an unrepaired 
DNA lesion. Even if enteroendocrine cells could be induced to divide with DNA damage, and 
the cells were able to resist apoptotic induction, the limited numbers of enteroendocrine cells 
make them unlikely targets to manifest the first cancer cells.  
There is scientific interest in deducing the role of enteroendocrine cells in colonic 
inflammatory disease and in colon cancer.(15)(16) Differentiated enteroendocrine cells have been 
detected in colorectal carcinomas.(17) Enteroendocrine cells secrete; serotonin, PYY, glicentin 
and GLP-2 that potentially enhance cellular proliferation within the colonic epithelium. This has 
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brought forth the hypothesis that CRCs with enteroendocrine support possess a proliferative 
advantage.(17) In some colonic tumors positive for enteroendocrince cells, the enteroendocrince 
cells also expressed vascular endothelial growth factor (VEGF).(17) However, it is unclear if the 
presence of enteroendocrine cells in a CRC actually results in a worse prognosis for patients.(18) 
1.3.2.4  Paneth Cells 
Paneth cells comprise the most unique of the four lineage differentiated cells in terms of 
their functional capacities. Paneth cells occupy the base of the intestinal crypts, which is also the 
stem cell niche. Paneth cells, which are named for their discoverer, are secretory cells that 
secrete antimicrobial peptides; α and β defensins, Lysozyme C, Phospholipases A2, and C-type 
Lectins.(19) Interestingly, Phospholipases A2 are not expressed by C57Bl/6 mice.(19) Paneth cells 
are considered to be stem cell niche regulators by expressing Wnt3, Wnt11, Egf, Tgfa and Notch 
Dll4, and all of these signaling molecules support stem cells.(20) Paneth cells are retained 
significantly longer than other lineage derived cells, possibly 60 days or longer.(21) Paneth cells 
are capable of dedifferentiation under ex vivo conditions and reacquire stem cell like 
proliferative abilities.(21)  
If Paneth cells are capable of dedifferentiation in vivo, as suggested by Roth, et al., then 
they may represent a potential source of new stem cells when crypts are damaged and the current 
stem cell population is depleted.(21) If Paneth cells are capable of clonal expansion, then they 
would also be vulnerable to fixing an inflammation derived RONS DNA lesion into a mutation 
during DNA replication. As they are also retained for a significant length of time, Paneth cells 
with a mutation fixed in their genome may be able to progress further toward becoming a cancer 
cell. 
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However, Paneth cells are not a normal part of the colonic epithelium,(20) and are only 
found in the small intestine under normal conditions. While a cell that is likely the colonic 
equivalent has been identified,(20) Paneth cells in the colon only arise in colonic disease states 
such as colitis or CRC.(19)(22) Paneth cell development in the distal colon as a result of the onset 
of colitis is termed metaplasia.(19) Since they are not a component of colonic crypts under 
homeostatic conditions and, therefore, not a part of the cancer initiation and promotion events, it 
is difficult to consider Paneth cells as the originating colonic adenocarcinoma cells without 
further findings. Paneth cell ablation studies only enhance the complexity of defining the role of 
Paneth cells as these cells can be depleted in the small intestine with no observed 
phenotype.(23)(24) Also, it is unknown if Paneth cells can undergo dedifferentiation and clonal 
expansion in vivo, in the same capacity they are capable of being induced to dedifferentiate ex 
vivo.   
1.3.2.5 Stem Cells 
Colonic epithelial stem cells are responsible for generating new cells that allow for the 
continuous turnover and renewal of the colonic epithelium. The stem cells reside in niches 
designed to maintain the stem cells unique characteristics of longevity and unlimited 
proliferative ability.(25)  Evidence for the existence of a stem cell population occupying the base 
of a colonic epithelial crypt was deduced to a large extent by the research of the Clevers lab,(26) 
as demonstrated in Figure 5. 
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Figure 5. Columnar Colonic Epithelial Crypts and the Stem Cell Niche 
       (adopted from reference 26) 
 
 
 
 
 
 
 
 
 
 
Figure 5. Colonic epithelial stem cells occupy the base of a crypt. Expression 
of Lrg5-EGFP-IRES-creERT2 coupled to a Cre activated Rosa26-lacZ. LGR5 
gene is restricted to stem cells and tamoxifen induced Cre expression led to the 
activation of the Rosa26-lacZ reporter gene leads to the coloration of the entire 
crypt as all the stem cell derived progeny cells express lacZ. 
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To characterize colonic stem cells as Lgr5 expressing cells, mice were generated with a 
complex knock-in allele. Lgr5 (leucine-rich-repeat-containing G coupled-protein-receptor 5) is 
an orphan G-coupled protein receptor(26) that is rarely expressed in adult tissues, and in the 
intestines Lgr5 expression is restricted to stem cells.(25) The Lgr5 gene was able to be 
reconstructed to introduce a GFP coding region, an Internal Ribosome Entry Site (IRES) region, 
and an inducible Cre expressing region.(26) The IRES allowed for the translation of the Cre 
cassette, which was coupled to another reporter gene Rosa26-lacZ.(27) In spite of the gene 
alterations the heterozygote mice generated with the knock-in allele were reported to be healthy 
and fertile.(26) 
By treating the knock-in mice with tamoxifen the expression of Cre in the stem cells was 
induced, which then excised the inhibitor of the Rosa26-lacZ gene. If the lacZ reporter is 
expressed in a cycling stem cell then all of the progeny of that stem cell will express the gene. 
The lacZ gene hydrolyses the reagent X-Gal into a blue precipitate that will accumulate at the 
site of the enzyme activity(28)(Figure 5).  
The inducible lacZ reporter expression is critical to understanding why a colonic stem 
cell produces the originating cells of a colonic adenocarcinoma.(29) It is reported that there are 
approximately 5 stem cells per crypt.(30) For an entire crypt to be comprised of lacZ expressing 
cells, that can metabolize X-Gal, then a lacZ expressing stem cell must be that crypt’s active 
proliferating stem cell, i.e., the dominate stem cell. A stem cell with induced lacZ expression 
dominating a crypt is equivalent to a stem cell with a fixed mutation surviving and dominating a 
crypt, so that the progeny cells harboring the mutation eventually occupy the entire crypt (Figure 
6). 
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 Figure 6. Colonic Epithelial Crypt Domination by a Mutated Stem Cell 
       (adopted from reference 35) 
 
 
 
 
 
 
 
 
 
Figure 6. (A) Colonic epithelial crypt. (B) A stem cell with a fixed mutation 
(blue) that confers a competitive advantage. (C) The stem cell begins to 
proliferate. (D) The mutation allows the stem cell to dominate the crypt. (E) All 
of the clonal cell progeny harbor the mutation. 
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One of the difficulties in studying colonic epithelial cells is that the majority of the data 
in the literature focuses on the small intestine. In the small intestine, a stem cell with a mutation 
that endows a competitive advantage will be more likely to generate self-copies, usurp the 
dominate stem cell position, and phase out the non-mutated stem cell population(30)(Figure 6). 
One example of a mutation that confers a competitive advantage is seen with beta-catenin 
overexpression or in the regulation of beta-catenin phosphodegradation.(30) Even if the chance of 
the mutated stem cell overtaking the crypt niche increases by only a slight percentage, it still has 
greater likelihood of usurping the crypt than a normal stem cell.(30) The progeny of this mutated 
stem cell will also harbor the same activated oncogene mutation, or loss of tumor suppressor 
gene function. While this data is based on research of the small intestine,(30) mutated stem cells 
having an increased probability of dominating crypts in the colon is supported by colonic niche 
succession studies.(31) 
Stem cells are long lived and one crypt will exist in the human colon for an average of 8 
years (2.7 to 19 years).(31) Over time a crypt will deplete its stem cell population until no stem 
cells remain to propagate new cells needed to replace the differentiated cell turnover in 
equilibrium. To maintain the colon architecture a crypt must still exist in that location, so a new 
stem cell niche is created from an adjacent crypt in a process termed niche succession.(31) A crypt 
sustained by a stem cell population with an adenomatous polyposis coli (APC) mutation may be 
retained for an average of 30 years.(31) The APC mutated stem cells have a competitive 
advantage that allows them to eventually dominate a stem cell niche, but they also exhibit a 
prolonged retention time.(30)(31) Furthermore, APC mutant crypts are retained longer than normal 
crypts so an APC mutant stem cell population is likely to be expanded by niche succession.(31) 
 19 
This will invariably lead to an accumulation of crypts with their entire cell population propagated 
by APC mutant stem cells. 
As colonic epithelial stem cells are readily dividing, an unrepaired DNA adduct could be 
fixed into a mutation during DNA replication. Stem cells harboring mutations that provide a 
selective advantage are more likely to dominate a niche and produce progeny. Since colonic stem 
cells are retained for much longer durations than their lineage differentiated progeny, stem cells 
represent the most likely cell type of the colonic epithelium to give rise to cells that could 
manifest as the first cancer cells.(29) However, stem cells do not behave independently but are in 
fact tightly regulated by stem cell niche signaling, and are clearly governed by a different set of 
parameters than any other epithelial cell type. These include being retained in a set position 
within the crypt and different parameters for their own turnover and replacement. 
1.3.2.6 The Stem Cell Niche 
The stem cell niche in any type of tissue is designed to maintain a stem cell population. A 
stem cell outside of this specialized region will begin lineage differentiation and lose the stem 
cell defining characteristics. Even a stem cell’s gene expression profile diverges greatly from its 
differentiated progeny.(6)  
A stem cell niche is comprised of more cell types than just stem cells, and these cells may 
or may not contribute to stem cell regulation. In the colonic stem cell niche there are cell types 
derived from the stem cells as well as; macrophages, dendritic cells, intraepithelial lymphocytes 
(IELs)(32) and pericryptal cells(33) that all arise from other cell lineages. In the small intestine and 
colonic crypts, the stem cells are separated by other cells so that the stem cells are not in physical 
contact with one another(25)(Figure 7). The colonic stem cells are connected to pericryptal cells 
on their basolateral border(34)(35)(Figure 8). The pericryptal cells connect to the underlining 
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mucosal muscularis, vasculature, and extracellular matrix which includes fibroblasts and 
mesenchymal cells.(35) Physical interactions with adjoining cells, through Notch signaling, and 
signaling with other niche cells in close proximity through the Wnt pathways are considered to 
be the source of the stem cell’s regulation.(6)(34)(35)(36)  
 
 
 
 
 
 
 
 
Figure 7. Colonic Epithelial Stem Cells are Separated in the Niche 
                                            (adopted from reference 25) 
 
 
Figure 7. (A) Colonic epithelial stem cells do not border one another in the 
stem cell niche. This is illustrated by confocal imaging of EGFP in the Lrg5-
EGFP-IRES-creERT2 expressing cells. (B) The CBC cells (columnar base cells) 
represent the Lgr5+ expressing stem cells in the small intestine and colon crypts. 
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 Figure 8.  Colonic Epithelial Crypts are Sheathed by Pericryptal Cells 
                                           (adopted from reference 35) 
 
 
 
 
 
 
  
 
Figure 8. Pericryptal cells sheath the colonic crypts starting from the stem 
cell niche and ascend the crypt.  These cells form a bridge for the colonic 
epithelial cells to the underlying tissue layer. Pericryptal cells actively signal to 
the stem cell niche and participate in stem cell regulation. 
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1.3.2.7 Stem Cell Niche Signaling Governs Stem Cell Behavior 
Niche signaling governs stem cells and maintains the homeostatic steady-state turnover 
of colonic crypt cells. Proliferating stem cells are considered to be capable of two types of 
division, symmetrical and asymmetrical(31)(35)(37)(38)(Figure 9).    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.   Colonic Epithelial Stem Cell Division 
                                          (adopted from reference 35) 
 
 
 
 
 
Figure 9. Stem cells (RED) are considered to be capable of both (A) 
asymmetric divisions and (B)(C) symmetric divisions.  Asymmetric divisions 
create one stem cell and one progeny cell (Yellow) to undergo linage 
differentiation to maintain the homeostatic epithelial cell turnover. Symmetric 
division generates 2 stem cells or 2 linage differentiation cells. Symmetric 
divisions create more clones of the dominate stem cell or, deletes the dominate 
stem cell population so a new dominate stem cell can usurp the niche. 
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Asymmetric stem cell division was first proposed by Dr. John Cairns.(37) In an 
asymmetric division the dominate stem cell divides with one of the new cell copies being 
retained in the crypt niche (parent cell) and one copy repositioning to undergo lineage 
differentiation (daughter cell)(30)(31)(35)(38)(Figure 9). Niche signaling determines the lineage 
differentiation fate of the newly divided cell.(6) The newly polymerized strands of DNA, that 
would potentially have fixed a mutation in their genome, may go on to lineage differentiation. 
Alternatively, the newly polymerized strands of DNA could be retained in the stem cell niche. 
While it is unknown how asymmetrical division determines the recombination of the DNA 
strands, the parent stem cell’s plasma membrane likely remains anchored in the niche during 
division, while the daughter cell’s plasma membrane moves to the edge of the transit-amplifying 
compartment. Whether or not this impacts how the DNA recombines remains to be determine, 
but is possible that the parent DNA strands are selected for and remain in the parent stem cell.    
Symmetrical divisions allow the dominate stem cell to expand its population within the 
niche by producing replicated copies of itself, copies that are subsequently retained in the 
niche(31)(35)(38)(Figure 9). Alternatively, both copies of the stem cells may proceed to lineage 
differentiation, allowing the crypt to be usurped by a new dominate stem cell(31)(35)(38)(Figure 9). 
When both copies of the stem cell turnover,  it is regarded as an evolutionary adaptation to 
prevent stem cells that may have fixed mutations from populating a crypt with potential pre-
cancer cells,(35) or other functionally impaired mutant cells.  
For a stem cell to propagate progeny with a fixed mutation it must first undergo cell 
division having failed to repair DNA damage. The new stem cell clone that harbors a mutation 
must then assume the dominate position in the niche. In an asymmetric division the original stem 
cell may harbor the DNA adduct but the daughter cell with the mutation would migrate from the 
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niche. Therefore, the mutated cell would not remain in a position to usurp the niche. With a 
symmetric division both the DNA damaged stem cell and the mutated stem cell would be 
equivalent stem cells. Both stem cells could move to undergo lineage differentiation. Or, both 
stem cells would be retained in the niche, allowing for the mutant cell to assume the dominate 
position the niche.  
1.3.2.8 The Niche in Question? 
What sequence of signals could lead to the survival and proliferation of a stem cell 
arrested in cell cycle division by DNA damage? Could events such as tissue damage and repair 
force an arrested stem cell to forego apoptotic induction, bypass unrepaired DNA adducts by 
recruiting translesion DNA polymerases, and continue to replicate its DNA to complete cell 
division? Tissue damage and cytotoxicity are accompanied by inflammation. However, it 
remains unclear if immune cell signaling affects the stem cell niche or would impact the 
dominate stem cell’s survival if it does have damaged DNA. 
The cells comprising the colonic stem cell niche are not clearly defined. Consequently, 
the signaling pathways in the niche are also not defined. In the small intestine, the stem cell 
niche comprises Paneth cells that separate the stem cells from physically sharing a cell-cell 
border. In the colon, Paneth cells are rarely expressed and do not constitute a regular part of the 
colonic crypts. However, as seen in Figure 7, the colonic Lgr5+ cells are separated from one 
another so some cell type occupies the area between the stem cells.  
In the small intestine, the stem cell niche is regarded as has having at least two stem cell 
populations, the Lgr5+ expressing cells and the Bmi1 expressing cells.(26)(39) The Bmi1 cells seem 
to make the Lgr5+ stem cells dispensable in the small intestine, as the Lgr5+ cells can be depleted 
and no phenotype is observed.(40) This has led to the questioning of Lgr5+ cells as the intestinal 
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stem cell population. However, colon crypts lack Bmi1 cells so if Lgr5+ cells are not the colonic 
stem cells then which cells are?(39)   
1.3.2.9 Which Colonic Epithelial Cell is the Potential Cancer Cell? 
Colonic stem cells seem to be the only logical cell to be the originating source of cancer 
cells. Dominant stem cells are undergoing continuous cell division which makes them capable of 
fixing a mutation into their genome. Stem cells also are retained for extensive periods of time 
and have unlimited proliferative capability. A dominant stem cell with a mutation could produce 
an unlimited number of progeny cells harboring that mutation for years, cells that are susceptible 
to further genetic and epigenetic changes leading to the first cancer cells. Furthermore, stem cells 
have the support of the stem cell niche to induce cell proliferation, which other colonic epithelial 
cells lack. 
A dominant stem cell forced to arrest cell division due to acquiring DNA lesion damage 
are likely to be induced to undergo apoptosis.(41) During an inflammatory insult however, an 
arrested stem cell could potentially be induced to divide and bypass DNA damage as cell 
turnover rates increase.(11)(12) This would make the dominant stem cell(s) susceptible to fixing an  
oncogenic mutation. 
This scenario seems reasonable as it is not known how long a crypt could wait for an 
arrested stem cell to repair DNA damage and begin renewing the crypt cells under normal 
conditions. It is also not known how long a crypt could wait for an arrested stem cell under 
inflammatory conditions. It may be possible that signaling can arise under non-homeostatic 
conditions which changes a stem cell’s rate of division and/or leads to resistance to apoptosis in 
an effort to keep the stem cell cycling.  
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Other fully differentiated colonic lineage cells have finite retention times when compared 
to the stem cells, which can cycle for years. Differentiated cells are readily induced into 
apoptosis, while stem cells do not turnover by apoptosis but by symmetric cell division under 
homeostatic conditions. This is a clear indication of the different regulatory parameters of stem 
cells. Some differentiated epithelial cell types may dedifferentiate ex vivo, allowing them to 
divide and expand their population, but it is not known if this would occur in vivo.  
Could a dedifferentiated mutant cell divide indefinitely under homeostatic conditions, or 
would dedifferentiation and clonal expansion be restricted to non-homeostatic conditions? 
Enterocytes at the edge of a wound dedifferentiate into a motile form and undergo rapid cell 
cycle division during intestinal wound repair.(42) However, all of the dedifferentiated cells mature 
and turnover rapidly as homeostasis is reestablished,(42) making it unlikely their retention time 
would be sufficient to allow for a cancer cell to manifest. 
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1.4 INFLAMMATION RELATED COLON CANCER INDUCTION MODEL 
1.4.1 Comparative Anatomy of the Human and Mouse Colon 
The human and mouse large intestines function in the same capacities that were discussed in 
section 1.2. The large intestine in both the human and the mouse are comprised of a cecum, 
colon, and rectum.(43) In the mouse the cecum comprises approximately one-third of the large 
intestine.(43) The mouse cecum has a high density of commensal bacteria, and actively ferments 
solid wastes.(43) This contrasts with the human cecum which functions to bridge the small 
intestine to the colon but lacks an enhanced bacterial presence or functional capacity. The mouse 
cecum empties into the proximal colon which transitions into the distal colon and then rectum 
and anus.(43) In contrast to the human large intestine, the mouse colon remains a long tube 
(Figure 10) that parallels the abdominal body cavity beginning behind the liver and running to 
the anus. The mouse rectum is very short and as a result will easily prolapse when various 
colonic pathologies occur, including colitis.(43)  
The human and mouse epithelium are comprised of the same layers: mucosa, submucosa, 
muscularis externa, and serosa,(43) discussed in section 1.2.1. Both the human and mouse large 
intestines are comprised of the same cell types; enterocytes, goblet cells, enteroendocrine cells, 
and stem cells,(43) discussed in section 1.2.2. Both the human and mouse large intestines are 
colonized by various types of microflora.  Immune compromised mice may have protozoal 
flagellates and ciliates.(43) The composition of the microflora can play a role in both ulcerative 
colitis and carcinogenesis, as discussed in section 1.5. 
It is appropriate to question how the data from an experimental model of a pathology will 
translate to the pathological disease in a human. Can the data generated be of scientific value? 
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When comparing the large intestines of the mouse and human there are significant similarities in 
the tissue regions, tissue layers, and epithelial cells. There are also significant differences in the 
cecum, the shape of the colon, and microflora composition. However, it is feasible that the onset 
of colitis and colon cancer in the mouse is similar to enough to onset of the diseases in humans to 
generate data of scientific value.  
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Figure 10. The Mouse Lower Intestine and Comprising Regions 
   (adopted from reference 43) 
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1.4.2 A Colon Cancer Inflammation Model 
A carcinogenesis animal model that requires two steps via the administration of a mutagen(44) 
and an inflammatory agent is referred to as a two-stage carcinogenesis model.(44)  The mutagen 
may be chemically reactive or metabolized into a chemically reactive form.(44) The active 
initiator will react with and damage DNA that results in mutations upon DNA replication.(44) In 
contrast, tumor promoters are not directly mutagenic and do not need to react with DNA.(44) Yet, 
tumor promoters are strongly associated with the generation of free radicals.(44) Interestingly, 
inflammation that results in the generation of reactive oxygen and nitrogen species (RONS) is 
considered a tumor promoter.  
The novel colon cancer induction model developed by Tanaka et. al., utilizes the initiator 
and promoter concept effectively in the B6 mouse strain that is resistant to carcinogenesis by 
treatment with an initiating reagent alone.(45) In the model, azoxymethane (AOM) is the mutagen. 
One advantage of utilizing AOM is the reagent’s organotropism for the colon.(46) Another 
advantage of utilizing AOM is that, as a DNA alkylating agent, it causes sporadic mutations, 
allowing for the study of sporadic colon cancers.(46)(47)(48) The tumor promoter utilized is dextran 
sulfate sodium (DSS). DSS recapitulates the onset of human inflammatory bowel disease 
(IBD).(46) As previously stated in section 1.1, humans with IBD have a greater risk of developing 
a CRC than the 1:20 incidence among the general population.  
The induction of CRC in mice treated with AOM and DSS is a scientifically accepted 
model to study the pathogenesis of inflammation related to the development of sporadic colon 
cancers.(46) It is reasonable to assume that experimental data derived from this model will impart 
a greater understanding of the etiology of the disease in humans. 
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1.5 AZOXYMETHANE 
1.5.1 Azoxymethane (AOM) is a DNA Alkylating Reagent 
Azoxymethane (AOM) generates DNA lesions that are both cytotoxic and mutagenic. Although 
cytotoxicity does induce inflammation, the DNA lesions generated by AOM primarily induce 
apoptosis and not necrotic cell death as will be discussed in this section. Also, the induced 
inflammation is likely to be rapidly resolved as the cytotoxicity is rapidly reduced within 24h.(41) 
Through its active metabolic intermediates, AOM methylates DNA. Therefore, AOM is 
considered a tumor initiator. The chemical structure of AOM is presented in Figure 12. AOM 
alkylates DNA through an SN1 substitution reaction.(49)(50) AOM is a monofunctional alkylating 
agent in its active form, meaning it contains one active moiety (methyl) that modifies a single 
site on a nucleobase of a nucleic acid.(50)(51) SN1-alkylating agents target both ring nitrogens and 
extracyclic oxygens on the nucleobases.(51)  
Monofunctional SN1-alkylating agents primarily generate three DNA adducts, 7-
methylguanine (7mG), 3-methyladenine (3mA), and O6-methylguanine (O6mG)(51)(Figure 11). 
7mG represents the majority (~60-80%) of the DNA adducts formed by monofunctional SN1-
alkylating agents.(52) While 7mG is not cytotoxic or mutagenic,(52) spontaneous or enzymatic 
excision of the methylated guanine results in an abasic site that, if not repaired, is cytotoxic and 
mutagenic.(51)(52) 3mA, which accounts for ~10% of DNA adducts formed,(51)(52) is cytotoxic by 
disrupting DNA polymerization leading to the induction of apoptosis, or spontaneous 
depurination can lead to abasic sites.(53) 
O6mG, which is formed in ~ 10% yield from AOM, is generated by methylation of the 
extracyclic oxygen O6 of guanine. O6mG is potent as both a mutagenic DNA adduct and as a 
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cytotoxic lesion. The mutagenic effect of O6mG arises from the fact that O6mG does not arrest 
DNA replication.(54)(55) The O6mG lesion mismatches with thymine instead of cytosine leading to 
GC>AT transitional mutations.(55)(56) O6mG is also cytotoxic, as O6mG generated mismatched 
base pairs O6mG:T are recognized by enzymatic DNA repair proteins that can induce 
apoptosis.(55)(57)  
It is noteworthy that O6mG is only generated in small quantities by monofunctional SN1-
alkylating agents yet O6mG is the primary mutagenic lesion in WT DNA repair mice. An 
example of another monofunctional SN1-methylating agent being employed as anti-cancer drug 
is temazolomide.(51) Cancer cell resistance to temozolomide comes from the overexpression of 
the enzyme that repairs O6mG, and from the inactivation of mismatch repair proteins.(51) 
 
 
 
 
 
 
 
 
   
 
Figure 11. Sites of DNA Methylation by Monofunctional Agents 
(adopted from reference 51) 
 
 
Figure 11. DNA Methylation target sites and the lesions caused by 
monofunctional SN1-alkylating agents. 
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1.5.2 Azoxymethane is a Procarcinogen that is Metabolized into its Active form 
AOM, which is itself the metabolite of 1,2-dimethylhydrazine (DMH),(46) requires metabolic 
activation to be able to alkylate DNA at nitrogen and extracyclic oxygen atoms.(46)  
 
 
 
 
Figure 12. AOM Metabolism into its DNA Alkylating Form 
(adopted from reference 46) 
 
 
 
Figure 12. AOM, and its precursor DMH, undergo N-oxidation and 
hydroxylation by CYP2E1and colonic Aldehyde Dehydrogenase into the DNA 
reactive methanediazonium ion. This reaction generates the mutagenic O6mG 
DNA adduct. 
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AOM is metabolized in vivo by the cytrochrome P450 CYP2E1 to methylazoxymethanol(MAM) 
(58)(59)(60)(Figure 12). AOM is prepared in PBS and administered to the mouse via intraperitoneal 
injection, as discussed in section 5.2. AOM is then absorbed into the bloodstream and perfuses 
the liver. The AOM permeates into the hepatocytes and once in the hepatocellular cytosol is 
oxidized and hydrolyzed by CYP2E1 into MAM,(59) and MAM is exported back into the 
circulation.   
It has been determined in different studies that CYP2E1 is the enzyme most active in 
metabolizing AOM. Rats treated with disulfiram, a reagent that inhibits CYP2E1 activity, had 
reduced concentrations of MAM measured in their urine and increased concentrations of 
unmetabolized AOM measured in their urine and exhaled air when compared to control rats that 
did not receive disulfiram.(58) CYP2E1 null 129/SV mice, both male and female, had 
significantly reduced levels of O6mG lesions in their colons and other tissues after treatment with 
AOM when compared to the WT 129/SV control mice.(60) 
1.5.3 AOM displays strong Organotropism 
AOM shows significant organotropism for the liver, kidney and colon.(60)(61) The volume of 
distribution of the AOM metabolite MAM is not known, but significant distribution of MAM to 
target organs is supported by the level of DNA adducts measured in each tissue.(60) Since one 
molecule of MAM potentially generates one adduct via an SN1 reaction, measuring adduct levels 
reflects the level of MAM distribution to the various organs of the body. The half-life of MAM is 
approximately 12 hours, providing time for the MAM to permeate its different target 
tissues.(55)(60)  
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Why is the organtropism observed in AOM treatments occurring? One reason that has 
strong support is that MAM is further metabolized in target organs, such as the colon, due to the 
expression of aldehyde dehydrogenase (ADH) in those tissues(46)(62)(Figure 12). MAM is capable 
of spontaneous degradation to its active methanediazonium ion form, but would need to 
selectively accumulate in the target organ to alkylate the DNA.(63) Schoental suggested that 
MAM could undergo further metabolism,(64) and the metabolism of MAM in the target tissue via 
the expression of a metabolizing enzyme would explain some of the organ specificity.(61)  
Inhibition of ADH with pyrazole in rats prior to treatment with [14C]-labeled AOM, 
decreased exhaled 14CO2 and increased urinary excretion of [14C]MAM when compared to 
untreated control rats.(62) The addition of pyrazole to colonic cytosol homogenate also inhibited 
ADH activity, which failed to reduce the ADH cofactor NAD+ after treatment with pyrazole.(62) It 
is noteworthy that in an ADH-/- null mouse strain showing no activity for ADH in the liver; 
kidney, lung, and colon, the levels of O6mG measured in liver homogenate were not significantly 
different between the WT and ADH null mice after treatment with methylazoxymethyl acetate 
(MAMOAc).(65) This suggests that in the liver there is either spontaneous breakdown of MAM, 
or other metabolic routes, which lead to O6mG adducts. 
1.5.4  Colonic stem cells could be more susceptible to AOM derived DNA Alkylation 
damage than the differentiated epithelial cells 
ADH expression could be restricted to the stem cell population in some organs, and ADH has 
been suggested to be a marker of adult stem cells.(66)(67) In the colon, the expression of ADH is 
localized to the very base of the colonic crypts, the location of the stem cell niche.(67) ADH 
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expressing cells increased in number and location in colonic adenomas and have been shown to 
be cancer stem cells.(67)  
Colonic stem cells express AHD at detectable levels but differentiated epithelial cells do 
not. This would suggest colonic stem cells are susceptible to accumulating significantly higher 
levels of DNA alkylation damage, as a result of the metabolic activation of MAM, than the 
differentiated cells would be susceptible to. At least some stem cells are undergoing division to 
support epithelial cell turnover, and rapidly accumulating high levels of DNA adducts could 
force stem cells to undergo division without arresting the cell cycle in order to repair the adducts.    
1.5.5 DNA Repair, Mutagenesis, and Cytotoxicity 
Treatment with AOM leads to the generation of three predominant DNA adducts that are 
biologically significant, as discussed in section 1.4.1 (Figure 11). The quantitatively major 
lesion, 7mG, is not biologically significant unless it results in a buildup of apurinic sites. 
Whereas, 3mA and O6mG are biologically significant because they are cytotoxic and/or 
mutagenic.  
The 3mA adduct creates a replication block to DNA synthesis.(53) The replication 
blocking effect of 3mA adducts can lead to mutagenesis due to error prone translesion bypass 
polymerases.(68) 3mA adducts are repaired by Base Excision Repair (BER) repair, initiated by the 
enzyme alkyladenine-DNA glycosylase (Aag).(53) The adverse effects of 3mA and the resulting 
BER include; sister chromatid exchange, chromosome aberrations, S-phase arrest, and p53 
induction,(53) which are all potentially mutagenic or cytotoxic forms of DNA damage. 
O6mG is biologically significant as a mutagenic DNA lesion. Arguably the most pro-
mutagenic lesion formed from AOM. O6mG repair can be carried out via at least two enzymatic 
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DNA repair pathways. The most efficient and desirable way to repair O6mG is direct reversal of 
the lesion. This is accomplished by the demethylation of the methylated extracyclic oxygen of 
the guanine base by the enzyme O6-methylguanine-DNA methyltransferase (MGMT).(55)(69) 
MGMT repair is enzymatic, however transferring the methyl group to the cysteine residue in 
MGMT’s active site is irreversible and inactivates the protein.(69) Hence, it requires one MGMT 
per O6mG lesion to reverse the damage. Thus, the rapid formation of O6mG lesions would need 
to be accompanied by the upregulation of MGMT expression to circumvent the DNA damage. 
Transgenic mice that have increased expression of MGMT display organ protective effects 
against AOM induced carcinogenesis, including the colon.(70)(71) While MGMT null B6 mice had 
significantly higher colon cancer incidence and higher mortality when treated with AOM than 
WT B6 control mice.(72)  
The O6mG lesion does not arrest DNA synthesis, and bypass translesion polymerases 
frequently generate a mismatched DNA base pairing O6mG:T.(73)(74) A mismatched DNA base 
pairing is a substrate for the mismatched DNA repair pathway (MMR). MMR operates through a 
complex series of interactions and proteins that excise a segment of the newly synthesized DNA 
strand that contains the T opposite the O6mG in the parental strand.(75)  
MMR ideally recognizes and reverses O6mG:T lesion mispairing,(76) however MMR 
proteins do not remove the O6mG lesion on the parental DNA strand.(75) This results in tolerance 
of the O6mG adduct as it is still in the DNA, but is not inducing a mutation or causing 
cytotoxicity.(75) However, repeated attempts at repairing the base opposite the O6mG lesion 
results in a futile cycle of repair as the O6mG:T pairing is continuously produced by DNA 
polymerases. This inevitably leads to the accumulation of single-strand DNA gaps, replication 
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fork collapse, double strand breaks, and chromosomal aberrations,(51) which are all potentially 
mutagenic or cytotoxic forms of DNA damage.  
 B6 mice deficient in both MGMT and MMR repair were able to tolerate O6mG lesions 
without experiencing the cytotoxicity and tissue damage observed in MGMT null mice.(77) 
However, in the dual repair deficient B6 mice the DNA alkylated cells do not die but instead 
survive with a high mutation rate. Normal cells can tolerate O6mG lesions as long as adequate 
levels of MGMT are expressed in the cells. However, if MGMT is rapidly exhausted cells 
become vulnerable to both mutagenesis and cytotoxicity induced by the O6mG lesions. Both the 
upregulation of MGMT and the loss of MMR activity are observed in tumor cells that are 
resistant to treatment with DNA alkylating agents that generate O6mG lesions,(51) as was 
previously mentioned in section 1.4.1.  
1.5.6 Colonic stem cells could be susceptible to O6mG induced cytotoxicity and 
mutagenicity than differentiated epithelial cells 
Data reported by Hong et. al. show that MGMT is not constitutively expressed in cells occupying 
the base of a colonic crypt, including the stem cell niche, in mouse colons stained for MGMT 
expression after treatment with AOM.(41) In contrast, the fully differentiated cells comprising the 
lumenal edge of the crypt expressed MGMT constitutively before AOM was administered.(41) 
Over a 12 hour time course, after treatment with AOM, MGMT expression increased in the 
lower colon crypt region until it reached expression levels equivalent to those in the 
differentiated cell region.(41) This implies that MGMT expression could be induced by outside 
signaling, such as immune mediated signaling.   
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As O6mG adduct levels increased in the cells at the base of the crypts, so did the 
apoptotic index in that region.(41) As MGMT expression levels rose in the cells of the crypt base, 
the number of apoptotic cells began to decrease.(41) This would indicate that initially O6mG 
lesions are highly cytotoxic to the colonic stem cells due to their low levels of MGMT 
expression. As discussed in the previous section, direct reversal of O6mG lesions by MGMT will 
enhance cell survival by impeding DNA repair enzymes that initiate apoptosis. 
Colonic crypt stem cells and early lineage progenitor cells may already be predisposed to 
accumulating higher levels of O6mG lesions due to the expression of ADH. Without MGMT 
expression to repair the O6mG lesions, the stem cells may be forced to initiate other enzymatic 
DNA repair pathways, specifically MMR and BER, that readily induce apoptosis. The initial 
cytotoxicity seen in the stem cells after treatment with AOM could induce signaling that causes 
an epigenetic expression change in the stem cells. This expression change would be geared 
toward the survival and continued proliferation of an indispensable cell population. 
1.6 DEXTRAN SULFATE SODIUM 
1.6.1 Dextran Sulfate Sodium 
Dextran Sulfate Sodium (DSS) is a negatively charged sulfated polysaccharide homoglycan of 
glucose,(78)(79)(80) produced by the esterification of dextran with chlorosulphonic acid and having 
approximately two sulphate groups per glucose residue.(81) Dextran is synthesized from sucrose 
by various bacteria into a complex polysaccharide.(82) DSS is comprised of straight and branched 
polysaccharide chains and is therefore water soluble.(80)(83)  
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1.6.2 Treatment with DSS Damages the Colonic Epithelial 
Colonic exposure to DSS results in ulcerations, hemorrhage and edema resulting from increased 
serous fluid swelling, which ultimately decreases or shortens the colon length due to the 
continuous cycles of tissue repair.(83)(84) DSS damage appears primarily superficial to the 
epithelium, but is capable of damaging the subepithelium and muscularis mucosa as well.(83) 
DSS treatment leads to the rapid onset of acute symptoms that include bloody stools, diarrhea, 
rectal bleeding and rectal prolapse.(83)(84) Chronic symptoms, which are dose-dependent, are 
weight loss due to a lack of appetite, anemia, rectal prolapse, bacterial infection, colitis, and 
mortality.(83) The duration of the DSS treatment also impacts the severity of the damage. 
Increasing the concentration and/or the duration of DSS exposure can rapidly change the severity 
of the symptoms and the mortality observed in the treated mice. 
Colonic epithelium changes due to DSS exposure are severe when examined 
histologically, yet reversible once the DSS exposure ceases. There is a total loss of colonic crypt 
architecture after 7 days of DSS treatment at both 3% and 5% percent doses(85)(86)(Figure 13). 
Even at a 1% DSS dose colonic crypts exhibited edema and separate from the muscularis 
mucosa, and total crypt loss was observed after 7 days of DSS treatment(86)(Figure 13). The 
duration required to return to homeostasis is significantly shorter at lower DSS concentrations 
and short treatments, while higher DSS concentrations and longer treatments require much 
longer intervals to reconstitute the colon tissue.(89) Histological results also show a massive 
influx of immune cell populations that included neutrophils, macrophages, and lymphocytes (NK 
cells, B cells, and T cells).(85)(86) As will be discussed in the following section, DSS can directly 
kill immune cells by non-apoptotic pathways. Since this will cause a strong pro-inflammatory 
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response, many different types of immune cells may influx into the DSS damaged areas of the 
colon.  
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 Figure 13.      Colonic Epithelial Changes after DSS Treatment 
(adopted from reference 142) 
 
A 
Figure 13. (A)(B) Colonic epithelial morphology of WT (B6) mice before 
DSS treatment. (C) B6 epithelial morphology after 7 days of 3% DSS 
treatment. (D) B6 epithelial morphology after 7 days of 1% DSS treatment. 
(E) 7 days after end of the 3% DSS treatment. (F) 7 days after end of the 3% 
DSS treatment. 
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1.6.3 DSS initiates Colonic Epithelial Injury and Inflammation 
The exact mechanism through which DSS induces injury and initiates inflammation is still 
undetermined. Preliminary studies with DSS treatment on the colonic mucosa indicated that 
macrophages are phagocytizing a metachromatic substance detected by toluidine blue 
staining.(84)(85) Okayasu et al. showed that colonic macrophages exhibit an altered swollen 
morphology due to enlarged lysosomes as seen by electron microscopy. Kitajima et al. reported 
that metachromatic substances were observed after 3 days of DSS treatment in colonic basal 
pericryptal macrophages, concomitant to the onset of epithelial crypt morphological alterations. 
If macrophages are undergoing morphological changes, then it is likely they are also undergoing 
phenotypical changes. Macrophages that have phagocytized DSS molecules are highly likely to 
be undergoing ischemic cell death, or oncosis,(87)(88) a form of non-apoptotic cell death. 
Furthermore DSS exposure depletes colonic tissue resident macrophages and disrupts the 
maturation and function of infiltrating naïve monocyte populations, the macrophage precursor 
cells.(89)  
If DSS induces macrophage cell death by oncosis, and not apoptosis, then inflammation 
is being initiated by the detection of non-apoptotic cell death. Oncosis may be partially mediated 
through intracellular mechanisms, such as PARP activation that depletes intracellular NAD and 
concomitantly depletes ATP.(90) While oncosis is a form of programmed cell death, the process 
differs from apoptosis and autophagy in that oncosis is pro-inflammatory.(88)(90)  
The effect of DSS depleting macrophages, and likely other phagocytic cells, leads to 
immediate deleterious effects. One damaging effect is the disruption of the colonic epithelial cell 
barrier through the disruption of cell-cell adhesion junctions. Macrophages, dendritic cells, and 
intraepithelial lymphocytes (IELs) are interspersed throughout the different layers of the 
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colon.(33)(91)(92) As mentioned previously in section 1.2.2.6, tissue resident myeloid cells and 
lymphocytes are not derived from colonic stem cells but are of the hematopoietic cell 
lineage.(89)(91) IELs integrate into the epithelium and form cell-cell adhesions, linking them to the 
epithelial cells and allowing for direct cell-cell communication.(93) Macrophages and dendritic 
cells localize just below the epithelium in the pericryptal sheath and lamina propria.(94) Through 
cell-cell adhesion colonic tissue resident immune cells work with epithelial cells to maintain 
homeostasis and mediate inflammation.(33)(91)(92)(95) However, tissue resident immune cells do not 
turnover at the same rate as the epithelial cells.(96) While data from Penney et al. is based on 
small intestinal studies, these studies demonstrate the clear differences in cell turnover rates 
between the two cell lineages.(96) If a significant depletion in one of the tissue resident immune 
cell populations occurs, the immune cells will not be renewed at the same rate as the mucosal 
cells. This will affect the rate at which an inflammatory event can be resolved, tissue repair can 
be carried out, and colonic homeostasis reestablished. 
Treatment with DSS also disrupts epithelial cell tight junction protein expression through 
the loss of ZO-1 expression.(97) IELs localize in the epithelium based on their adhesion molecule 
expression.(98) It has been demonstrated that DSS treatments disrupted IEL adhesion to epithelial 
cells, however this finding was based on in vitro studies.(99) Evidence of the loss of adhesion 
molecules can also be observed in the histology of DSS induced damage. One of the first 
changes in the colonic epithelial morphology is the detachment of the base of the colonic crypts 
from the underlying mucularis mucosa.(85) 
A second damaging effect of DSS treatment is the loss of the mucus layer that separates 
and inhibits bacterial interactions with the colonic epithelium and resident immune cells. Goblet 
cell numbers were decreased in rat colons in areas of DSS induced colonic ulcers as determined 
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by histological assessment.(100)(101) The synthesis of mucus proteins were diminished and 
numbers of goblet cells devoid of mucus increased with increased duration of epithelium 
exposure to DSS.(100)(101) The disruption of mucosal secretions allows the bacteria unimpeded 
access to physically contact the epithelial cells.(102) It is noteworthy that a substantial bacterial 
load is in contact with the colonic epithelium within 12 hours of the onset of DSS treatment.(102) 
However, it requires 3 to 5 days before gross symptoms occur and the disruption of epithelial 
morphology is discernable, and 5 to 7 days for the morbidity to peak. 
1.6.4 Inflammation, Bacteria, and RONS 
Certain strains of bacteria are tolerated when localized to the exterior surfaces of the body, as 
their potentially cytotoxic metabolic processes are ameliorated. Mucosal secretion into the lumen 
is a necessary component of colonic bacterial regulation, as are the tight cell-cell junctions 
created when colonic epithelial cells link with one another. DSS treatment disrupts this barrier 
and as a result the colonic microflora are capable of migrating into areas that were previously 
inaccessible. This leads to the breaking of immune tolerance to the commensal microflora, 
mediated by the localization of bacteria into the subepithelial region of the epithelium. 
The presence of microbiota in both the small intestine and colon does not induce 
inflammation due to the complex development of natural tolerance. Enterocytes, in particular, 
play a role in bacterial tolerance. The polarization of enterocyte cells results in two different 
borders, the luminal brush border and the basolateral border, as discussed in section 1.2.2.2. Both 
borders express Pattern Recognition Receptors (PPRs) and specifically the PPRs class Toll-like 
receptors (TLRs).(33)(95)(103) PRRs are the primary initiators of anti-pathogenic responses.(104) 
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Apical brush border PRR signaling is essential to maintaining colonic immune 
tolerance.(33)(105)(106) While basolateral PRR signaling initiates inflammatory responses.(33)(95)   
Once immune tolerance has broken down the tissue resident phagocytic immune cells, 
the macrophages and dendritic cells, are the first cells to detect and initiate an immune response. 
PRR activation induces a signaling cascade leading to the activation of various transcription 
factors,(104) which transcribe the expression of immune mediators that then signal to the 
infiltrating immune cells.(104)  
The anti-pathogenic response toward a bacterial infection can be mediated by both innate 
and adaptive host immune responses. Humoral immune response results in the generation of 
antibodies by mature B-cells, that specifically bind to epitopes expressed on bacterial cell surface 
molecules.(107) Antibody binding will impede the bacterial pathogenesis and prime the bacteria to 
be phagocytized by one of several phagocytic cell types.(107) Humoral immunity is a coordinated 
response carried out by myeloid and lymphoid immune cells, and is an adaptive immune 
response due to the targeting of specific bacterial epitopes. (107)  
Innate antibacterial defense is mediated through immune responses that attack pathogens 
with non-specific mechanisms. The liver synthesizes proteins capable of directly binding to 
bacterial cells, such as complement, making them vulnerable to phagocytosis or 
cytolysis.(108)(109)(110)(111) Phagocytic neutrophils and macrophages express cell surface receptors 
that capture bacterial cell components, or antibodies and complement covering the bacteria, and 
ingest them.(110)(111)(112) Macrophages and neutrophils also secrete antimicrobial peptides and 
proteases at the site of the infection.(110)(112) All of these mechanisms attack a broad spectrum of 
bacterial targets and are not targeting an epitope specific to one strain of bacteria.   
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Neutrophils and macrophages also generate reactive oxygen and nitrogen species 
(RONS) to attack bacterial DNA and bacterial cell wall electron transport targets.(110)(112) 
Neutrophils and macrophages express enzymes that produce RONS(112)(113). These include:        
(i) NADPH oxidase that oxidizes NADPH to NADP and produces the superoxide radical 
(O2·−);(114) (ii) superoxide dismutase that catalyzes the superoxide radical (O2·−) to molecular 
oxygen (O2) and hydrogen peroxide (H2O2);(115) and (iii) myeloperoxidase that catalyses a 
reaction between hydrogen peroxide and chloride (Cl-) to produce the microbicidal hypochlorous 
acid (HOCl).(116) 
H2O2 can freely cross membranes and, therefore, is able to reach phagocytized bacterial 
targets in lysosomes and extracellular bacterial targets.(117) H2O2 mediates DNA damage by 
interacting with intracellular iron to generate neutral hydroxyl radicals (OH·) that damage 
DNA.(118)(119)(120) Myeloperoxidase is transported either intraphagosomally or extracellularly 
where it catalyses the production of HOCl.(112)(121) HOCl chlorinates amines, cytochromes, iron-
sulfur proteins, and other vulnerable components of the bacterial cell wall,(122)(123) such as 
aerobic and anaerobic electron transport systems.(123)   
 Nitric Oxide (NO·) is a reactive bactericidal molecule produced by inducible Nitric 
Oxide Synthase (iNOS2).(124) iNOS2 is a cytokine inducible enzyme that produces NO· by the 
oxidization of L-arginine.(124) NO· is capable of diffusing across membranes to directly attack 
bacterial DNA and other intracellular targets.(125) NO· molecules may interact with other RONS 
to mediate attacks on bacterial targets.(124) One example of this occurs when diffused NO· 
combines with (O2·−) and generates peroxynitrite (ONOO–),(126) which occurs without enzymatic 
catalysation. Modifying RONS and combinations of RONS create a much broader range of 
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microbicidal activity against many different strains of bacteria.(124) NO· and peroxynitrite attack 
DNA by deaminating nucleobases and generating abasic sites.(127)(128)(129) Peroxynitrite 
inactivates bacterial proteins with iron and sulfur clusters.(130)(131) Amino acid residues cysteine 
and tyrosine are also targets of peroxynitrite mediated damage.(129) 
Bacteria have sophisticated mechanisms in place to combat RONS and repair the damage 
they inflict. Bacteria express various classes of peroxiredoxin enzymes that oxidize a cysteine 
residue in their active site to sulfenic acid and this enzymatic action reduces peroxides, 
specifically H2O2 into 2 H2O molecules.(132)(133) The active site is then reset by the reduction of 
other proteins or molecules, depending on the peroxiredoxin’s class.(132) Class II peroxiredoxins 
restore their active site by reducing thiols, primarily glutathione.(132) Bacteria express various 
classes of catalases that rapidly degrade H2O2 into 2 H2O + O2.(134)(135) Bacteria also express 
superoxide dismutases that scavenge (O2·−) and convert it into H2O2.(136) Superoxide dismutases 
activity increases the H2O2 levels that the bacteria are exposed to, but decrease the level of 
(O2·−). This strategy relies on catalases and peroxiredoxins to metabolize the H2O2 into water. 
Depleting (O2·−) also prevents the generation of other RONS, primarily peroxynitrite.(136) 
Bacterial expression of glutathione and similar enzymes mitigate NO· mediated damage.(124) 
Bacteria that express high concentrations of glutathione are resistant to NO· derived damage 
when compared to bacteria expressing low levels of glutathione.(124)  
Bacteria mitigating the effects of RONS also involve enzymatic DNA repair pathways. 
MGMT is conserved from bacteria to humans, reversing the O6mG lesion.(137) The BER pathway 
is essential for bacteria to reverse NO· derived deamination damage.(138) To overcome the many 
defenses employed by bacteria that counteract RONS, it is necessary for host phagocytic cells to 
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generate RONS species in massive amounts. The caveat to producing elevated levels of RONS is 
that this makes normal host cells at the site of the inflammation vulnerable to the same damage 
that is intended to eliminate the infectious bacteria.  
1.6.5 Bacterial Inflammation Induced by DSS Treatment Modulates Carcinogenesis 
As discussed in section 1.3.2., tumor promoters do not directly damage DNA or result in 
mutations, but they induce inflammation and specifically induce RONS.(44) The effect of DSS 
treatment seems to generate two inflammatory immune events. The DSS itself causes a severe 
disruption of the colonic epithelium, leading to the localization of commensal bacteria into the 
subepithelial breaking natural tolerance. This then forces the initiation of an antibacterial 
immune response and delays the repair of the epithelium.  
 Since dextran is a bacterial derived polymer of glucose, it is reasonable that it would be 
detectable by one of the many phagocytic cell’s surface receptors. Also, DSS only promotes 
colonic carcinogenesis when mice are treated with a selective molecular weight range of the 
polymer, 36kD-50kD.(139) Other molecular weights of the DSS polymer only induce mild 
inflammation or no inflammation in the colon.(139) DSS may interact with bacterially synthesized 
fermentation products that configure the dextran polymers into an inflammation initiating 
structure.(140)  
Why does DSS induce oncosis in tissue resident phagocytes that disrupts the colonic 
epithelium? Why does mucus secretion decrease after DSS exposure? The pathogenic effect of 
DSS on the colonic epithelium develops independently of the commensal microflora, however 
the effect of DSS treatment on the development of colitis and carcinogenesis is not independent 
of the microbiota. Innate  
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Treatment of germ-free mice with DSS drastically enhances the effect of the DSS. Germ-
free IQI/Jic mice treated with 5% DSS experienced a severe pathology that lead to mortality, 
while conventional mice were able to tolerate the 5% DSS treatment.(141) Yet, no evidence of 
colitis was seen in the histology of the colonic epithelium in the mice that died.(141) A 1% DSS 
dose was tolerated by both germ-free and conventional mice, yet the germ-free animals 
developed severe colitis 14 days after the DSS treatment ended.(141) As previously described in 
section 1.5.2., DSS treatment has a pronounced dose effect. Apparently, the presence of colonic 
bacteria ameliorate the DSS treatment in a protective manner. Rose et al., in an experiment not 
considering bacterial composition, reported that 7 days after a 1% DSS treatment had ended in 
WT B6 mice the colon had completely recovered from the DSS treatment.(142) This finding 
contrasts with the results of the Kitajima et. al. study. Maslowski et. al. reported exacerbated 
DSS induced inflammation in germ-free B6 mice at 4% DSS treatment.(143) Interestingly, this 
outcome was ameliorated by reintroducting gut microbiota from conventional mice to the germ-
free mice.(143) 
One of the common pathologies seen in human patients with IBD is the dysbiosis of the 
commensal flora.(144) Microbial dysbiosis resulting from DSS treatment may exacerbate the loss 
of natural tolerance for commensal flora. Microbial dysbiosis is also likely to prevent the 
reestablishment of natural tolerance, prolonging the antibacterial proinflammatory response. 
Bacterially fermented short chain fatty acids (SCFAs) are physiological signaling molecules to 
various cell receptors.(145)(146) SCFA signals are capable of modulating anti-inflammatory 
immune cells and their functions, including inducing Il-10 expression.(147)(148) Dysregulating the 
normal SCFA expression could partially explain the chronic inflammation in colitis morbidity.    
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While the presence and composition of commensal microflora can ameliorate DSS 
damage, defining the effect on cancer promotion is obscure. Specific pathogen free B6 mice 
treated with antibiotics prior to the induction of colon carcinogenesis with an AOM+DSS 
treatment were resistant to tumor development as compared to the WT control mice.(149) 
However, germ-free B6 mice had a much higher tumor multiplicity and more extensive tumor 
growth in comparison to specific pathogen free B6 mice after AOM+DSS treatment.(150)  
Il-10-/- B6 mice develop colitis spontaneously without DSS treatment.(151) If treated with 
AOM, the Il-10-/- B6 mice develop colon tumors.(152) However, germ-free Il-10-/- B6 mice do not 
develop colitis or any other immune response.(151) Therefore, germ-free Il-10-/- B6 mice can be 
reconstituted with a specific bacterial flora and then treated with AOM, to determine the tumor 
initiating effect of a bacterial strain.(152)  
The tumor promoting activity of reagents such as DSS is strongly associated with the 
generation of RONS. It is assumed the RONS resulting from DSS treatment is generated purely 
as a bactericidal innate immune response. The inadvertent RONS mediated damage to the 
epithelial cells, that causes mutagenic DNA damage and cytotoxicity, is what is thought to 
potentiate cancer development. However, the cancer potentiation associated with RONS could 
actually be the result of the physiological signaling that these small molecules mediate.  
A study by Ahmad et. al., showed that the expression of multiple cytokines/chemokines 
were upregulated in WT B6 mice treated with DSS.(383) The investigators reported that the 
expression of iNOS in macrophages supported that these cells were polarized into their pro-
inflammatory M1 phenotype (discussed in section 3.1).(288)(383) The results support the 
involvement of the innate immune cells in generating significantly high levels of RONS. 
Interestingly, the caludin-2 overexpressing transgenic mice in the study by Ahmed, et. al. were 
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resistant to DSS induced inflammation and showed increased anti-inflammatory adaptive 
immune Treg cell activity (discussed in section 3.1).(320)(321)(322)(323)(383) While these investigators 
identify iNOS as pro-inflammatoy, NO· is capable of regulating the expression of immune 
mediators that produce both pro and anti-inflammatory effects.(153)(154)(155)(156)(157)(158) 
Beyond the inducible isoforms of NOS, there are several constitutively expressed 
isoforms found in various tissues, which generate NO· involved in signaling pathways that 
maintain tissue homeostasis.(156) The concentration of RONS in an inflammatory environment 
impacts how signals are transduced, with high RONS concentrations shifting immune cells 
toward anti-inflammatory functions.(157)(158) NO· signaling plays a role in regulating the 
expression of anti-inflammatory cytokines IL-4, IL-13, TGF-beta, and IL-10.(158) Surgical 
lacerations in the abdomen of female Balb/c mice treated with a NOS inhibitor exhibit aberrant 
and delayed wound contraction and repair when compared to the lacerations made in the 
untreated control mice.(159) The role of RONS in tumor promotion cannot be simply be attributed 
to cytotoxicity and the potential mutagenic DNA damage resulting from high concentrations of 
RONS generated to eliminate bacteria.  
1.7 AOM+DSS 
1.7.1 The Genetic Background of a Mouse Strain Modulates the Strains Response to 
AOM Treatment alone or combine with DSS Treatment 
Different strains of mice exhibit different susceptibilities to colon cancer initiation with AOM 
treatment. Treating some mouse strains with several doses of AOM will induce colon cancer 
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development.(160)(161)(162) In these mouse strains AOM acts as complete carcinogen.(44) In a study 
treating various strains of mice with the same AOM dosing regimen, the mice were classified as 
highly susceptible, moderately susceptible, and resistant.(160) With resistant mouse strains not 
developing tumors after the same AOM treatment.(160) Balb/c mice are moderately susceptible to 
AOM induced colon cancer, while B6 mice are resistant when treated with the same AOM 
dosing regimen. 
Mouse strain’s exhibit different susceptibility to AOM treatment.(163) Therefore knowing 
a mouse strain’s susceptibility is crucial to utilizing either AOM or AOM+DSS for the colon 
cancer induction treatment. Most animal studies require a transgenic or a gene knockout 
animal,(163) and many gene knockouts are only available in the B6 background. The B6 mouse 
strain is resistant to colon cancer induction with AOM treatment.(163) However, while B6 mice 
are resistant to AOM treatments used to induce colon cancer they are susceptible to a combined 
treatment of AOM+DSS.(164)  
It is not understood why some genetic backgrounds of the inbred mouse strains are 
resistant to AOM treatments to induce colon tumors. Cross breeding a resistant mouse strain with 
moderately susceptible strain will lead to an increased susceptibility to AOM treatments in the 
hybrid mouse strain compared to the resistant background strain.(162)(165) This implies a genetic 
component to the resistance in some mouse strains, and the resistance may not be a dominate 
genetic factor.  
It is also unclear why mouse strains resistant to AOM treatments used to induce colon 
cancer are susceptible to a combined AOM+DSS treatment. Strain differences have also been 
observed in response to AOM+DSS treatments.(164) Balb/c mice show an increased incidence and 
significantly greater tumor multiplicity after a AOM+DSS treatment in comparison to B6 
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mice.(164) However, it is unlikely the strain differences to AOM or AOM+DSS treatments are due 
to differences in commensal flora. As different studies with animals purchased from different 
suppliers and housed in different facilities still report the same resistance and susceptibility in the 
various mouse strains.  
1.7.2 AOM Treatment must be closely followed by Treatment with DSS to Induce Colon 
Cancer  
The order in which the tumor initiator and promoter are administered is critical to the efficacy of 
model. Mice must be treated with one AOM dose followed within a few days by a DSS treatment 
to induce colon cancer.(45) A commonly employed effective timecourse for an AOM+DSS 
treatment is to dose the mice with AOM and wait for one week, then treat the mice with DSS for 
5 to 7 days. Treating mice with AOM in the middle of a DSS treatment yields a very low tumor 
incidence,(45) well below the incidence observed when the reagents are administered in the 
optimal order. Mice treated with DSS and then treated with AOM, either one day or one week 
after the DSS treatment ends, did not develop colon tumors.(45) Mice treated with one dose of 
AOM do not have any incidence of colon tumors.(45) Mice treated with one week of DSS do not 
develop colon tumors.(45)   
1.7.3 Basic research questions  
Why is the order of the AOM+DSS treatment and timecourse so inflexible to effectively induce 
colon cancer in mice? This could imply two separate effects of the mutagen and the 
inflammatory promoter, effects that must follow one another. Tumor promoters are not 
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mutagenic, yet the cancer promoting effect of DSS treatment is commonly associated with 
inadvertent cytotoxicity and mutagenesis resulting from RONS generated in response to bacterial 
infection. Is the DSS acting as a mutagen in a similar manner to the AOM and, if it does, then 
why is the AOM necessary for the models efficacy?  
The immune system response to AOM+DSS treatment factors into every aspect of the 
model. The AOM treatment leads to apoptosis, and likely necrotic cell death, and then tissue 
repair to counter the sudden and rapid loss of colonic epithelial cells. Tissue damage from DSS 
treatment is likely initiated by depleting tissue resident macrophages, and involves immune cells 
from initiation until resolution, while promoting cancer development through an unknown 
interplay of cellular signaling and responses. Do immune cells impede or enhance 
carcinogenesis? Which immune cells could be involved in mediating the promotion of cancer?  
 The AOM+DSS model of colon cancer induction is utilized exclusively as a combine 
treatment in experimental studies. We will attempt to break the model into its individual 
components to assess the effect of each agent on the colonic epithelium and colon cancer 
development. We will also attempt to dissect the role of the immune response as either a source 
of mutations, or cell mediated pro-survival signaling, that would circumvent apoptotic induction. 
This would inadvertently lead to the survival of stem cells with mutations, that are capable of 
producing a population of cells that potentially would develop into cancer. 
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2.0  MUTAGENESIS STUDY 
2.1 SCOPE AND SYNOPSIS 
Chapter 2 presents the results and discussion of the mutagenesis study. The chapter is divided 
into three sections. The first section is an introduction to the study and provides new material 
that supports the relevance of the basic research questions and concludes by clearly stating the 
basic research aim and an overview of the experimental method. The second section of Chapter 2 
outlines the significance of the study, the experimental design, the important details of the 
enzyme histochemistry assay and the statistical analyses. The experimental data and results 
tables are then presented. The third section presents a summary of the experimental results and 
then a discussion of those results, including possible explanations and interpretations.       
2.2 INTRODUCTION 
Elucidation of the etiology of human colon cancer remains a difficult challenge facing medical 
science. Certain colon cancer cases are the result of an inheritable genetic risk factor, and the 
most well characterized of these is familial adenomatous polyposis (FAP).(166) FAP is the result 
of an adenomatous polyposis coli (APC) mutation in the Wnt signaling pathway that regulates 
the phosphodegradation of the transcription factor beta-catenin.(167) However, hereditary colon 
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cancer cases represent approximately 5% of the total number of colon cancer cases,(166) while the 
vast majority are sporadic cancer cases. A tissue associated chronic inflammatory disease 
significantly increases an individual’s chances for developing cancer.(1) The onset of the chronic 
inflammatory disease ulcerative colitis is a high risk factor for developing a sporadic colon 
cancer.(1)    
In well characterized two-stage models of cancer induction, both in the skin and intestinal 
epithelium, treatment with an inflammatory agent is required to potentiate cancer 
development.(44) It is unclear exactly how inflammation potentiates cancer development, but 
tumor promoting reagents induce the expression of radical oxygen and nitrogen species (RONS) 
from phagocytic immune cells.(44)(112) A commonly employed two-stage colon cancer induction 
model treats mice with azoxymethane (AOM),(45) a reagent that acts as the mutagenic tumor 
initiator,(44) and dextran sulfate sodium(DSS) which induces acute and chronic colonic 
inflammation.(44)(45)  
Treatment with AOM is mutagenic and cytotoxic as a result of creating substantial DNA 
alkylation damage,(49)(50)(51) as discussed in section 1.4. AOM is metabolized by enzymes into its 
DNA alkylating active metabolite(58)(60)(61)(62)(Figure 12). The primary mutagenic DNA 
alkylation lesion generated by an AOM treatment is O6-methylguanine (O6mG)(51)(55)(56)(Figure 
11). DNA lesions generated by AOM are cytotoxic by blocking DNA replication that induces 
apoptosis.(51)(52)(53) 
AOM can both initiate and promote colon cancer in some inbred mouse strains, 
(160)(161)(162) acting as a complete carcinogen,(44) as discussed in section 1.6.1. While other inbred 
strains of mice are resistant to AOM treatment as a complete carcinogen.(163) The susceptibility 
or resistance seen to AOM treatments acting as a carcinogen highlights how significantly the 
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different inbred mouse strains vary genetically. AOM is desirable to utilize as a sporadic colon 
cancer initiator for its ease of administration, for the reproducibility of AOM treatments, and its 
colon specific organotropism.  
To conduct a sporadic colon cancer study utilizing the B6 inbred mouse strain and 
employing AOM as the mutagenic initiator requires that the mice are treated with DSS,(164)(167) as 
the mice of the B6 genetic background are resistant to treatment with AOM alone.(163) The 
adverse effects of DSS treatments on mice are discussed in section 1.5. DSS treatments are easily 
administered and the outcomes of the treatments are reproducible, once the dosing has been 
optimized to account for strain related morbidity and possible mortality.(167)  
AOM+DSS treatment renders B6 mice susceptible to colon cancer induction, 
circumventing the B6 strain resistance to AOM treatments. So long as the mice are treated with 
AOM first, followed shortly afterward by the DSS treatment in a very precise timecourse(45) as 
discussed in section 1.6.2. Treatment with DSS leads to the onset of inflammation and colitis in 
mice, with a very similar pathology to colitis morbidity in humans as determined by histological 
assessment.(84)  
What is the role of inflammation as a tumor potentiating mechanism? DSS initiates 
inflammation and colon mucosal damage by inducing cell mediated oncosis in colon tissue 
resident macrophages,(84)(85)(87)(88) as discussed in section 1.5.3. Through this effect DSS 
treatments disrupt cell-cell tight junction adhesion proteins that link epithelial cells together and 
to the tissue resident immune cell populations integrated into the epithelium.(97)(98)(99) By 
disrupting the mucosal barrier commensal microflora are subsequently freed to migrate into the 
underlying mucosal regions that were previously inaccessible, breaking the natural tolerance that 
was established with the microbiota.(33)(93)(95) The proinflammatory signaling caused by the 
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oncosis of tissue resident macrophages following their uptake of DSS molecules,(84)(85)(88)(90) and 
the basolateral detection of bacteria by enterocytes through toll-like receptors in the subepithelial 
regions of the colon,(88)(90) engages the immune system response.  
The initiation of the innate anti-bacterial immune response will cause an influx of 
myeloid linage phagocytic cells,(110) as discussed in section 1.5.4. Monocytes, which are the 
myeloid linage precursors of macrophages and dendritic cells, and neutrophils express enzymes 
specifically to generate RONS intended to attack bacterial DNA and bacterial cell wall electron 
transport targets.(110) Among the most important bactericidal RONS are; the superoxide radical 
(O2·−), hydrogen peroxide (H2O2), nitric oxide (NO·), and peroxynitrite (ONOO–), which is a 
spontaneous non-enzymatic combination of (O2·−) and NO·.(114)(115)(124)(126) These small 
molecules diffuse across non-polar plasma membranes and attack intracellular bacterial DNA 
and proteins and also target cell wall aerobic and anaerobic respiratory proteins.(117)(125)(129)(130) 
Innate antimicrobial responses to bacterial infections produce high concentrations of RONS to 
eliminate the pathogens,  placing normal healthy cells near the inflammatory environment at risk 
of exposure to significantly elevated levels of RONS.(168) Colonic epithelial cells are placed in 
exactly that scenario after DSS treatment is initiated.  
All aerobic organisms are exposed to endogenously generated intracellular RONS.(168)(169) 
In mammalian cells, reactive oxygen species (ROS) are produced mainly in the mitochondria as 
a result of the normal metabolism of cellular oxygen.(170)(171) NO· is also produced in 
mitochondria and, therefore, so is endogenous peroxynitrite.(172)(173) Mammalian cells eliminate 
intracellular RONS by multiple antioxidant mechanisms, and these mechanisms maintain a 
homeostatic balance with the endogenously generated RONS levels to prevent cellular 
damage.(174)(175) Mammalian cells express catalases, peroxiredoxins, and super oxide dismutases, 
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as well as other antioxidant enzymes to eliminate RONS.(176)(177) The enzyme functions have 
been conserved from the bacterial isoforms of the enzymes, the antioxidant enzyme mechanisms 
of action are discussed in section 1.5.4.  
Oxidative stress is a term used to describe a state in which the intracellular RONS levels 
exceed a mammalian cell’s ability to detoxify the RONS. Excessive H2O2 damages DNA by 
reacting with intracellular iron to generate neutral hydroxyl radicals (OH·), which then reacts 
with purine and pyrimidine bases.(178) In vitro, at least 20 oxidized DNA bases have been 
identified,(168)(169) although some may not occur in vivo. Of these oxidation lesions, 8-
oxoguanine (8-hydroxyguanine) is considered highly significant, and measuring 8-oxoguanine 
levels is used as a marker of the overall ROS damage occurring in a tissue.(168)(178) Unrepaired 8-
oxoguanine lesions are mutagenic by creating G>T and A>C nucleobase transversions.(179) 8-
oxoguanine is also mutagenic at the site of the lesion as polymerases insert adenine and not 
cytosine in the newly polymerized DNA strand opposite the lesion.(180) Reactive nitrogen species 
(RNS) arising from NO· modifications deaminate DNA bases causing abasic sites and DNA 
strand breaks.(181)(182) The subsequent polymerase detection of this DNA damage activates 
enzymatic DNA repair that can induce apoptosis.  
Proteins are also targets of RONS mediated damage and can act as indirect mutagenic 
agents. Amino acids, both free and incorporated into proteins, are targets of oxidative 
damage.(183) RONS oxidized DNA polymerases can have diminished fidelity for incorporating 
the correct DNA bases into a newly polymerized DNA strand and create mutations.(168) Oxidized 
amino acids in DNA repair proteins can cause the failure to repair DNA damage and force a cell 
into apoptosis.(168)  
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The peroxidation of lipids is another indirect mutagenic initiator. Lipid peroxidation 
resulting from RONS degrade lipids into carbonyl products, such as malondialdehyde 
(MDA).(184) MDA, which is both electrophilic and nuertophilic, can react with DNA to from 
adducts.(185)(186) MDA-guanine lesions lead polymerases to insert G>A transitions and G>T 
transversions with equal frequency to the correct G>C pairing.(187) MDA lesions are repaired by 
the nucleotide excision repair pathway.(187)  
Alkyladenine-DNA glycosylase (Aag) is a mammalian DNA base excision repair (BER) 
enzyme that is required for the identification and removal of some RONS generated DNA 
adducts.(188) Aag recognizes and initiates BER repair of lipid peroxidation adducts 1,N2-
ethenoguanine and 1,N6-ethenoadenine, but Aag also has a broad specificity of adduct targets 
generated by deamination.(188)(189)(190) Aag also repairs the 3-methyladenine adduct generated by 
AOM treatment,(53) as discussed in section 1.4.5.  B6 mice deficient for Aag-/- showed increased 
tumor multiplicity and more severe inflammation when compare to WT B6 mice after 
AOM+DSS treatment.(188) The inflammation score was used to assess the severity of the tissue 
inflammation.(188) Alkbh2 is a mammalian DNA repair enzyme that repairs lipid peroxidation 
generated DNA and RNA adducts 1,N6-ethenoadenine and 3,N4-ethenocytosine.(191)(192) B6 mice 
deficient for Alkbh2-/- showed increased tumor multiplicity and more severe inflammation when 
compare to WT B6 mice after AOM+DSS treatment.(192) In the same study B6 mice deficient in 
both Aag-/- and Alkbh2-/- also showed increased tumor multiplicity and more severe inflammation 
when compare to WT B6 mice after AOM+DSS treatment.(192) These studies demonstrated that 
mice deficient in DNA repair enzymes necessary to eliminate oxidative DNA adducts have an 
enhanced susceptibility to cancer development. These studies also suggest that unrepaired DNA 
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adducts lead to the accumulation of mutations, and further implying that DSS treatments are 
mutagenic through RONS mediated damage. 
Three different studies examining colon cancer induction by AOM+DSS treatment in 
mice deficient for MGMT-/- and Msh6-/- (mutS homolog 6), Aag-/-, and Alkbh2-/- DNA repair 
enzymes demonstrated that DNA repair reduces colon cacner;(55)(192) as all of the DNA repair 
enzyme deficient strains of mice had a significantly higher tumor incidence and multiplicity than 
the WT control mice.(55)(192) Understanding how successful DNA repair relates to cancer 
susceptibility is essential scientific knowledge, but it remains unclear how this knowledge relates 
to carcinogenesis in WT mice and in humans? The overwhelming number of cancers occur in 
humans that have normal DNA repair enzyme activity.  
The generation of significantly elevated levels of RONS in mammalian tissues resulting 
from combating infections and other disease morbidity, epidermal exogenous exposure to 
ionizing UV radiation, and ingested drugs and other chemical agents, would seem to represent an 
insurmountable obstacle to preventing tissue destruction and/or carcinogenesis. However, these 
RONS generating insults, while occurring infrequently, are not unique or even rare events. Even 
chronic inflammatory diseases, that cause oxidative stress, do not immediately lead to an 
increased cancer risk. For example, ulcerative colitis does not increase cancer risk for 8-10 years 
after its onset in patients.(193) 
Mitochondrial DNA is at even greater risk than nuclear DNA to oxidative stress, as 
mitochondria already generate substantial levels of RONS endogenously.(178)(194) However, 
mitochondrial DNA repair mechanisms are the same as the nuclear DNA repair mechanisms, 
since mitochondrial DNA repair enzymes are encoded in the nuclear DNA.(194)(195) Mammalian 
cells express a BER glycosylase family specifically to remove 8-oxoguanine oxidation lesions 
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from DNA.(196)(197) Also, mammalian cells protect their intracellular components with several 
classes of antioxidant enzymes that utilize multiple mechanisms to eliminate RONS species, as  
was previously discussed. The innate immune system would not utilize an anti-pathogenic 
mechanism based on the generation of excessively high RONS levels without cellular 
mechanisms in place to prevent tissue damage and carcinogenesis. However, inflammation and 
the subsequent generation of RONS is strongly associated with carcinogenesis as RONS is 
produced by tumor potentiating inflammatory reagents. 
In the AOM+DSS two-stage colon cancer induction model, treatment with one dose of 
AOM followed by one treatment with DSS leads to a high incidence of tumors in several 
different strains of mice.(164) However, treating mice with one dose of the mutagen AOM does 
not induce colon tumor development.(45) Even in inbred mouse strains susceptible to AOM 
treatments, it requires multiple doses to induce colon tumor development,(160)(161)(162) as discussed 
in section 1.6.1. One treatment with DSS does not lead to colon cancer development.(45) Twenty-
five CBA/J mice treated with nine treatments of 3% DSS, resulted in tumor incidence in twelve 
of the mice.(198) While this DSS treatment regimen resulted in a 50% tumor incidence, the DSS 
concentration was high compared to the DSS concentrations needed to induce colon tumors in 
AOM+DSS studies, and number of DSS treatment cycles was uncommonly high. Meira et. al. 
treated ten WT B6 mice with five treatments of 2.5% DSS and induced two colon tumors.(188) In 
the same paper they treated a separate set of seven WT B6 with seven cycles of 2.5% DSS and 
did not observe any colon tumors.(188) The DNA repair deficient B6 mice were more susceptible 
to tumor induction with a DSS treatment, after seven cycles of 2.5% DSS treatment seven out of 
eighteen Aag-/- deficient B6 mice showed tumor incidence.(188) These studies clearly indicated 
that oxidative stress is leading to RONS derived DNA damage, and the DNA repair deficient B6 
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mice are more susceptible to oxidative lesions inducing cancer than the WT B6 mice. However, 
even at high DSS concentrations and multiple cycles of DSS treatment there is little to no 
carcinogenic effect on the WT B6 mice. The duration and severity of the DSS treatments 
required to induce a low tumor incidence in the WT B6 mouse strain suggests that DSS is a poor 
mutagenic agent, yet still possesses a high efficacy as a tumor potentiating agent. 
The AOM+DSS treatment makes it impossible to compare the effect of the two 
individual reagents separately in a study. Few studies have dissected the model to attempt to 
understand the individual effect of the AOM and the DSS treatments, only focusing on the 
combine effect of the treatment. Here, we propose to study the mutagenic and cytotoxic effect of 
the AOM treatment, the DSS treatment, and the combine AOM+DSS treatment that is necessary 
to induce colon cancer development. 
The critical initiating event in cancer cell development is the fixation of a mutation in a 
somatic cell’s genome. The mutation must occur in or affect the function of an oncogene or 
tumor suppressor gene. To fix a mutation into the genome of a cell requires several mutually 
exclusive events to occur. A DNA damaging agent must interact with a cell’s DNA to generate a 
potential mutagenic adduct that must not be repaired. Then the cell must undergo cell division 
and during DNA replication the polymerase must make an error in the base pairing where the 
newly polymerized DNA strand would acquire the mutation. All of this must occur without the 
cell undergoing apoptosis. While there is a very low probability of all of these events occurring, 
the cancer incidence seen in the human population is quite high and cancer risk increases with 
age. 
The measurement of DNA adduct levels in colon tissue has been associated with cancer 
incidence, as DNA damaging lesions are mutagenic initiators.(199)(200) The measurement of DNA 
 65 
adducts in the colon requires the tissue be excised and homogenized to extract the total DNA for 
analysis. While measuring potentially mutagenic DNA adducts levels does correlate high adduct 
levels to an increased risk of colon cancer development, it does not allow for analysis of actual 
mutations generated. An adduct generating a fixed mutation in a somatic cell’s DNA is a low 
probability event. The rational for measuring adduct levels is that high adduct levels overwhelm 
a cell’s ability to mitigate the DNA damage, increasing the probability that a mutation will be 
generated; as mice deficient in the DNA repair of oxidative lesion and mice deficient in the 
repair of AOM generated methyl adducts are more susceptible to colon cancer incidence. 
(55)(188)(192) 
In contrast to measuring DNA levels, it is possible to study the generation of actual 
mutations formed in vivo. The glucose-6 phosphate dehydrogenase (G6PD) gene is a 
constitutively expressed X-linked gene with several hundred known mutations caused by various 
DNA damaging agents. G6PD is the rate-limiting enzyme in the synthesis of pentose phosphates, 
and is a critical antioxidant by supplying NADPH that is used against ROS generated lipid 
peroxidases and in reducing H2O2 levels.(201) G6PD mutations are also non-lethal to a cell. A 
enzyme histochemisrty assay allows for the measurement of colonic epithelial crypts completely 
populated by G6PD mutant cells.(202)(203) This assay measures the number of colonic stem cells 
that fixed a somatic G6PD mutation, avoided apoptotic induction, and continued to undergo cell 
division and generate progeny. 
We propose to study the generation of somatic stem cell mutations by treating mice with 
AOM, DSS, and AOM+DSS treatments. By measuring colonic crypts in male mice deficient in 
G6PD activity, we will ascertain the mutagenic potential of AOM, DSS, and AOM+DSS. We 
will treat both WT B6 mice and T-cell receptor (TCR) α/β deficient B6 mice in this study. The 
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purpose of using the α/β T-cell deficient mice is to impair both pro-inflammatory and anti-
inflammatory immune cell response. We will ascertain if the immune response supports or 
impedes the fixation of colonic somatic stem cell mutations. The animals in this study are the 
same mice in the carcinogenicity experimental group 5 presented in Chapter 3. Therefore, no 
other strains of mice, either WT or genetically modified, were incorporated into this study. Also, 
no other analysis of the effect of the microflora composition on carcinogenesis were performed 
for this work.  
As previously discussed, the pro-inflammatory immune response is associated with 
cancer development. However, anti-pathogenic immune responses lead to cytotoxicity and do 
not support cell survival. Anti-inflammatory immune cell mediation resolves pro-inflammatory 
events and is a component of tissue repair and regeneration. As discussed in section 1.5.5., the 
potential role of RONS and the immune response in potentiating cancer may actually involve 
enhancing stem cell survival and proliferation.   
In applying AOM, DSS, and AOM+DSS treatments to the WT B6 mice and α/β T-cell 
deficient B6 mice, we predict to see greater numbers of G6PD deficient colonic crypts in the 
AOM+DSS treated mice. Only the AOM+DSS treated mice will develop colon cancer.(45) We 
also predict to see greater numbers of G6PD deficient colonic crypts in the WT mice in 
comparison to the α/β T-cell deficient mice, if the role of T-cells is potentially mutagenic or 
enhancing cell survival. If the role of the T-cells is purely related to eliminating potential tumor 
cells, then we would predict greater numbers of G6PD deficient colonic crypts in the α/β T-cell 
deficient mice in comparison to the WT mice, due to the loss and/or impairment of α/β T-cell 
mediated cytotoxicity. 
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2.3 DATA 
2.3.1 Mice Strains and Treatment Groups Studied 
Male (B6) WT mice and TCRβ-/- mice were divided into four treatment groups. Untreated 
controls (administered PBS), 10 mg/kg AOM, 2% DSS, and combine 10 mg/kg AOM + 2% 
DSS. The presentation and analysis of each of these results and a summary of the combine 
results, which includes comparisons of the treatments effects on each of the strains, are presented 
in this section. 
2.3.2 Significance of the Method for Studying G6PD Mutations 
The G6PD mutation assay allows for the in vivo detection of somatic stem cell mutations. 
Mutations in G6PD are only one of many mutations that can occur after treatment with AOM. In 
relation to carcinogenesis, mutations occurring in oncogenes or tumor suppressor genes are 
likely the critical targets. However, measuring G6PD activity allows for an estimation of the 
incidence of random somatic mutations in colonic stem cells without any selection pressure. 
Therefore, mutations in G6PD provide a conservative estimation of the random gene mutations 
that arise from AOM treatment. The G6PD assay also allows for comparisons of the effect of the 
AOM and AOM+DSS treatment on mutagenesis between WT mice and different strains of gene 
knockout mice.  
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2.3.3 G6PD Deficient Mutant Crypts 
Figure 14.   G6PD Mutant Crypts 
 
 
Figure 14. Representative G6PD mutant crypts in WT mice (a & b) and 
TCRβ-/- mice (c & d) treated with 10 mg/kg AOM + 2% DSS. G6PD deficient 
crypts, and the cells that comprise them, appear transparent or white in contrast 
to the formazan containing “blue” staining crypts. a & c are representative of 
crypts viewed horizontally. b & d are vertically viewed crypts. 
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2.3.3.1  Analysis of G6PD Deficient Mutant Crypts 
The generation of a G6PD mutant crypt requires that a mutation is fixed in the G6PD loci 
in the X chromosome of the male mice. If a newly replicated stem cell, with its G6PD gene 
inactivated, rises to dominate a crypt, all of the progeny cells will also lack G6PD activity. The 
G6PD deficient mutant crypts cannot oxidize glucose-6 phosphate, and cannot reduce nitro blue 
tetrazolium (NBT) into formazan. When the G6PD enzyme is functional, the NBT in the reaction 
mix will be reduced to insoluble formazan and precipitate out of the reaction mixture, 
accumulating at the location of the enzyme and “staining” cells with a deep blue color. Without 
the accumulation of reduced insoluble formazan, the cells will not stain and, therefore, will not 
acquire the deep blue color. Thus, the fully mutant crypts stand out as “white” in a dark blue 
background (Figure 14). The cells on the periphery of the mutant crypts acquire some color as a 
result of the submucosal pericryptal cells and immune cells that comprise the “sheath” 
surrounding the crypt. These cell populations anchor to the basal axis of the epithelial cells, and 
are not derived from the G6PD deficient epithelial stem cell, so these cells will express normal 
G6PD and reduce NBT to formazan. Potential false mutant crypts can occur when the tissue is 
very slightly torn, or in a region where the color of the stain was very light but the crypts are 
normal in appearance. However, these conditions are easy to distinguish from the optimal 
staining regions and were not regarded as G6PD mutant crypts. Another approach used to 
eliminate false mutants was to cut two sequentially located tissue sections and stain them on the 
same slide under the exact same conditions, with the same batch of reaction mix. As the 
sequential sections were only seven microns apart, it is highly probable G6PD mutant crypts will 
be represented in the exact same location on both slides. Hence a true G6PD mutant crypt will be 
identifiable in sequential sections. However, not every section is identical as tissue folds and 
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tears can occur, or the staining may have a poor quality in the region where the mutant crypt is 
located. Regardless, a conservative and consistent characterization of a mutant G6PD crypt in 
consecutive sections reduces the probability of missing a true G6PD mutant or identifying a false 
mutant.  
2.3.4 Animal Treatments, Colon Tissue Harvesting and Preparation for G6PD analysis 
Six WT mice and six TCRβ-/- mice were treated with one i.p. injection of sterile PBS (200 ul) 
and represented the untreated control groups. The AOM treated groups were comprised of twelve 
WT mice and twelve TCRβ-/- mice treated with one i.p. injection of 10 mg/kg AOM. The DSS 
treated groups were comprised of twelve WT mice and twelve TCRβ-/- mice treated with 2% 
DSS for one week. The AOM+DSS treated groups were comprised of twelve WT mice and 
twelve TCRβ-/- mice and were treated with 10 mg/kg AOM + 2% DSS, where the 10 mg/kg i.p. 
injection of AOM was followed one week later by a one week treatment with 2% DSS. The mice 
were then housed for 90 days in the sterile animal facility. The 90 day timecourse was sufficient 
for carcinogenesis based on previous carcinogenicity experiments. This data is presented in 
Chapter 3. However, no mutagenesis studies were conducted on any of the treated animal groups 
except the above mentioned animal groups. Therefore, the 90 day timecourse for the mutagenesis 
analysis was based off of the cancer development data. Upon completion of the timecourse, the 
mice were euthanized and their colons excised, immersed in OCT medium (Tissue-Tek® 
Optimal Cutting Temperature Compound, Ted Pella, Inc., Redding, CA), and frozen on liquid 
N2. Sections were then cut for each animal and stained for G6PD activity. Sections were 
generated until a minimum of 10,000 colon crypts had been observed per animal. Sections were 
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also analyzed for G6PD mutant crypts. Full details of the experimental methods are written in 
Chapter 5. 
2.3.5 Mutation Frequency and Statistical Analysis 
The mutation frequency (M.F.) is the ratio of G6PD mutant crypts observed in the histological 
sections from a mouse’s colon divided by the total number of colonic crypts assessed for that 
mouse’s colon. As it is unlikely any one study would have the time and resources necessary to 
examine all of the colonic crypts in all of the mice used in a study, the M.F. estimates the total 
number of G6PD mutated colonic crypts that would arise in an animal after treatment with a 
carcinogen. Combining the M.F. results for all of the animals in one treatment group will allow 
for the calculation of the average M.F. for that group.  
Calculating the M.F. allows for a statistical analysis of differences within or between 
treated groups of animals. In this study, the t-test was sufficient to perform the statistical analysis 
of the different treated groups of mice. Before statistical comparisons were made, the data sets 
were administered the normality test to show the values of the data followed a Gaussian 
distribution. Also, the F-test for Two Data Sets was used to determine the equality of variances 
between the data sets being compared. All of the data sets satisfied the requirements for the t-test 
to be used to analyze the data. The software used and details of the statistical methods are 
discussed in section 5.  
2.3.6 G6DP mutation assay results summary table 
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Table 1: G6PD Mutation Assay results summary table 
Mouse 
Strain 
(B6) 
Treatment 
Incidence of 
Mutant 
Crypts 
G6PD 
Mutant 
Crypts 
Total # 
Crypts 
Analyzed 
M.F. 
(x 10-4) 
WT solvent 0/6 mice 0 > 105 < 0.02 
TCRβ-/- solvent 0/6 mice 0 > 105 < 0.02 
WT AOM 10/12 mice 43 96821 4.44a,b 
TCRβ-/- AOM 11/12 mice 59 288512 2.04a,c 
WT DSS 0/12 mice 0 133770 < 0.02 
TCRβ-/- DSS 1/12 mice 1 163406 0.06 
WT AOM+DSS 7/12 mice 17 161755 1.05b,d 
TCRβ-/- AOM+DSS 5/12 mice 7 167374 0.42c,d 
a) WT AOM vs. TCRβ-/- AOM (p-0.03749) t-test 
Result: The M.F. is significantly higher in the WT AOM treated group compared 
to the TCRβ-/- AOM treated group.  
b) WT AOM vs. WT AOM+DSS (p-0.0041) t-test 
Result: The M.F. is significantly higher in the WT AOM treated group compared 
to the WT AOM+DSS treated group.   
c) TCRβ-/- AOM vs. TCRβ-/- AOM+DSS (p-0.00039) t-test 
Result: The M.F. is significantly higher in the TCRβ-/- AOM treated group 
compared to the TCRβ-/- AOM+DSS treated group.   
d) WT AOM+DSS vs. TCRβ-/- AOM+DSS (p-0.04878) t-test 
Result: The M.F. is significantly higher in the TCRβ-/- AOM treated group 
compared to the TCRβ-/- AOM+DSS treated group. 
G6PD:  Glucose-6 Phosphate Dehydrogenase   AOM:  Azoxymethane  
DSS:  Dextran Sulfate Sodium    M.F. = Mutation Frequency 
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Table 2.    G6PD M.F. results comparison table 
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2.4  G6PD MUTATION ASSAY RESULTS SUMMARY  
2.4.1.1 Analysis of WT AOM treated mice vs. TCRβ-/- AOM treated mice 
The G6PD M.F. is significantly higher in the WT AOM treated mice when compared to 
the TCRβ-/- AOM treated mice (p-0.037) (Table 1). The immune competent WT mice exhibited 
greater numbers of stem cells that acquired a mutation in the G6PD gene loci during DNA 
replication, avoided apoptotic induction by DNA repair pathways, rose to dominate the stem cell 
niche, and proliferated to produce the epithelial cells of the crypt, when compared to the  TCRβ-/- 
AOM treated mice. The significance of this result indicated that stem cells are more likely to 
replicate with unrepaired DNA alkylation damage when α/β T-cells are viable.  
2.4.1.2 Analysis of WT AOM treated mice vs. WT AOM+DSS treated mice 
The G6PD M.F. is significantly higher in the WT AOM treated mice when compared to 
the WT AOM+DSS treated mice (p-0.0041) (Table 1). It is likely the reduction in the occurrence 
of G6PD mutant crypts is the result of the DSS damage and subsequent tissue repair reducing the 
overall number of crypts in the colon, including crypts with AOM derived mutated stem cells. As 
both the AOM and AOM+DSS treatments were administered to WT mice, which are immune 
competent, the decrease in G6PD mutant crypts cannot be linked to a deficiency in the immune 
response. Nor could consideration be given to expression differences between DNA repair 
enzymes or detoxifying enzymes due to strain differences. As discussed in section 1.5.2, 
treatment with DSS significantly disrupts the colonic epithelial and results in a shortening of the 
colon.(83)(84) In this study mice receiving a DSS treatment always had a reduced the colon length 
when compared to the mice that did not receive a DSS treatment. However, the reduction in 
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colon lengths was not significantly different in the mice that received the DSS treatment in 
comparison to the mice that did not receive the DSS treatment. A discussion of these results will 
be presented in section 2.6. 
2.4.1.3 Analysis of TCRβ-/- AOM treated mice vs. TCRβ-/- AOM+DSS treated mice 
The G6PD M.F. is significantly higher in the TCRβ-/- AOM treated mice compared to the 
TCRβ-/- AOM+DSS treated mice (p-0.00039) (Table 1). As with the WT mice, it is likely that the 
effect of the DSS treatment is the reason for the decreased numbers of the G6PD mutant crypts 
observed in the TCRβ-/- AOM+DSS mice treated when compared to the TCRβ-/- AOM treated 
mice.  
2.4.1.4 Analysis of WT AOM+DSS treated mice vs. TCR β-/- AOM+DSS treated mice 
The G6PD M.F. is significantly higher in the WT AOM+DSS compared to the TCRβ-/-
AOM+DSS (p-0.04878) (Table 1). The p-value is virtually 0.05, indicating that the statistical 
significance is marginal. As previously discussed, it is unlikely that the expression of DNA 
repair enzymes or detoxifying enzymes would be altered in the TCRβ-/- mice when compared to 
the WT mice, and therefore would not explain the significant difference in the G6PD M.F. 
between the two strains of mice. Treatment with DSS reduced the G6PD M.F. in the WT AOM 
treated mice by 75% of the value calculated for the G6PD M.F. in the WT AOM treated mice 
without the DSS treatment. There was an equivalent 75% decrease in G6PD M.F. observed in the 
TCRβ-/- AOM treated mice after treatment with DSS. The decrease of the M.F. in both mouse 
strains by a 75% reduction shows that the effect of the DSS treatment was equivalent on both the 
WT mice and the TCRβ-/- mice.  
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The significant impact of the DSS treatment on the mutagenesis is that it reduced the 
G6PD M.F. Treatment with the inflammatory reagent DSS did not result in an increase in the 
G6PD M.F.; therefore, it did not increase the number of G6PD mutant crypts after the AOM 
treatment. Also, the effect of DSS treatment on the G6PD M.F. did not depend on the immune 
status of the mice. Both the immune competent WT mice and the immune deficient TCRβ-/- mice 
showed the same reduction in their respective G6PD M.F. after the DSS treatment. 
2.4.1.5 Analysis of WT DSS treated mice vs. TCRβ-/- DSS treated mice 
No G6PD deficient mutant crypts were observed in the WT DSS treated mice. One G6PD 
mutant was observed in the TCRβ-/- DSS treated mice. However, this is likely a spontaneous 
mutation and not a result of the DSS treatment.(204) This result is highly significant as the RONS 
produced by the DSS treatment did not cause G6PD mutant crypts in either the immune 
competent or immune deficient mice, although, it is thought that RONS should generate somatic 
stem cell mutations,(178)(179)(181)(183)(188)(192) as discussed in section 2.1. This result strongly 
suggests that the DNA repair of RONS derived oxidative lesions was equivalent in both strains 
of mice. Also, this result strongly suggests that the oxidative stress did not significantly 
overwhelm the cellular repair of RONS derived oxidative DNA damage, and that inflammation’s 
role in carcinogenesis is not due to a mutagenic effect.  
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2.5 DATA TABLES AND RESULTS FOR THE INDIVIDUAL TREATED GROUPS 
Table 3.  WT Untreated Control Mice 
WT B6 Untreated Control Mice 
 
Table 3.       Incidence: No mice had G6PD mutant crypts 
WT B6 
(6) Treatment 
# of G6PD 
Mutant 
Crypts 
Total # of 
Crypts 
Observed 
Mutation 
Frequency 
(M.F.) 
M1 PBS 0 10,000 + n/a 
M2 PBS 0 10,000 + n/a 
M3 PBS 0 10,000 + n/a 
M4 PBS 0 10,000 + n/a 
M5 PBS 0 10,000 + n/a 
M6 PBS 0 10,000 + n/a 
Result:  No G6PD mutant crypts were observed in the WT control mice. 
Treatment:  200 ul PBS i.p. injection. 
G6PD:  Glucose-6 Phosphate Dehydrogenase. 
n/a:  not applicable 
 
 
 
 
 78 
2.5.1.1 Results Summary and Analysis of Table 3, previous page 
There were no G6PD mutant colonic crypts observed in the histology sections generated 
from the WT untreated control mice. Other studies have reported spontaneous G6PD mutants in 
mouse colons at very low numbers, (<0.04 ± 0.02x10-4), that are well below the values observed 
after treatment with a mutagenic tumor initiator.(204) This observation is consistent with other 
reported studies. 
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Table 4.  TCRβ-/- Untreated Control mice 
TCRβ-/- B6 Untreated Control Mice 
 
Table 4.         Incidence: No mice had G6PD mutant crypts  
TCRβ-/- B6 
(6)  Treatment 
# of G6PD 
Mutant 
Crypts 
Total # of 
Crypts 
Observed 
Mutation 
Frequency 
(M.F.) 
M1 PBS 0 10,000 + n/a 
M2  PBS 0 10,000 + n/a 
M3 PBS 0 10,000 + n/a 
M4 PBS 0 10,000 + n/a 
M5 PBS 0 10,000 + n/a 
M6 PBS 0 10,000 + n/a 
Result:  No G6PD mutant crypts were observed in the TCRβ
-/-
 control mice.  
Treatment:  200 ul PBS i.p. injection. 
G6PD:  Glucose-6 Phosphate Dehydrogenase 
n/a:  not applicable 
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2.5.1.2 Results Summary and Analysis of Table 4, previous page 
No G6PD mutant colonic crypts observed in the histology sections generated from the 
TCRβ-/- untreated control mice. 
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Table 5.  WT AOM treated mice 
WT B6 treated with AOM  
 
Table 5.    Incidence: 11 out of 12 mice had G6PD mutant crypts 
WT B6 
(12) Treatment 
# of G6PD 
Mutant 
Crypts 
Total # of 
Crypts 
Observed 
Mutant 
Frequency 
(M.F.) 
M1 AOM 5 10564 4.73e-04 
M2 AOM 5 6422 7.79e-04 
M3 AOM 13 10805 1.20e-03 
M4 AOM 1 5265 1.90e-04 
M5 AOM 2 6368 3.14e-04 
M6 AOM 2 6524 3.07e-04 
M7 AOM 0 6282 0 
M8 AOM 0 8889 0 
M9 AOM 5 9195 5.44e-04 
M10 AOM 5 10640 4.70e-04 
M11 AOM 1 8064 1.24e-04 
M12 AOM 4 7803 5.13e-04 
Totals  43 96821 4.44e
-04 
Results:  43 G6PD mutant crypts were observed in the WT AOM treated mice. 
Treatment:  10 mg/kg b.w. AOM i.p. injection 
G6PD:  Glucose-6 Phosphate Dehydrogenase 
AOM:  Azoxymethane 
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2.5.1.3 Results Summary and Analysis of Table 5, previous page 
Forty-three G6PD mutant crypts were observed in the twelve WT mice treated with 
AOM. There is variability in the distribution of G6PD mutant crypts observed in each WT AOM 
treated mouse. One limitation of the experimental method used to determine the M.F. is that not 
every crypt can be observed due to practical reasons. G6PD mutant crypts can be present in the 
tissue that did not in appear in the tissue sections assessed. Each mouse is likely to have variable 
expression of the enzymes that metabolize AOM, variability in the volume of distribution of the 
AOM active metabolite, and variable expression of DNA repair enzymes. Therefore, it is not 
surprising to observe variability in the numbers of G6PD mutant crypts between the mice.  
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 Table 6.  TCRβ-/- AOM treated mice 
TCRβ-/- B6 treated with AOM  
 
Table 6.   Incidence: 9 out of 12 mice had G6PD mutant crypts 
TCRβ-/-
 
B6  
 (12) Treatment 
# of G6PD 
Mutant 
Crypts 
Total # of 
Crypts 
Observed 
Mutant  
Frequency 
(M.F.) 
M1 AOM 2 20795 9.62e-05 
M2  AOM 11 21574 5.10e-04 
M3 AOM 9 27933 3.22e-04 
M4 AOM 6 22618 2.65e-04 
M5 AOM 0 31952 0 
M6 AOM 2 24786 8.07e-05 
M7 AOM 8 27206 2.94e-04 
M8 AOM 4 28164 1.42e-04 
M9 AOM 5 16795 2.98e-04 
M10 AOM 2 19916 1.00e-04 
M11 AOM 3 20436 1.47e-04 
M12 AOM 7 26337 2.66e-04 
Totals  59 288512 2.04e
-04 
Results:  59 G6PD mutant crypts were observed in the TCRβ
-/-
 AOM treated mice.  
Treatment:  10 mg/kg bw AOM i.p. injection 
G6PD:  Glucose-6 Phosphate Dehydrogenase  
AOM:  Azoxymethane 
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2.5.1.4 Results Summary and Analysis of Table 6, previous page 
Fifty-nine G6PD mutant crypts were observed in the twelve TCRβ-/- mice treated with 
AOM.  
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Table 7.  WT DSS treated mice 
WT B6 treated with DSS 
 
Table 7.         Incidence: No mice had G6PD mutant crypts 
WT B6 
(12) Treatment 
 # of G6PD 
Mutant  
Crypts 
Total # of 
Crypts 
Observed 
Mutation 
Frequency 
(M.F.) 
M1 DSS 0 11914 1.00e-06 
M2 DSS 0 10193 1.00e-06 
M3 DSS 0 11285 1.00e-06 
M4 DSS 0 11395 1.00e-06 
M5 DSS 0 12780 1.00e-06 
M6 DSS 0 11280 1.00e-06 
M7 DSS 0 13881 1.00e-06 
M8 DSS 0 8183 1.00e-06 
M9 DSS 0 14094 1.00e-06 
M10 DSS 0 17224 1.00e-06 
M11 DSS 0 11541 1.00e-06 
Total  0 133770 1.00e
-06 
Results:  No G6PD mutant crypts were observed in the WT DSS treated mice. 
Treatment:  2% DSS in drinking water for seven days. 
G6PD:  Glucose-6 Phosphate Dehydrogenase 
DSS:  Dextran Sulfate Sodium 
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2.5.1.5 Results Summary and Analysis of Table 7, previous page 
There were no G6PD mutant crypts observed in the histology sections generated from the 
WT mice treated with DSS. 
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 Table 8.  TCRβ-/- DSS treated mice 
TCRβ-/- B6 treated with DSS 
 
Table 8.       Incidence: One mouse had one G6PD mutant crypt 
TCRβ-/- B6 
(12)  Treatment 
# of G6PD 
Mutant  
Crypts 
Total # of 
Crypts 
Observed 
Mutation 
Frequency 
(M.F.) 
M1 DSS 0 13464 1.00e-06 
M2 DSS 0 13640 1.00e-06 
M3 DSS 0 15121 1.00e-06 
M4 DSS 0 14737 1.00e-06 
M5 DSS 0 13716 1.00e-06 
M6 DSS 0 11280 1.00e-06 
M7 DSS 0 17208 1.00e-06 
M8 DSS 1 14339 6.97e-05 
M9 DSS 0 14118 1.00e-06 
M10 DSS 0 11767 1.00e-06 
M11 DSS 0 12608 1.00e-06 
M12 DSS 0 11408 1.00e-06 
Total  1 163406 6.1197e
-06 
Results: One G6PD mutant crypts were observed in the TCRβ-/- DSS treated mice.  
Treatment:  2% DSS in drinking water for seven days 
G6PD:  Glucose-6 Phosphate Dehydrogenase 
DSS:  Dextran Sulfate Sodium 
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2.5.1.6 Results Summary and Analysis of Table 8, previous page 
There was one G6PD mutant crypt observed in the histology sections generated from the 
TCRβ-/- DSS treated mice. The one mutant crypt is likely a spontaneous mutant and is unlikely to 
have been generated as a result of the DSS treatment.(204) 
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Table 9.  WT AOM+DSS treated mice 
WT B6 treated with AOM+DSS 
 
Table 9.   Incidence: 7 out of 12 mice had G6PD mutant crypts 
WT B6 
(12) Treatment 
# of G6PD 
Mutant  
Crypts 
Total # of 
Crypts 
Observed 
Mutant  
Frequency 
(M.F.) 
M1 AOM+DSS 2 12879 1.55e-04 
M2  AOM+DSS 0 13862 0 
M3 AOM+DSS 2 10605 1.89e-04 
M4 AOM+DSS 1 12490 8.01e-05 
M5 AOM+DSS 0 16672 0 
M6 AOM+DSS 3 16134 1.86e-04 
M7 AOM+DSS 1 11513 8.69e-05 
M8 AOM+DSS 3 15846 1.89e-04 
M9 AOM+DSS 0 18767 0 
M10 AOM+DSS 0 15456 0 
M11 AOM+DSS 5 13015 3.84e-04 
M12 AOM+DSS 0 4516 0 
Totals  17 161755 1.05e
-04 
Results:  17 G6PD mutant crypts were observed in the WT AOM+DSS treated 
mice.  
Treatment:  10 mg/kg b.w. AOM i.p. injection + 2% DSS in the drinking water for 
seven days 
G6PD:  Glucose-6 Phosphate Dehydrogenase   
DSS:  Dextran Sulfate Sodium    AOM: Azoxymethane 
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2.5.1.7 Results Summary and Analysis of Table 9, previous page 
Seventeen G6PD mutant crypts were observed in the twelve WT mice treated with 
AOM+DSS. The colons of these mice were excised at 90 days after the completion of the DSS 
treatment, so this was clearly not a transient effect caused by the DSS induced tissue damage and 
subsequent tissue repair and regeneration (discussed in section 1.5). Also, most of the WT 
AOM+DSS treated mice had tumors in their colons. This reduced the number of normal crypts 
per slide when compared to the mice that were not treated with AOM+DSS, as dysplastic crypts 
from the tumor tissue were not included in the total counts. No G6PD mutant crypts were 
observed in the tumor tissue. Nor were there any complete G6PD mutant tumors, although these 
have been reported in other studies.(205) 
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Table 10.  TCRβ-/- AOM+DSS treated mice 
TCRβ-/- B6 treated with AOM+DSS 
 
Table 10.      Incidence: 5 out of 12 mice had G6PD mutants 
TCRβ-/-
 
B6   
(12) Treatment 
# of G6PD 
Mutant  
Crypts 
Total # of 
Crypts 
Observed 
Mutant 
Frequency 
(M.F.) 
M1 AOM+DSS 0 11340 0 
M2  AOM+DSS 1 12704 7.87e-05 
M3 AOM+DSS 0 15290 0 
M4 AOM+DSS 2 15331 1.30e-04 
M5 AOM+DSS 1 15696 6.37e-05 
M6 AOM+DSS 1 16928 5.91e-05 
M7 AOM+DSS 2 13441 1.49e-04 
M8 AOM+DSS 0 10898 0 
M9 AOM+DSS 0 13650 0 
M10 AOM+DSS 0 10409 0 
M11 AOM+DSS 0 20540 0 
M12 AOM+DSS 0 11147 0 
Totals  7 167374 4.182e
-05 
Results:  17 G6PD mutant crypts were observed in the TCRβ-/- AOM+DSS treated 
mice.  
Treatment:  10 mg/kg b.w. AOM i.p. injection + 2% DSS in the drinking water for 
seven days 
G6PD:  Glucose-6 Phosphate Dehydrogenase   
DSS:  Dextran Sulfate Sodium    AOM:  Azoxymethane 
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2.5.1.8 Results Summary and Analysis of Table 10, previous page 
Seven G6PD mutant crypts were observed in the twelve TCRβ-/- mice treated with 
AOM+DSS. TCRβ-/- AOM+DSS treated mice also had tumors that further decreased the amount 
of normal crypts. No G6PD mutant tumors, or G6PD mutant crypts within the tumor tissue, were 
observed during the analysis. 
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2.6 CALCULATING THE EFFICIENCY OF THE CONVERSION OF AN O6-
METHYLGUANINE DNA ADDUCT INTO A G6PD MUTATION BY UTILIZING THE 
STEM CELL MUTATION FREQUENCY 
The M.F. is calculated by dividing the number of G6PD mutant crypts by the total number of 
crypts assessed. G6PD mutant crypts arise from stem cells that have fixed a mutation in the 
G6PD gene. Generating a mutation is a complex process that involves multiple cellular pathways 
and events. Studies have used the detection of DNA adducts as a predictor of 
mutagenesis.(199)(200) However, the formation of a DNA lesion does not indicate that a mutation 
will arise as a result of the lesion. 
 Measuring the actual occurrence of a mutation in a marker gene, G6PD, indicates that a 
DNA lesion was effectively converted into an actual DNA mutation. Treating mice with AOM 
produces the pro-mutagenic DNA lesion O6mG in colon epithelial cells,(49)(50)(51) as discussed in 
section 1.4. O6mG levels have been determined in the colon after AOM treatment.(206) Knowing 
the level of colonic O6mG adducts after an AOM dose and calculating the M.F. of G6PD mutant 
crypts allows for an estimation of the efficiency of O6mG adduct conversion into a G6PD 
mutation.  
For a stem cell to fix a somatic mutation several events must occur. The parent stem cell 
must undergo division while harboring a DNA lesion without the lesion being repaired and 
without cell cycle arrest and the subsequent induction of apoptosis.(41)(71)(72)(77) The DNA 
polymerase must insert an incorrect DNA base, or mismatch, across from the DNA lesion.(51) 
While some DNA polymerases, such as translesion synthesis polymerases, exhibit poor accuracy 
in pairing DNA bases during DNA replication,(73)(74) a correct base pairing can still be produced 
despite the presence of the DNA lesion.  
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Assuming that O6mG adducts are the critical lesion in the generation of a G6PD 
mutation,(41)(55)(71)(72)(73)(74) estimating the number of O6mG adducts generated in the colon by a 
10 mg/kg dose of AOM,(206) and knowing the number of possible phenotypic guanine targets in 
G6PD gene loci,(207)(208) an estimation of the efficiency in which O6mG adducts are converted 
into G6PD mutations can be made: 
a) A 10 mg/kg dose of AOM will generate 1.2x105 O6mG adducts per colonic stem cell, 
based on a reported 14 mg/kg dose of AOM producing 78 pmol O6mG/µmol guanine bases in 
the proximal and distal colon of WT B6 mice, and that there are a total of 2x109 guanine 
bases/stem cell.  
b) There are ~400 potential guanine base targets in the G6PD gene loci that could lead to 
a G6PD null phenotype, and this number is based on phenotypic G6PD deficiency studies in 
humans.(207)(208) This makes the odds generating an O6mG adduct at a potential phenotypic 
mutating base in the G6PD gene loci of a stem cell equal to (400 guanine target bases)/(2x109 
total guanine O6mG adducts) = 2.0x10-7. 
c) Multiplying the odds of an O6mG adduct occurring at a phenotypic G6PD mutation 
target base (hit) multiplied by the number of O6mG adducts per stem cell (2.0x10-7 x 1.2x105) = 
2.4x10-2 O6mG adducts at potential phenotypic mutating guanine bases in the G6PD gene 
loci/stem cell. 
d) A million crypts represents a conservative estimate of the number of crypts in the 
mouse large intestine based on the reported value of 1.1x106 crypts in the mouse small 
intestine,(209) and knowing that the mouse colon is ~ one quarter of the small intestine’s 
length.(43) The greater the number of crypts the more colonic stem cells will be present, 
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increasing the number of G6PD phenotypic mutant target bases, and therefore the chance of 
observing a G6PD mutated crypt in the colon increases proportionately. 
e) It is reported there are roughly 5 stem cells per crypt,(30) and multiplying the number of  
O6mG adducts at potentially phenotypic G6PD mutant target bases by in the total number of 
stem cells per colon (2.4x10-2  O6mG adducts at potential mutating sites) x (5x106 stem cells/total 
crypts) = 1.2x105 O6mG adducts at G6PD mutating sites per mouse colon.   
f) If one hundred percent of O6mG adducts at the G6PD mutating sites generated 
phenotypic mutations, then 1.2 x105 G6PD mutant crypts would be expected to be observed in 
the colon. 
g) The observed G6PD M.F. in the WT AOM treated mice was 4.4 x10-4. Multiplying the 
G6PD M.F. by the total number of colon crypts (4.4x10-4 G6PD mutants/total crypts assessed) x 
(1x106 total colon crypts) = 400 G6PD mutant crypts/colon. 
f) Dividing the observed number of G6PD mutant crypts per colon by the expected 
number of G6PD mutant crypts per colon at a 100% O6mG adduct conversion efficiency 
(4x102)/(1.2x105) = 0.003, or 0.3% O6mG adduct conversion efficiency.  
Only 0.3% of all of the O6mG adducts formed at potential phenotypic G6PD mutating 
sites in the G6PD gene loci are successfully converted into phenotypic somatic stem cell 
mutations in the male WT B6 mouse colon. Interestingly, this value reasonably approximates the 
value reported in WT E.coli studies(210)(211) for the efficiency of O6mG adducts converted into 
mutations.  
If only 0.3% of O6mG adducts are converted into phenotypic G6PD mutations, how many 
mutations actually manifest in genes critical to carcinogenesis? A somatic G6PD stem cell 
mutation is only a conservative marker of mutagenesis in stem cells, and it is assumed many 
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more different somatic mutations occurred in stem cells throughout the colon. However, the 
O6mG adduct conversion efficiency demonstrates how rare of an event mutagenesis actually is. 
How likely is it that one or more phenotypic somatic mutations would occur in a stem cell, if any 
O6mG adducts are converted into mutations? Can mutagenesis really be the rate limiting step in 
carcinogenesis? 
Beta-catenin is an oncogenic transcription factor and a component of the E-cadherin cell-
cell adhesion protein complex that would likely have a significantly lower conversion efficiency 
than G6PD. Beta-catenin is frequently mutated after AOM treatments.(212)(213)(214)(215)(216) There 
are five potential phenotypic mutating guanine bases in  beta-catenin, and as there are two alleles 
that can be mutated. Therefore are ten total potential guanine bases that lead to phenotypic 
mutations.(214) This compares to the 400 phenotypic mutating guanine bases in G6PD on the x-
linked allele in the male mice.(207)(208) There are significantly fewer  potential sites for phenotypic 
beta-catenin mutations than there are with phenotypic G6PD mutations, signifying that 
phenotypic beta-catenin mutations are an extremely rare event. However, in a study assessing 
beta-catenin mutations in AOM+DSS induced colon tumors there was a 100% incidence of 
phenotypic mutations in beta-catenin.(215) 
The value of studying actual somatic stem cell mutations is that real differences can be 
elucidated between test groups. WT mice generated mutations with greater efficiency than the 
TCRβ-/- mice. This implies that a competent immune response potentiates mutagenesis through 
stem cell survival and enhances DNA replication with unrepaired DNA lesions present in a stem 
cell. So what differences will be observed in cancer development between the two strains of 
mice? 
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2.7 SUMMARY AND DISCUSSION 
The study of the effects of AOM, DSS, and AOM+DSS treatment on G6PD mutagenesis 
provides several important insights into the relationship between DNA damage and 
inflammation. The WT mice treated with AOM had a significantly higher G6PD M.F. than the 
immune deficient TCRβ-/- mice, implying a role for the α/β T-cell mediated immune signaling in 
the fixation of mutations in stem cells. The role of inflammation as a tumor promoter that 
generates RONS is thought in part to involve oxidative DNA damage and mutagenesis. Yet, WT 
mice and TCRβ-/- mice treated with DSS did not have a statistically different G6PD M.F. than 
the untreated control mice and actually there was no M.F. to compare between the treated 
groups. When treated with the combination of AOM+DSS WT mice showed a significantly 
higher G6PD M.F. compared to the TCRβ-/- mice, but the G6PD M.F. in both of the strains 
decreased by approximately 75% relative to the M.F. calculated for the corresponding mice 
treated with AOM as a single agent. Therefore, the DSS treatment had a deleterious impact on 
the generation or survival of stem cells with somatic mutations, not an enhancing effect. 
Calculating the efficiency of converting a pro-mutagenic O6mG adduct into a somatic stem cell 
mutation in the WT mice demonstrated how rare mutations actually are relative to the number of 
adducts that are formed. Furthermore, mutations must be phenotypic to affect cancer 
development. Since the conversion efficiency was calculated based on an actual count of somatic 
stem cell mutations, the efficiency of converting an O6mG adduct into a mutation is even lower 
in the immune deficient mice than the 0.3% efficiency calculated for the WT mice. The 
observation of stem cell mutations in AOM treated mice that subsequently do not develop colon 
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tumors, strongly implies that mutations are not the rate limiting step in cancer development and 
other factors related to the immune response play a critical role in carcinogenesis. 
2.7.1 More G6PD mutant crypts occurred in the WT mice than occur in the immune 
deficient TCRβ-/- mice after treatment with AOM? 
Studying G6PD M.F. requires that a phenotypic G6PD mutation occurs in newly polymerized 
DNA strands during stem cell division. After the stem cell divides and the DNA recombines, the 
DNA strands with the mutation in the G6PD loci must be retained in the stem cell niche and 
assume the dominate position to propagate the crypt with G6PD mutant cells. 
As discussed in section 1.4.6., a study by Hong et. al. reported that the base regions of 
colonic crypts, including the stem cell niche, showed severe cytotoxicity immediately after 
treatment with AOM.(41) It is likely the rapid increase in DNA adducts levels induced 
cytotoxicity that depleted the crypt stem cells. To attempt to reconstitute the stem cell population 
the remaining dominate stem cell(s) would need to bypass cell cycle arrest and DNA repair, and 
undergo symmetrical stem cell divisions(35)(Figure 9), as discussed in section 1.2.2.7. The 
outcome of a symmetrical division is that two equivalent stem cells are produced.(35) Therefore, 
if the parent stem cell divides with unrepaired O6mG lesions a mutation could be fixed in the 
newly polymerized DNA strands, and the DNA strands with the mutation will be retained in the 
niche after the DNA recombines, unless both stem cells move to lineage differentiation.(35) 
This would mean a stem cell with a somatic mutation is in a position to usurp the niche 
and propagate the cells of the crypt. If the mutation confers a selective advantage then the 
mutated stem cell will be more likely to assume the dominate position.(30) A mutation may even 
enhance the stem cell’s survival or elongate its retention time.(31) One example of this is seen in 
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the APC gene in human colon cancer,(31) which is mutated in ~80% of sporadic human colon 
cancer cases as well as being an inheritable mutation(FAP).(217) APC mutations provide both a 
selective advantage and enhance the stem cell’s retention time in the dominate position of the 
niche.(30)(31) Interestingly, a G6PD mutation would not confer a selective advantage on a stem 
cell. A G6PD mutation could impair a cell’s ability to combat RONS mediated damage,(205) but 
should not otherwise deleteriously impact a cell. 
 Could α/β T-cell signaling play a role in inducing more symmetrical stem cell divisions 
and potentially expanding a stem cell population with a somatic mutation? WT mice had a 
significantly higher G6PD M.F. vs. the TCRβ-/- mice after treatment with AOM. In this way α/β 
T-cell signaling could have inadvertently led to both the generation of somatic stem cell 
mutations and also prime stem cells with mutations to propagate a colonic crypt.  
The colonic stem cell populations in the TCRβ-/- mice would not have received α/β T-cell 
signaling support. Therefore, the TCRβ-/- mice had fewer stem cells successfully fix a mutation, 
and the newly mutated stem cell usurped the stem cell niche, resulting in a significantly lower 
G6PD M.F. in comparison to the WT mice. While asymmetrical stem cell division is capable of 
producing DNA strands with a fixed mutation, there is a least a 50% chance the cell copy with 
mutated DNA strands is not retained in the stem cell niche but moves to undergo lineage 
differentiation. If α/β T-cell signaling does help to produce more stem cells with a somatic 
G6PD stem cell mutation, this would partially explain why there was a significant difference in 
the G6PD M.F. between the two strains of mice.  
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2.7.1.1 α/β T-cell signaling may modulate how a newly divided cell positions itself within 
the stem cell niche 
A mechanism through which α/β T-cell signaling could direct stem cell division toward a 
symmetrical cell division may be through modulating the expression of the cell-cell adhesion 
protein junctions on the basolateral border of the stem cells. Pericryptal cells, macrophages, 
dendritic cells, and tissue resident intraepithelial (IELs) T-cells, form cell-cell adhesions 
junctions on the basal border of the stem cells. This then anchors the stem cells to the 
subepithelial and fixes them in place, as well as establishing signaling pathways outside of the 
niche.(6)(32)(33)(34)(35)(36)  
α/β T-cell signaling can modulate all of these cell types and could influence how stem 
cells reposition themselves within the niche. The colonic Lgr5+ expressing stem cells do not 
share a border in the stem cell niche(25)(Figure 7), so at least one of the cell copies produced after 
a stem cell divides must reposition itself within the niche. This is critical to determining the fate 
of the cell: if it is destined to undergo lineage differentiation or remain in the niche. So α/β T-
cell signaling may generate more “slots” for the stem cells, positions within the niche where a 
stem cell will receive the signaling support necessary to retain its stem cell characteristics and 
maintain its functions.  
2.7.1.2 α/β T-cell signaling may alter a stem cell’s epigenetic gene expression to enhance 
stem cell survival 
The study by Hong et. al. demonstrated that the cells in the base regions of colonic 
crypts, the stem cell niche, had significantly lower MGMT expression under homeostatic 
conditions than the fully differentiated epithelial cells on the luminal border of the crypt.(41) 
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Consequently, treatment with AOM showed substantial apoptotic induction in the stem cell 
niche, and significantly fewer cells died in the luminal regions of the crypts.(41) Twelve hours 
after the AOM treatment, the MGMT expression levels in the niche were equivalent to the levels 
of MGMT expression in the fully differentiate cells and the apoptotic cell numbers substantially 
decreased.(41)  
 α/β T-cell signaling impact the change in MGMT expression observed in the stem cell 
niche. If the TCRβ-/- mice were unable to upregulate MGMT expression after the AOM 
treatment due to a lack of α/β T-cell signaling, then they may experience more stem cells dying 
than in the WT mice. This could explain why the G6PD M.F. was significantly lower in the 
TCRβ-/- mice after the AOM treatment when compared to the WT mice.  
One caveat to this hypothesis is that increased MGMT expression would repair the O6mG 
lesions and drive down the mutation rate. While this is invariably true, the more significant 
impact could be that increased MGMT expression allows stem cells to avoid apoptosis. This 
would inadvertently enhance stem cell survival and allow some stem cells to successfully fix 
mutations during DNA replication before the DNA lesions are repaired. 
Another possible mechanism by which α/β T-cell signaling might play a role in stem cell 
mutagenesis is inducing translesion DNA polymerase expression, or inducing the preferential 
utilization of translesion polymerases during DNA replication once a lesion has been detected. 
α/β T-cells induce translesion DNA polymerases to replicate variable regions of the antibody 
gene loci, as part of their role in the maturation of B-cells into antibody producing plasma cells. 
This ensures that DNA replication of the variable regions of antibody binding sites have a high 
degree of variability. So that the target bacterial cell surface antigens are constantly susceptible 
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to antibody binding.(218) This proves that α/β T-cells possess the ability to modulate translesion 
DNA polymerases in select scenarios.  
Could α/β T-cell signaling also lead to the preferential use of translesion DNA 
polymerases in DNA alkylation damaged stem cells, as a means of preventing cell cycle arrest to 
keep the stem cells dividing? While this would increase the risk of cells acquiring mutations, it 
could also help to explain how stem cells increase their rate of cell division and compensate for 
the loss of epithelial cells during an inflammatory event.(11)(12) This could explain why the G6PD 
M.F. was significantly lower in the TCRβ-/- mice after the AOM treatment when compared to the 
WT mice.   
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2.7.2 Why were no G6PD mutant crypts detected in the immune competent WT mice and 
in the immune deficient TCRβ-/- mice treated with 2% DSS? 
The most direct answer to this question is that the oxidative stress resulting from the actions of 
the innate immune response did not overwhelm the colonic stem cell’s ability to mitigate the 
RONS derived DNA damage. G6PD mutant crypts are the result of a stem cell that has fixed a 
mutation in the G6PD gene, and this result demonstrates that no stem cells fixed a G6PD 
mutation and subsequently came to dominate a crypt. Also, the lack of G6PD mutant crypts in 
both strains of mice after the DSS treatment shows this result was not related to the immune 
status of the mice.  
It is significant that at least one DSS treatment is not leading to cancer promotion by 
acting as a mutagen. As somatic G6PD mutations in stem cells act as a marker for mutagenesis, 
it suggests a very low number of mutations resulted in any genes. In the carcinogenic 
AOM+DSS treatments, mutations must manifest as a result of the AOM derived DNA alkylation 
damage. So the DSS treatment is not amplifying the number of mutations in the colonic stem 
cells.  
Could NO· generation actually initiate anti-apoptotic, immune suppressive, and tissue 
regenerative mechanisms that inadvertently protect burgeoning cell populations with 
oncogenic/tumor suppressor mutations? Studies have suggested that NO· can mediate several 
anti-inflammatory effects as well as survival effects on cells,(158)(159) as discussed in section 1.5.5. 
NO· inhibits neutrophil β2 integrin function, decreases endothelial P-selectin expression and 
reduces chemotactic responses to various chemokines, such as interleukin (IL)-8 and monocyte 
chemotactic protein-1 (MCP-1).(384) NO· concentration is a factor in the transition from Th1 to 
 104 
Th2 immune mediation.(358)(384)(385) The association of RONS generated by treatments with tumor 
promoters acting as a mutagen may not have been accurate. The multifaceted capabilities of 
RONS acting as signaling molecules, especially at higher than normal intracellular and 
extracellular concentrations,(158)(358)(384)(385) could explain part of the mechanism through which 
DSS treatments potentiate cancer development. 
2.7.2.1  The loss of crypt morphology may explain why no G6PD mutant crypts arose in the 
DSS treated mice 
DSS treatment is very disruptive to the colon architecture, even at low doses. So much so 
that it is impossible to determine where the stem cell niche is located after the DSS treatment 
(Figure 13). There could have been sufficient spatial separation from the site of the anti-
pathogenic innate immune response to decrease the concentration of RONS molecules reaching 
the stem cells, so that they had no deleterious impact. Therefore, the cancer promoting 
mechanism of DSS must occur during the tissue restoration which could be partially mediated by 
NO· signaling.  
The result of the DSS treatment in this study does not mean other tumor promoting 
reagents applied to different tissues are not mutagenic. However, tumor promoting reagents are 
considered to be poor carcinogens when used independently of a tumor initiator.(44) The fact that 
no G6PD mutants were observed in the DSS treated mice, at one dose, corroborates this theory.   
 
 105 
2.7.3 Treating the WT mice and the TCRβ-/- mice with AOM+DSS resulted in a lower 
G6PD mutation frequency in both strains of mice when compared to the mutation 
frequency observed after the strains were treated with AOM alone 
After treatment with AOM+DSS the G6PD M.F. calculated for both the WT mice and the TCR 
β-/- mice was approximately 75% lower for both strains than the M.F. calculated after the AOM 
treatment for both strains. This decrease in the observed number of G6PD mutant crypts, and the 
corresponding decrease in M.F., is likely due to destructive effect of the DSS treatment on the 
colon. DSS treatments result in several deleterious effects on the treated mice and invariably 
cause a shortening of the entire colon length when compared to untreated mice, as discussed in 
section 1.5.2. The loss of colon length due to scaring depleted the total number of colonic crypts, 
including crypts with mutated stem cells. Alternatively, as G6PD is a critical antioxidant, the 
DSS treatment may have selectively killed stem cells with a somatic G6PD mutation as these 
cells would have been more susceptible the cytotoxic effects of RONS.(205) 
It was much more difficult to generate a total count of 10,000 crypts observed per animal 
with mice that received a DSS treatment than with the mice that did not undergo a DSS 
treatment. The DSS treatment reduced the number of crypts appearing on each section of colon 
tissue in both strains of mice when compared to mice that did not receive DSS treatments. The 
mice treated with AOM+DSS also had fewer crypts per slide than the other treatment groups due 
to the presence of tumor tissue.  
   The effect of the DSS treatment following an AOM treatment was a significant 
reduction in the number of mutated stem cells and therefore a reduction in potential cancer cells. 
This result is paradoxical to the assumed effect of DSS treatment potentiating cancer 
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development. G6PD mutant stem cells act as a marker for mutagenesis. A reduction in G6PD 
mutant crypts means that a substantial number of crypts with stem cells harboring phenotypic 
somatic mutations in any gene were also eliminated. Therefore, DSS treatments should lower the 
probability of cancer incidence in a mouse after treatment with AOM. However, colon cancer 
development in WT mice, regardless of the strain, is substantial after treatment with AOM+DSS. 
This relationship will be related to the carcinogenicity data for these same treated groups of mice 
in the Summary Chapter (Chapter 4).   
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3.0  CARCINOGENESIS STUDY 
3.1 SCOPE AND SYNOPSIS 
Chapter 3 presents the results of several different carcinogenesis experiments and a discussion of 
those results. The first section is an introduction to the carcinogenesis experiments and provides 
new material focusing on the immune system and how different immune cells may affect colon 
cancer induction by AOM+DSS. The goal is to help the reader understand the relevance and 
novelty of treating T-cell deficient mice with AOM+DSS to determine how colon cancer may 
develop in a immune compromised animal. The second section outlines the significance of the 
study, the experimental design, the important details of the assay and the statistical analyses. The 
experimental data and results tables will then be presented. The final section is a summary of the 
experimental results and a discussion, including possible explanations and interpretations of how 
and why the results occurred. 
3.2 INTRODUCTION 
A tissue associated chronic inflammatory disease significantly increases an individual’s chances 
for developing cancer. Chronic inflammatory colitis is a high risk factor for CRC.(1) The first 
person credited with studying the relationship between inflammation and cancer was Rudolph 
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Virchow, who suggested that lymphatic infiltrate discovered in solid tumor samples supported 
the cancer pathology.(219)  
The function of the immune system is to eliminate infectious agents, such as viruses, 
bacteria, small parasites, and even large helminthes. Considering the sheer number of different 
and potentially lethal infectious agents in the environment, the immune response has evolved a 
substantial number of mechanisms to combat infections. However, immune responses represent 
considerable risk to the host tissue environment where disease or wounding occurs. The immune 
response tightly regulates cytolytic cell activity and minimizes the duration of the immune 
response, to prevent immune cell mediated damage to the host tissue while still eliminating 
pathogenic threats. Dysregulation of the immune response can lead to severe morbidity and 
mortality. The pathology of cancer requires multiple levels of immune dysregulation. Primarily, 
cancer progression requires that cancer cells either remain undetected by cytolytic immune cells 
and/or impair their cytolytic activity.  
Immune cells are unique in the body as cells that exist and function as individual units. 
Immune cells are able to traffic throughout the body by moving through the circulatory and 
lymphatic systems, and infiltrate into areas of inflammation. Some immune cells become tissue 
resident cells that integrate into a tissue’s normal structure and remain a part of the normal tissue 
architecture. The colonic epithelium incorporates macrophages, dendritic cells (DCs), and 
intraepithelial lymphoctes (IEL) T-cells, among others. Immune cells exhibit a wide range of 
functional plasticity, while fully differentiated cells in other tissues specialize to fulfill one set of 
functions.  
Immune cells support tissue wound repair and regeneration.(220)(221)(222)(223) Neutrophils 
and monocytes debride wound areas of dead cell components and pathogens.(223) Monocytes 
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express TGF-beta(transforming growth factor beta) upon infiltrating into inflamed and wounded 
tissues.(224)(225)(226)(227) TGF-beta induces macrophages and DCs to express angiogenic and 
lymphangiogenic growth factors, such as VEGF(vascular endothelial growth factors), TGF-
alpha(transforming growth factor alpha) and IGF-1(insulin-like growth factor 
1).(228)(229)(230)(231)(232)(233) IGF-1 is a mitogenic growth factor and causes the partial 
dedifferentiation of epithelial cells, altering an epithelial cell’s morphology from a columnar 
axial polarized shape into a flattened motile cell capable of migrating into the wound 
space.(234)(235) The physiological process of epithelial cell migration into the wound space in an 
attempt to reconstitute the epithelial barrier is termed epithelial restitution.(235) α/β T-cells, which 
are discussed extensively in section 3.1.4, express IL-4/IL-13 expression polarize monocyte 
maturation into the M2 macrophage phenotype which drives immune suppression and tissue 
regeneration.(305)(306)(307)(308) 
 γ/δ IELs support colonic epithelial wound repair mechanisms by expressing keratinocyte 
growth factor (KGF) after the γ/δ IELs are activated by a tissue insult.(221) KGF (KGF-1 and 2) is 
a member of the fibroblast growth factor (FGF) family of protein ligands that modulate multiple 
pathways of growth and regeneration.(236) WT B6 mice, that express KGF-2, showed enhanced 
repair and regeneration of epidermal lacerations when compared to Tcrδ-/- B6 mice.(237) WT B6 
mice treated with dextran sulfate sodium (DSS) at a 2.5% dose for 5 days showed enhanced 
colonic epithelial repair and regeneration in comparison to Tcrδ-/- B6 mice.(238) 
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3.2.1 The same mechanisms that immune cells use to provide a benefit for wound repair 
and tissue regeneration support the growth of cancer cells and their progression toward 
malignancy  
The colonic tumor microenvironment is hypoxic and hypoglycemic due to the high metabolic 
demands of cancer cells mitogenic activity.(239)(240)(241) Anaerobic glycolysis causes 
hypoglycemia that may induce oncogenic mutations in K-ras and other genes,(239) and produces 
lactic acid and carbon dioxide causing acidosis in the local tumor environment.(242)(243)(244) An 
acidic physiological pH can lead to misfolding and dysregulation in many proteins, although a 
few proteins can enhance their functional capacity in acidic environments.  
For these reasons the tumor microenvironment is highly cytotoxic compared to normal 
tissue, and many tumor cells die through necrosis as a result. Many normal cells bordering the 
tumor tissue also die through necrosis, leading to a highly inflammatory environment. Modifying 
immune cells to assume wound healing phenotypes may be a necessary component of tumor 
malignancy, as hypoxic conditions seem to be the driving force behind tumor cell metastasis,(245) 
and immune cell mediated angiogenesis and lymphangiogenesis provide tumor cells the ability to 
metastasize.(246)(247) 
Tumor cells release cheomattractant cytokines that induce the migration of immune cells 
into the tumor environment by expressing cheomattractant cytokines.(248)(249) Many different 
immune cells can function in support of the tumor microenvironment. Tumor-associated 
macrophages (TAMs) are macrophages in a tumor environment that support tumor progression 
and impede cytolytic anti-tumor cell mediated immune responses.(250)(251)(252)(253) To counter the 
hypoxia, hypoglycemia, and acidosis in the tumor microenvironment, TAMs express the same 
array of angiogenic and lymphangiogenic growth factors expressed by normal macrophages 
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during tissue wound repair.(253)(254)(255)(256) The function and behavior of TAMs resembles the M2 
macrophage phenotype (M2 cells) that mediates wound repair responses and facilitates the anti-
inflammatory immune suppression of inflammation.(251)(252)(257)(258)(259)(260) This implies that 
TAMs begin as monocytes that are polarized into M2 cells before they manifest as TAM 
populations, although macrophages and TAMs show extensive heterogeneity both within and 
between their respective populations.(253)(261)(262)(263)  
Tumor microenvironments also affect DCs, as VEGF expression by TAM’s will prevent 
DC maturation and maintains high numbers of immature DCs.(264)(265)(266) Inhibiting DC 
maturation would severely impair or completely inhibit the generation of cytolytic T-cells, as 
DCs would not traffic to nearby lymph nodes to activate and expand cytolytic T-cell populations 
that specifically target tumor antigens.(264)(265)(266)  
3.2.2  The earliest cancer cells lack a fully developed tumor microenvironment to support 
their development and progression, yet are still able to survive and proliferate 
 As cancer cells are able to induce immune cells to stimulate angiogenesis they help to 
satisfy their own energy demands. In addition, cancer cells prevent immune cell mediated 
cytolytic and/or cytotoxic elimination of the cancer cells. However, tumor microenvironments 
develop after cancer cells have manifested in tissues, and are required for the more advanced 
stages of cancer rather than the early stages of cancer. Cancer cells should be more vulnerable to 
energy depletion and cytolytic cell attacks during the earliest stages of cancer development. 
Early stage cancer cells must lack the ability to remodel the vasculature and alter their 
environment to compensate for the energy demands of anaerobic glycolysis. Moreover, the 
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expression of intracellular stress signaling proteins should mark cancer cells for cytolytic 
deletion by natural killer (NK) cells.(267)(268)(269)  
While it is likely that significant numbers of early stage cancer cells are either killed by 
cytolytic immune cells or die by necrosis, enough cancer cells persist to alter their 
microenvironment and conscript immune cell support. This implies that some immune 
modulation occurs in the earliest stages of cancer, perhaps even potentiating the development of 
the first cancer cells. What would be the result of a sporadic colon cancer induction model used 
to treat immune compromised mice? Would cancer development be enhanced in the immune 
compromised animals, or possibly impaired when compared to immune competent WT mice?  
3.2.3 AOM+DSS treatment studies with WT and immune compromised mice  
Several studies have examined the relationship of colon cancer induction after treatment with 
AOM+DSS in immune deficient mice. These studies addressed the role of TLR/NLR PRRs 
receptors that initiate inflammatory responses in colon cancer development.(104)(270)(271) The 
reason for studying these receptors is the unique relationship the colon exhibits with commensal 
microbiota. Many cells of the body express PRRs including macrophages; DCs, and neutrophils, 
but also endothelial and epithelial cells.(33)(93)(94)(95)(110)(112) It is through TLR/NRL signaling that 
natural tolerance for microbiota is established and broken.(33)(93)(95)(103)(105)(106) DSS disrupts the 
colon architecture allowing bacteria access to the subepithelial regions of the colon, which 
induces inflammation when bacteria are detected in this region,(33)(95) as discussed in section 
1.5.4. 
When WT B6 mice and TLR2-/- B6 mice were treated with AOM+DSS it was found that 
the TLR2-/- B6 mice developed significantly more and larger colon tumors than the WT B6 
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control mice.(272) It was also reported that colonic epithelium of TLR2-/- B6 mice had altered 
immune responses and dysregulated cell proliferation during colitis, which resulted in 
inflammation derived growth signals and that potentiated neoplastic growth.(272) The 
investigators concluded that TRL2 signaling inhibits colon cancer development in WT B6 
mice.(272)  
In another study in which that treated WT B6 mice and TLR4-/- B6 mice were treated 
with AOM+DSS it was shown that the TLR4-/- B6 mice were resistant to colon cancer 
development in comparison to the WT B6 mice.(273) WT B6 mice treated with AOM+DSS 
developed significantly more tumors in comparison to the TLR4-/- B6 mice treated with 
AOM+DSS.(273) The TLR4-/- B6 mice also exhibited a significantly decreased number of tumors 
per animal and a significantly decreased tumor size.(273) The investigators concluded that TRL4 
signaling potentiates colon cancer development in WT B6 mice.(273)  
In a third study in which WT B6 mice and NLR3-/- B6 mice treated with AOM+DSS, the 
NLR3-/- B6 mice developed significantly more colon tumors with significantly larger size and 
weight than the WT B6 mice.(274) Interestingly, in this study the cancer development was 
assessed by endoscopy as well as H+E histological evaluation in both mouse strains.(274) The 
investigators concluded NLR3 and inflammasome signaling inhibits colon cancer development 
in WT B6 mice.(274)  
Studies examining the effect of AOM+DSS treatment inducing colon cancer in TLR/NLR 
deficient mice showed conflicting results in that TLR/NLR receptors may either potentiate or 
inhibit colon cancer development. Explaining these discrepant results will likely require a deeper 
understanding of the inflammatory response initiated by each of these receptors. These results 
also imply that each TLR/NLR will have its own individual effect on AOM+DSS induced colon 
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cancer development, and the effect will not be synonymous for all of the receptors in a specific 
class.  
TLR/NRL receptors are initiators of inflammation, but what colon cancer development 
result would occur in an immune deficient mouse lacking the cells that mediate the immune 
response? α/β T-cells (thymus derived cells) are the dominate effectors of the adaptive immune 
response, comprising both cytolytic cells and immune response mediators. α/β T-cells are a 
complex heterogeneous population of cells, often capable of overlapping and compensatory 
functions. An α/β T-cell deficient animal would be severely immune compromised, and 
therefore, would represent a compelling test group to determine how a cancer induction 
treatment would affect an immune compromised animal model. 
A study was done on T-cell deficient B6 mice treated with AOM (10 mg/kg b.w.), but the 
mice did not receive a DSS treatment. In this study five AOM treatments were administered to 
TCRα-/- B6 mice, TCRδ-/- B6 mice, and WT B6 mice.(275) Interestingly, the investigators choose 
to study the WT B6 mice although they are resistant to colon cancer induction by AOM 
treatments.(160) In this study only the TCRδ-/- B6 mice developed colon cancer, with only one 
tumor reported in six TCRδ-/- B6 mice after five months.(275) However, after seven months five 
out of ten TCRδ-/- B6 mice treated with AOM developed tumors.(275) The results of this study 
confirmed that the WT B6 mice are resistant to AOM treatments inducing colon cancer, but 
interestingly so were the  TCRα-/- B6 mice. This study also indicated a role for γ/δ T-cells in 
resisting colon cancer development in WT B6 mice. 
We predict that the lack of α/β T-cells in the immune compromised mice will reduce the 
incidence, multiplicity, and progression of colon cancer in a model that involves inflammation, 
when compared to the WT immune competent mice. This prediction is based on the rational that 
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inflammation, and the multitude of immune responses that result from inflammation, are required 
to promote cancer development. The dysregulation of the immune response by the lack of α/β T-
cells will inhibit, not enhance, cancer development. This prediction contrasts with the idea that 
the immune response is required to impede cancer development. 
3.2.4 The potential effects of the loss of α/β T-cell functions on a colon cancer induction 
model that requires inflammation to promote cancer development  
The thymus is a small organ of the thoracic cavity, sitting superior to the heart. The primary 
function of the thymus to induce the expression of the thymus cell receptor (TCR) on T-cell 
precursors, that must interact with the intraepithelial of the thymus.(276)(277) The T-cell precursors 
will express the beta and alpha chains of the T-cell receptor and the CD4 and CD8 co-
stimulatory molecules that will determine the T-cells phenotype. (276)(277)(278)(279)(280) 
Athymic mice do not properly develop the intraepithelial of the thymus to facilitate the 
expression of the α/β TCR, as the athymic mice are null for the expression of the Fox n1 
transcription factor.(281) This means that athymic mice are α/β T-cell deficient. A beta chain null 
mouse would lack the beta chain gene loci and not express the beta chain of the α/β TCR, also 
resulting in an α/β T-cell deficient phenotype.   
CD8+ α/β T-cells (CTLs) are the cytolytic T-cells that identify and lyse virally infected 
cells.(282) CTLs are predominate to other cytolytic cell populations, which utilize less specific 
recognition signals to identify cells for cytolysis, as employing the less specific mechanisms of 
selecting cells for cytolysis would result in more extensive and severe tissue destruction. 
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 α/β T-cell deficient mice will lack CTLs and consequently would be vulnerable to viral 
infections, and unable to impede cancer cell development by selectively eliminating cancer cells 
through CTL cytolysis. Cancer cells may express detectable non-self antigens from degraded 
proteins that are altered due to mutations or novel proteins expressed due to genomic instability, 
such as carcinoembryonic-antigen (CEA) in colon cancer.(283)(284) CTLs could be a critical 
component of cancer cell elimination, if CTLs were not immune suppressed by the tumor 
microenvironment.(285)(286)  
CD4+ α/β T-cells Th1 (T-helper 1) cells are immune pro-inflammatory mediators. They 
express, Interferon-gamma (IFNγ), Lymphotoxin α (LTα), IL-2, and TNF-beta, among other 
cytokines to mediate the elimination of pathogens.(286)(287) IFNγ expression modulates several 
immune responses to enhance CTL activity. INFγ also polarizes macrophages into their anti-
microbial M1 phenotype, which generates RONS.(288)  
Th1 cell mediation potentiates CTLs and other anti-microbial mechanisms, and as α/β T-
cell deficient mice also lack CTLs, burgeoning cancer cells would have less potent anti-tumor 
cell cytolytic immune responses to attenuate in α/β T-cell deficient mice. Interestingly, the lack 
of Th1 cell mediation may also attenuate RONS generation as deficient INFγ expression would 
repress the polarization of monocytes into M1 macrophages. A reduction in RONS may impede 
cancer development in the α/β T-cell deficient mice. 
CD4+ α/β T-cells Th17 (T-helper 17) cells are also pro-inflammatory mediators. 
Interestingly, Th-17 cell mechanisms are directed toward non-immune cells to induce immune 
responses. Th-17 cells mediate anti-pathogenic responses to extracellular pathogens, including 
bacteria and fungi, through the expression of IL-17a, IL-17f,(289) and array of other cytokines to 
potentiate the activity of neutrophils and monocytes.(290)(291)(292)(293)(294) IL-22 is an IL-10 family 
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cytokine expressed by Th17 cells that enhances colonic epithelial barrier protection, maintains 
homeostasis, and enhances tissue repair.(295)(296)(297)(298) However, IL-22 expression may also 
exacerbate chronic inflammatory conditions, such as psoriasis, rheumatoid arthritis, and 
ulcerative colitis.(299)(300)(301)  
The lack of Th17 mediated signaling in α/β T-cell deficient mice could strongly diminish 
neutrophil and monocyte activity. Diminishing phagocyte function could significantly reduce 
RONS generation that is associated with potentiating cancer development. The loss of Th17 
mediated IL-22 expression in α/β T-cell deficient mice may impair wound repair and tissue 
regeneration, or conversely could result in a less severe immune response.   
CD4+ α/β T-cells Th2 (T-helper 2) cells mediate anti-inflammatory signals that suppress 
Th1 polarized immune responses. Th2 cells express IL-4, IL-13, and other cytokines.(302)(303)(304) 
IL-4 and IL-13 expression polarize monocyte maturation into the M2 macrophage phenotype 
which drives immune suppression and tissue regeneration.(305)(306)(307)(308) Interestingly, many of 
the Th2 derived cytokines exacerbate allergic reactions by enhancing eosinophil and mast cell 
functions, and causing IgE antibody class-switch.(309)(310)(311)(312)(313)(314)(315)(316)(317)(318)(319)  
α/β T-cell deficient mice lacking Th2 cell mediated signaling would not be able to drive 
monocyte polarization into M2 macrophages through the expression of IL-4/IL-13. This would 
impact the development of the tumor microenvironment, as Th2 cells are recruited by cancer 
cells to facilitate the development of TAMs, as discussed in section 3.1.1. Without the normal 
TAM development would tumors be more or less capable of progressing to the advanced 
metastatic stages of colon cancer? 
CD4+ α/β T-cells T-regulatory cells (Treg) suppress immune responses to restore tissue 
homeostasis, as well as maintaining self-tolerance in auto-immune diseases. Tregs express IL-10, 
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IL-35, and TGF-beta, to suppress immune responses.(320)(321)(322)(323) IL-10 inhibits monocytes 
from expressing multiple cytokines and chemokines to prevent INFγ from polarizing monocytes 
into M1 macrophages,(324)(325)(326)(327)(328) inhibits M1 macrophage functions,(329) and inhibits the 
development of DCs, both classical and plasmacytoid, from monocytes.(330)(331)  
IL-10 expression inhibits neutrophil phagocytosis and the killing of phagocytosed 
bacteria.(332)(333)(334)(335) Interestingly, IL-10 expression does not directly inhibit CTLs and may 
actually enhance CTLs cytolytic activity.(336)(337) IL-10 also enhances activated cytolytic NK 
cells, and does not directly suppress them(338) but does drive down INFγ expression. TGF-beta 
also mediates immunosuppression to facilitate the initiation of tissue repair. TGF-beta inhibits 
NK (natural killer) cell activation, cytokine production, and cytolytic activity.(339)(340) TGF-beta 
mediated T-cell immunosuppression seems to be directed against CD4+α/β T-cells.(341)  
Tregs are recruited to tumor microenvironments where they mediate immune suppression 
through the previously discussed mechanisms.(342)(343)(344)(345)(346)(347) Cancer cells in α/β T-cell 
deficient mice would lack the multiple immune suppressive benefits that Tregs would provide in 
a tumor microenvironment. However, a reduction in IL-10 expression could result in enhanced 
RONS production for a longer duration in α/β T-cell deficient mice that may potentiate cancer 
development. 
Could innate cytolytic NK cell and γ/δ T-cell populations have enhanced anti-tumor cell 
cytolytic activity in Treg deficient mice? Would this drive down cancer incidence in the α/β T-
cell deficient mice? 
 Both NK cells and γ/δ T-cell populations (peripheral circulating γ/δ T-cells and γ/δ IEL 
cells) will have normal development and a normal range of functions in α/β T-cell deficient 
mice. Both populations are potent anti-tumor cell cytolytic cells.(348)(349)(350)(351) Interestingly, 
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both populations may mediate cytolytic activity against tumor cells through NKG2D 
expression.(348)(349)(352) The cytolytic potential of these cell populations, and the pro-inflammatory 
responses they can mount, will not be suppressed by Tregs in the α/β Τ-cell deficient mice.  
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3.3 DATA 
3.3.1 Mice Strains and Treatment Groups Studied 
Male (B6) Fox n1/J, Fox n1nu/J athymic, WT, TCR β-/-, TCR δ-/-, TCR β-/-δ-/- strains of mice 
were treated with AOM, DSS, or AOM+DSS to induce colon cancer. A summary table of these 
experimental results, that compares the colon cancer induction outcomes for each of the 
treatments on each of the strains, will be presented in this section. For a more comprehensive 
analysis of the results of each experiment, a table detailing the outcome of each experiment will 
be presented that will include a results summary.    
3.3.2 The Significance of Studying a Sporadic Colon Cancer Induction model 
The AOM+DSS treatment is a two-stage colon cancer induction model.(44) Treatment with 
AOM+DSS approximates sporadic colon cancer development in humans.(46) As the majority of 
colon cancer cases lack a known hereditary mutation as the primary driving force behind colon 
cancer incidence, sporadic colon cancer models are more reflective of the cancer development 
seen in most patients.(217) As the causative mutations of cancer are not predetermined, the effect 
of inducing colon cancer on a genetic knockout mouse strain can produce a novel result when 
compared to the WT mouse strain. Studying colon cancer induction in an immune compromised 
mouse model is not the same experiment as inoculating an immune compromised athymic or 
SCID mouse with cancer cells from another animal. The former study relates to the development 
of new cancer cells, while latter study reflects the effects of the immune response on established 
cancer cells. Treating α/β T-cell deficient mice with a sporadic colon cancer induction model 
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will provide novel insight into the development of colon cancer in an immune compromised 
system when compared to an immune competent WT mouse. 
3.3.3 Colon cancer induction animal treatments 
During the course of this work five different colon cancer induction animal experiments were 
performed using WT mice and immune compromised mice treated of the B6 mouse strain (Table 
10): 
Carcinogenicity Experiment 1: 20 Fox n1/J mice and 20 Fox n1nu/J athymic mice were 
treated with one 10 mg/kg dose of AOM followed after one week by a 2% DSS treatment lasting 
one week.  
Carcinogenicity Experiment 2: 20 Fox n1/J mice and 20 Fox n1nu/J athymic mice were 
treated with one 10 mg/kg dose of AOM followed after one week by a 1% DSS treatment lasting 
one week.  
Carcinogenicity Experiment 3: 15 Fox n1/J mice and 15 Fox n1nu/J athymic mice were 
treated with one 15 mg/kg dose of AOM followed after one week by a 1.5% DSS treatment 
lasting one week.  
Carcinogenicity Experiment 4: 12 WT mice, 10 TCRβ-/- mice, 10 TCRδ-/- mice, and 10 
TCRβ-/-δ-/- mice were treated with one 15 mg/kg dose of AOM followed after one week by a 
1.5% DSS treatment lasting one week. 
Carcinogenicity Experiment 5: 6 WT mice and 6 TCRβ-/- mice were treated with 200 ul 
of PBS. 12 WT mice and 12 TCRβ-/- mice were treated with one 10 mg/kg dose of AOM. 12 WT 
mice and 12 TCRβ-/- mice with treated with one 2% DSS treatment lasting one week. 12 WT 
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mice and 12 TCRβ-/- mice were treated with one 10 mg/kg dose of AOM followed after one 
week by one 2% DSS treatment lasting one week.  
3.3.3.1  Colon Tissue Harvesting and Preparation for H+E Staining  
After the completion of their respective DSS treatments, the Fox n1/J mice and Fox 
n1nu/J athymic mice used in Carcinogenicity Experiments 1, 2, and 3 were housed in the sterile 
animal facility for 120 days. At the end of the timecourse the mice were euthanized and their 
colons excised, placed in 4% formalin, and embedded in paraffin. Sections were cut and mounted 
on slides for H+E staining histological analysis.  
After the completion of the DSS treatment the WT, TCRβ-/-, TCRδ-/- mice, and       
TCRβ-/-δ-/- mice used in Carcinogenicity Experiment 4 were housed in the sterile animal facility 
for 90 days. Upon completion of the timecourse the mice were euthanized and their colons 
excised, placed in 4% formalin, and embedded in paraffin. Sections were cut and mounted on 
slides for H+E staining histological analysis. 
After the completion of the DSS treatment the WT mice and TCRβ-/- mice used in 
Carcinogenicity Experiment 5 were housed in the sterile animal facility for 90 days. Upon 
completion of the timecourse the mice were euthanized and their colons excised, immersed in 
OCT medium (Tissue-Tek® Optimal Cutting Temperature Compound, Ted Pella, Inc., Redding, 
CA), and frozen on liquid N2. Sections were then cut for each animal, the slides were placed in 
4% formalin for 3 hours, and H+E stained histological analysis. Full details of all of the 
experimental methods are written in Chapter 5. 
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3.3.4 H+E Staining and Statistical Analysis 
All of the histological analysis was performed by a medical pathologist. Briefly, in the normal 
colonic crypt architecture crypts appear as long test tube like glands with a regular diameter top 
to bottom, and display regular spacing between the crypts. The cells are in a single layer and 
have small nuclei, and goblet cells are abundant in the normal colon architecture. 
 Adenomas have small flat or polypoidal crypts that are similar in size, and have an 
approximate glandular size. There is more stromal space between the crypts, and there is more 
lymphatic infiltrate than is observed in the normal colon crypt architecture. The cells of the 
adenoma crypts have elongated nuclei that resemble a cigar like shape. The adenoma cells may 
or may not layer. Crypts at the edge of the adenoma do not exhibit any signs of invasion into the 
normal tissue layers. Also, adenomas do not show desmoplasia, the development of dense 
fibrous connective tissue from proliferating fibroblasts.(353) 
 Adenocarcinomas have large polypoidal crypts of varying glandular sizes. There is very 
scant stroma between the crypts and heavy lymphatic infiltrate. The cells of the adenocarcinoma 
crypts have large round nuclei and prominent nucleoli. Nucleoli are granular structures forming 
within the nucleus of a cell, composed of protein and RNA, for ribosomal RNA synthesis and the 
formation of ribosomes.(354) The adenocarcinoma cells form layers and the crypts appear to 
thicken in comparison to normal epithelial crypts. Crypts at the edge of the adenocarcinoma 
bordering the normal tissue do exhibit signs of invasion into the normal tissue layers. 
Adenocarcinoma crypts are also positive for desmoplasia.  
Although the carcinogenesis results of the AOM+DSS treatments were generated with 
only standard histological evaluation performed by a clinical pathologist, more advanced 
immunohistochemistry techniques could potentially distinguish between adenomas and 
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carcinomas. The expression of various marker proteins in human samples have shown significant 
changes in their expression between normal, adenomas, and adenocarcinomas. It has not been 
reported if the quantification of the expression of these marker proteins would correlate to mouse 
samples in the B6 background. 
p53 expression was reported to have a significantly higher expression rate in colonic 
carcinomas in comparison to adenomas.(373) Adenomas with high-grade dysplasia also showed 
more p53 expression.(373) p53 is a tumor suppressor(374) and it seems counterintuitive that p53 
expression would increase in more progressed colonic epithelial cancer cell populations. No 
mutations in p53 that would inactivate the protein were reported in the article by Saleh, et. al.(373) 
Nor were any mutations in mdm2 reported. Mdm2 serves as a negative regulator of p53 
activity.(375) p53 expression levels may indicate differences in the colonic tumors resulting from 
the AOM+DSS treated mice in this study. However, further studies in mice may be required to 
determine if p53 expression levels vary significantly between adenomas and adenocarcinomas as 
they appear to in human cancers.  
Studies have also attempted to associate PCNA and CD34 expression levels to the 
progression of human colonic tumors.(376)(377) The expression of PCNA (proliferating cell nuclear 
antigen) was found to be significantly higher in carcinoma cells than in adenomas and normal 
epithelial cells.(377) CD34 expression levels were also significantly higher in colonic carcinoma 
cells than in adenoma cells or normal epithelial cells. CD34 (hematopoietic progenitor cell 
antigen) is a multifunctional protein that mediating the attachment of stem cells to the bone 
marrow extracellular matrix or directly to stromal cells.(378) Both CD34 and PCNA expression 
levels may indicate differences in the colonic tumors resulting from the AOM+DSS treated mice 
in this study. However, further studies in mice may be required to determine if the expression 
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levels of either protein vary significantly between adenomas and adenocarcinomas as they appear 
to in human cancers.  
  Statistically significant differences in colon cancer incidence among the mice in the 
different experiments were determined using the Fisher’s Exact Test. Cancer incidence (yes or 
no) is a categorical variable having no intrinsic value,(355) and differences in categorical variables 
between two test groups undergoing the same treatment can be determined using a contingency 
table.(356) The Fisher’s Exact Test is a contingency table test best utilized when the treatment 
groups have small sample sizes.(357) The t-test was used to determine the statistical differences in 
the multiplicity (total number of tumors), numbers of adenomas, and the number of 
adenocarcinomas, between treated groups of mice in the different experiments. Before statistical 
comparisons were made, the data sets were administered the normality test to show the values of 
the data followed a Gaussian distribution. Also, the F-test for Two Data Sets was used to 
determine the equality of variances between the data sets being compared. All of the data sets 
satisfied the requirements for the t-test to be used to analyze the data. The software used and 
details of the statistical methods are discussed in section 5.  
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3.4 CARCINOGENICITY EXPERIMENTS RESULTS SUMMARY  
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Table 11. Carcinogenicity Experiments Results Summary table 
Experiment (#) 
Treatment 
Mouse 
Strain 
(B6) 
Incidence Adenoma Carcinoma Multiplicity (Total) 
Experiment I 
10 mg/kg AOM 
2% DSS 
Fox n1/J  14/20 6 16 22 
Fox n1nu/J 
athymic  n/a n/a n/a n/a 
Experiment II 
10 mg/kg AOM 
1% DSS 
Fox n1/J  6/20   6 n/a   6 
Fox n1nu/J 
athymic  3/20   3 n/a  3 
Experiment III  
15 mg/kg AOM 
1.5% DSS 
Fox n1/J  12/14 11a 22b,g 32 
Fox n1nu/J 
athymic 11/12 19
a 7b 26 
Experiment IV 
15 mg/kg AOM 
1.5% DSS 
WT  7/12c,d 7 6g 13e,f 
TCRβ-/-  1/10c,h 1i 0 1e,j 
TCRδ-/-  3/9 3 0 3 
TCRβ-/-δ-/- 1/9d 1 0 1f 
Experiment V* 
10 mg/kg AOM 
2% DSS 
WT  10/12 11 10 21 
TCRβ-/- 11/12h 10i 12 22j 
Results:    p-0.01180  t-test 
a) p-0.02016  t-test                          e) p-0.02369  t-test           i) p-0.01180  t-test 
b) p-0.04593  t-test                          f) p-0.02513  t-test           j) p-9.250e-05 t-test 
c) p-0.02630  Fisher’s exact test     g) p-0.02660  t-test           n/a = not applicable 
d) p-0.03750  Fisher’s exact test     h) p-0.0151  Fisher’s exact test 
Note:* no tumors developed in mice treated with AOM, treated with DSS, or were untreated.                                                                                            
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Table 12.  Carcinogenicity Experiment 1 
Experiment I:  Fox n1/J mice vs. Fox n1nu/J athymic mice                  
(B6) treated with AOM+DSS 
Table 12. 
Treatment 
Mouse 
Strain 
(B6) 
Incidence Adenoma Carcinoma Multiplicity (Total) 
10 mg/kg AOM 
2% DSS 
Fox n1/J  14/20 6 16 22 
Fox n1
nu
/J 
athymic  
n/a* n/a* n/a* n/a* 
Results: 
Incidence:  14 out of 20 Fox n1/J mice developed tumors. 
Adenomas:  6 adenomas occurred in the Fox n1/J mice. 
Carcinomas:  16 carcinomas occurred in the Fox n1/J mice. 
Multiplicity:  22 total tumors occurred in the Fox n1/J mice. 
n/a:  not applicable. 
 
Note: *19 out of the 20 Fox n1nu/J athymic mice died as a result of the 2% DSS treatment.  
 
 
 
 
 
 
 
 
 
 129 
3.4.1.1  Results Summary and Analysis of Table 12, previous page 
The Fox n1/J mice showed a high tumor incidence (70%), multiplicity (22 developed in 
14 mice), and progression (16 out of 22 tumors were classified as carcinomas), after treatment 
with AOM+DSS. Fox n1/J mice are not immune compromised as these mice are heterozygotes 
for the Foxn1 transcription factor. The Foxn1 gene plays a part in the development of the 
intraepithelial of the thymus.(281) Since Fox n1/J mice have normal expression of one allele of the 
Foxn1 gene, their immune development should be normal.   
73% of the total tumors in the Fox n1/J mice had progressed to carcinomas.  The Fox n1/J 
mice exhibited a potent response to the 2% DSS treatment. The animals displayed the adverse 
symptoms common to severe DSS induced inflammation that included; blood in the stools, soft 
wet enlarged stools, rectal bleeding, and prolapsed rectums occurred in the mice after the DSS 
treatment.  
The athymic mice could not tolerate the 2% DSS dose, and all of the mice died or were 
euthanized by seven days after the initiation of the DSS treatment. As they are immune 
compromised this result could indicate delayed and/or impaired colonic epithelial repair due to 
the loss of α/β T-cell mediated signaling. For example; if the expression of IL-22 was 
significantly reduced in the athymic mice compared to the WT mice, then the athymic mice 
might have experienced an impaired tissue wound repair response in the colon epithelium. 
However, the lack of the Foxn1 gene expression causes other developmental defects in the 
athymic mice, so more research would be needed to determine if the lack of α/β T-cell mediated 
signaling impacted this result. 
 
 
 130 
Table 13.  Carcinogenicity Experiment 2 
Experiment II: Fox n1/J mice vs. Fox n1nu/J athymic mice                  
(B6) treated with AOM+DSS 
Table 13. 
Treatment 
Mouse 
Strain 
(B6) 
Incidence Adenoma Carcinoma Multiplicity (Total) 
10 mg/kg AOM 
1% DSS 
Fox n1/J  6/20   6 n/a  6 
Fox n1nu/J 
athymic  3/20   3 n/a  3 
Results: 
Incidence:   6 out of 20 Fox n1/J mice developed tumors. 
                    3 out of 20 Fox n1nu/J athymic mice developed tumors.  
Adenomas:   6 adenomas occurred in the Fox n1/J mice. 
                     3 adenomas occurred in the Fox n1nu/J athymic mice. 
Carcinomas:   No carcinomas occurred in the Fox n1/J mice. 
                       No carcinomas occurred in the Fox n1nu/J athymic mice. 
Multiplicity:   6 total tumors occurred in the Fox n1/J mice. 
                       3 total tumors occurred in the Fox n1nu/J athymic mice. 
n/a:  not applicable. 
Statistical Analysis:  There were no statistical differences in the tumor incidence or multiplicity 
between the two strains of mice. 
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3.4.1.2 Results Summary and Analysis of Table 13, previous page 
There were no significant differences in the tumor incidence or tumor multiplicity 
between the Fox n1/J mice and the athymic mice with this AOM+DSS treatment. Also, no 
adenocarcinomas developed in either strain. Only mild adverse effects of the DSS treatment were 
observed; soft stools with very little or no blood, no rectal bleeding, and no prolapsed rectums 
occurred. The effect of the 1% DSS dose as a tumor promoter on the immune compromised 
athymic mice could not be effectively assessed or compared to the immune competent control 
Fox n1/J mice since neither mouse strain exhibited a significant inflammatory response to the 
DSS treatment to potentiate tumor development, and produce a statically distinguishable 
difference between the strains. 
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 Table 14.  Carcinogenicity Experiment 3 
Experiment III: Fox n1/J mice vs. Fox n1nu/J athymic mice                   
(B6) treated with AOM+DSS 
Table 14. 
Treatment 
Mouse 
Strain  
(B6) 
Incidence Adenoma Carcinoma Multiplicity (Total) 
15 mg/kg AOM 
1.5% DSS 
Fox n1/J  12/14 11a 22b 32 
Fox n1nu/J 
athymic 11/12 19
a 7b 26 
Results: 
Incidence:  12 out of 14 Fox n1/J mice developed tumors. 
                   11 out of 12 Fox n1nu/J athymic mice developed tumors.  
Adenomas:   11 adenomas occurred in the Fox n1/J mice. 
                     19 adenomas occurred in the Fox n1nu/J athymic mice. 
Carcinomas:  22 carcinomas occurred in the Fox n1/J mice. 
                        7 carcinomas occurred in the Fox n1nu/J athymic mice. 
Multiplicity:   32 total tumors occurred in the Fox n1/J mice. 
                       26 total tumors occurred in the Fox n1nu/J athymic mice. 
Statistical Analysis:  a) p-0.02016  t-test;   
Significantly higher numbers of adenomas occurred in the Fox n1nu/J athymic mice when 
compared to the Fox n1/J mice.     
b) p-0.04593  t-test;   
Significantly higher numbers of adenocarcinomas occurred in the Fox n1/J mice when compared 
to the Fox n1nu/J athymic mice.   
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3.4.1.3 Results Summary and Analysis of Table 14, previous page 
Note that the AOM dose was increased from 10 mg/kg to 15 mg/kg to attempt to enhance 
the carcinogenic effect of the AOM+DSS treatment. Both strains of mice were able to tolerate 
the 15 mg/kg AOM treatment and the 1.5% DSS treatment. Typical adverse symptoms resulting 
from the DSS treatment were observed, but no mice died or had to be euthanized due to the 
adverse effects of the DSS treatment.  
There was no significant difference in the tumor incidence or multiplicity between the 
Fox n1/J mice and the athymic mice. A significantly higher number of adenomas occurred in the 
athymic mice (19 adenomas) when compared to the Fox n1/J mice (11 adenomas) (p-0.02016 t-
test). Also, a significantly higher number of adenocarcinomas occurred in the Fox n1/J mice (22 
carcinomas) when compared to the athymic mice (7 carcinomas) (p-0.04593 t-test).  
The lack of α/β T-cell populations in the immune deficient athymic mice did not lead to a 
significant change in the tumor incidence or multiplicity vs. the immune competent Fox n1/J 
mice. However, there is a significant difference in tumor progression between the two strains of 
mice.  
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Table 15.  Carcinogenicity Experiment 4 
Experiment IV: WT, TCRβ-/-, TCRδ-/-, and TCRβ-/-δ-/- mice  
(B6) treated with AOM+DSS 
Table 15. 
Treatment 
Mouse 
Strain 
(B6) 
Incidence Adenoma Carcinoma Multiplicity (Total) 
15 mg/kg 
AOM 1.5% 
DSS 
WT 7/12c,d 7 6 13e,f 
TCRβ-/-  1/10c 1 0 1e 
TCRδ-/-  3/9 3 0 3 
TCRβ-/-δ-/-  1/9d 1 0 1f 
Results: 
Incidence:   7 out of 12 WT mice developed tumors. 
                    1 out of 10 TCRβ-/- mice developed tumors. 
                    3 out of 9 TCRδ-/- mice developed tumors. 
                    1 out of 9 TCRβ-/-δ-/- mice developed tumors. 
Adenomas:   7 adenomas occurred in the WT mice. 
                     1 adenomas occurred in the TCRβ-/- mice. 
                     3 adenomas occurred in the TCRδ-/- mice. 
                     1 adenomas occurred in the TCRβ-/-δ-/- mice. 
Carcinomas:  6 carcinomas occurred in the WT mice. 
Multiplicity:  13 total tumors occurred in the WT mice. 
                       1 tumor occurred in the TCRβ-/- mice. 
                       3 total tumors occurred in the TCRδ-/- mice. 
                       1 tumor occurred in the TCRβ-/-δ-/- mice.  
Statistical Analysis: c) p-0.0263  Fisher’s Exact Test  d) p-0.0375  Fisher’s Exact Test;   
A significantly higher incidence of tumors occurred in the WT mice when compared to the        
(c) TCRβ-/- mice and the (d) TCRβ-/-δ-/- mice.  
e) p-0.02369  t-test  f) p-0.02513  t-test;   
A significantly higher number of tumors occurred in the WT mice when compared to the            
(e) TCRβ-/- mice and the (f) TCRβ-/-δ-/- mice.  
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3.4.1.4 Results Summary and Analysis of Table 15, previous page 
The Fox n1nu/J mice were poor breeders with high mortality among the pups, and orders 
could not be efficiently filled. Due to the difficulty of obtaining the athymic mice, and the 
problem of determining a tolerable DSS dose, the immune compromised athymic mice were 
replaced with TCRβ-/- mice, TCRδ-/- mice, TCRβ-/-δ-/- mice. The control mice for these knockout 
B6 mice strains is the WT mouse. The immune compromised T-cell deficient phenotype of the 
athymic and T-cell knockout mice should be the same.  
The WT mice had a significantly higher incidence of mice with tumors (7 mice) than the 
TCRβ-/- mice in which one mouse had one tumor (p-0.0263 Fisher’s Exact Test). The tumor 
multiplicity was also significantly greater in the WT mice (13 tumors) than in the TCRβ-/- mice 
(one tumor) (p-0.02369 t-test). Seven adenomas and six carcinomas developed in the WT mice 
while the TCRβ-/- mice developed only one adenoma. With nearly half of the tumors classified as 
adenocarcinomas, there is also a more rapid cancer cell progression in the WT mice.  
The TCRβ-/-δ-/- mice responded to the AOM+DSS treatment in nearly identical fashion to 
the TCRβ-/- mice. The WT mice had significantly higher incidence of mice with tumors (7 mice) 
compared to one mouse with one tumor in the TCRβ-/-δ-/- mice (p-0.0375 Fisher’s Exact Test). 
The total number of tumors was also significantly greater in the WT mice (13 tumors) than in the 
TCRβ-/-δ-/- mice where only one tumor developed (p-0.02513 t-test). As with the TCRβ-/- mice, 
there was only one adenoma and no carcinomas in the TCRβ-/-δ-/- mice. However, these values 
are not significantly different from the numbers of adenomas and adenocarcinomas in the WT 
mice. 
The TCRδ-/- mice were not significantly different from the WT mice in tumor incidence 
or tumor multiplicity after the AOM+DSS treatment. Three TCRδ-/- mice did have adenomas, 
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with one adenoma developing per mouse, which was approximately half of number of adenomas 
observed in the WT mice. There were no adenocarcinomas reported in the TCRδ-/- mice.  
While all of the immune compromised strains of mice showed inhibited colon tumor 
development, the α/β T-cell deficient mice and the T-cell double knockout mice showed the most 
significant restriction in cancer development. Emphasizing α/β T-cells as the most significant T-
cell type related to DSS mediated tumor promotion. The mechanisms through which α/β T-cells 
mediate anti-pathogenic and tissue repair responses are thoroughly discussed in section 3.1.  
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Table 16.  Carcinogenicity Experiment 5 
Experiment V: WT mice and TCRβ-/- mice (B6) treated  
with AOM, DSS, AOM+DSS, or untreated 
(Carcinogenicity Results for Mutagenesis Data) 
Table 16. 
Treatment 
Mouse 
Strain  
(B6) 
Incidence Adenoma Carcinoma Multiplicity (Total) 
PBS 
WT  0/6 n/a n/a n/a 
TCRβ-/-  0/6 n/a n/a n/a 
10 mg/kg AOM 
WT  0/12 n/a n/a n/a 
TCRβ-/-  0/12 n/a n/a n/a 
2% DSS 
WT  0/12 n/a n/a n/a 
TCRβ-/-  0/12 n/a n/a n/a 
10 mg/kg AOM 
2% DSS 
WT  10/12 11 10 21 
TCRβ-/- 11/12 10 12 22 
Results: 
Incidence:   10 out of 12 WT mice developed tumors. 
                    11 out of 12 TCRβ-/- mice developed tumors. 
Adenomas:   11 adenomas occurred in the WT mice. 
                     10 adenomas occurred in the TCRβ-/- mice. 
Carcinomas:   10 carcinomas occurred in the WT mice. 
                       12 carcinomas occurred in the TCRβ-/- mice. 
Multiplicity:   21 total tumors occurred in the WT mice. 
                       22 total tumors occurred in the TCRβ-/- mice. 
n/a: not applicable        
Statistical Analysis: There were no statically significant differences in the tumor incidence, 
multiplicity, or progression between the WT mice and the TCRβ-/- mice. 
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3.4.1.5 Results Summary and Analysis of Table 16, previous page 
The AOM used in this experiment was a higher purity (98%) compound than the AOM 
used in the previous experiment (90%). The (98%) AOM led to toxicity and mortality (one-third 
of the mice treated died) at the 15 mg/kg dose. Therefore, the AOM dose had to be lowered so 
the mice could tolerate the AOM treatment. The DSS dose was increased to enhance the 
carcinogenic effect of the AOM+DSS treatment. As the WT mice and the TCRβ-/- mice were 
more tolerant of the DSS treatment than the Fox n1 deficient mice, it was reasonable to assume a 
0.5% increase in the DSS dose would be tolerated by both strains of mice. The WT mice and the 
TCRβ-/- mice exhibited only mild adverse effects of the 2% DSS treatment, although several 
mice developed prolapsed rectums near the end of the timecourse. 
There were no tumors reported in the WT mice and the TCRβ-/- mice treated with PBS 
(untreated), 10 mg/kg AOM, or 2% DSS. There were no statically significant differences in the 
tumor incidence, multiplicity, or progression between the WT mice and the TCRβ-/- mice treated 
with 10 mg/kg AOM + 2% DSS treatment. This is a striking contrast to the previous experiment 
which showed a strong inhibition of cancer development in the immune compromised mice. The 
WT mice and TCRβ-/- mice show nearly identical numbers of tumor incidence, multiplicity, 
adenomas, and carcinomas.  
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3.4.2 Differences between the Carcinogenicity Experimental Groups 
3.4.2.1  Fox n1/J mice developed significantly more carcinomas than the WT mice (Table 
11)   
Fox n1/J mice developed significantly more carcinomas (22 carcinomas) than the WT 
mice (6 carcinomas) using the same AOM+DSS treatment doses (p-0.02660 t-test). The Fox n1/J 
mice are heterozygotes for the Fox n1 transcription factor gene so these mice should be 
expressing the gene normally, as they carry one copy of the allele. However, the Fox n1/J mice 
are clearly more susceptible to DSS induced inflammation, as they exhibited more severe 
adverse effects of the DSS treatment when compare the WT mice treated at the same DSS dose. 
This result may indicate that the Fox n1/J mice heterozygotes have a significantly different 
differential gene expression than the WT mice. 
3.4.2.2  Cancer incidence, multiplicity, and progression was significantly higher in the 
TCRβ-/- mice after Carcinogenicity Experiment 5 than was observed for the TCRβ-/- mice 
after Carcinogenicity Experiment 4 (Table 11) 
There was a striking increase in the tumor incidence, multiplicity, and progression in the 
TCRβ-/- mice after the 10 mg/kg AOM + 2% DSS treatment used in Carcinogenicity Experiment 
5 (Table 11) vs. what resulted in the TCRβ-/- mice after the 15 mg/kg AOM + 1.5% DSS 
treatment used in Carcinogenicity Experiment 4 (Table 11). The tumor incidence increased from 
one mouse in ten TCRβ-/- mice after Carcinogenicity Experiment 4 to eleven mice in twelve 
TCRβ-/- mice after Carcinogenicity Experiment 5. The tumor multiplicity increased from one 
tumor in the TCRβ-/- mice after Carcinogenicity Experiment 4 to twenty-two total tumors in the 
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TCRβ-/- mice after Carcinogenicity Experiment 5. The number of adenomas increased from one 
in the TCRβ-/- mice after Carcinogenicity Experiment 4 to ten adenomas in the TCRβ-/- mice 
after Carcinogenicity Experiment 5. Finally, no adenocarcinomas developed in the TCRβ-/- mice 
after Carcinogenicity Experiment 4, but twelve developed in the TCRβ-/- mice with the 
AOM+DSS treatment used in Carcinogenicity Experiment 5.  
A DSS dose effect has been observed in AOM+DSS studies,(167) DSS treatments range 
from a 1-5% concentration for one week, so a 0.5% DSS dose increase can produce a 
substantially more severe colonic inflammation. Also, the composition of the colonic microbiota, 
both the bacterial strains and density, can alter the tolerance to the DSS dose of the mice being 
treated.(141)(143)    
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3.5 SUMMARY AND DISCUSSION 
Studying the effect of colon carcinogenesis induced by AOM+DSS treatment on immune 
competent mice and immune compromised mice produced results that were both insightful and 
confounding. The 2% DSS treatment in the first experiment was toxic to the Fox n1nu/J athymic 
mice, while the 1% DSS treatment in the second experiment failed to elicit a severe enough 
inflammatory response to potentiate cancer development in either mouse strain. In the third 
experiment, the Fox n1nu/J athymic mice had significantly more adenomas and significantly 
fewer adenocarcinomas than Fox n1/J mice, while the mice had a similar total number of tumors. 
This result suggests a role for α/β T-cell mediated tumor promotion, where the immune 
competent mice have more rapid progression of cancer cell development. In the fourth 
experiment the AOM+DSS treated WT mice had a significantly higher cancer incidence, 
multiplicity, and faster progression of cancers than the TCRβ-/- mice and TCRβ-/-δ-/- mice. These 
results would indicate that cancer cell development is actually being impeded in the absence of 
α/β T-cell mediated signaling.  
The fifth experiment was performed to study the mutagenic and carcinogenic effect of the 
AOM, DSS, and AOM+DSS treatments. In the fifth experiment there was no statistical 
difference between the WT mice and TCRβ-/- mice in cancer incidence, multiplicity, or the 
progression of cancer after treatment with AOM+DSS. The result seen in the TCRβ-/- mice 
occurred in response to a 0.5% DSS dose increase between the fourth and fifth carcinogenicity 
experiments. This could suggest that the severity of the inflammation may determine how 
immune cells respond after treatment with DSS, and it is possible the α/β T-cell mediated 
signaling that is absent in the TCRβ-/- mice was compensated for by other cells in a more severe 
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inflammation. Interestingly, there was a very significant increase in the cancer incidence, 
multiplicity, and progression of cancer observed in the TCRβ-/- mice treated in the fifth 
carcinogenicity experiment in comparison to the TCRβ-/- mice treated in the fourth 
carcinogenicity experiment. However, there was no significant difference in cancer incidence 
and tumor multiplicity in the WT mice treated in the fifth carcinogenicity experiment in 
comparison to the WT mice treated in the fourth carcinogenicity experiment.  
If the severity of the inflammation potentiates cancer development, then factors that 
determine the severity of an inflammatory event must be a significant factor impacting 
carcinogenesis. A deficiency in α/β T-cell mediated signaling impeded cancer development in a 
mild or moderate inflammatory environment, but a more severe inflammation in the colon 
negated the inhibition seen in the α/β T-cell deficient mice. The results of these studies would 
suggest that immune competent WT mice are in fact more susceptible to cancer development 
than α/β T-cell deficient mice.  
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3.5.1 Discussion of the potential reasons why the athymic mice so adversely affected by 
the DSS treatment 
Treating the athymic mice with 2% DSS for one week resulted in 19 out of 20 mice dying or 
being euthanized (Table 12). It is likely the athymic mice were affected more severely than the 
Fox n1/J mice due to the composition of their commensal microflora. Germ-free and some 
specific-pathogen free mice are more severely affected by high doses of DSS, and it is likely the 
microbiota in the athymic mice were not able to protect the colon epithelium. This result is 
reminiscent of the effect of DSS treatments above 1% in germ-free mice reported in the 
literature.(141)(143) While the athymic mice were littermates of the Fox n1/J mice, the animals are 
eventually housed separately. Since the athymic mice are not all siblings it is likely their floral 
composition diverged from the Fox n1/J mice.  
The athymic mice may also have been unable to tolerate higher DSS doses due to 
deficient immune cell signaling. IEL T-cells are strongly associated with homeostatic functions 
and tissue repair in the colonic epithelium,(32)(237) and the lack of resident IELs in the athymic 
mice could have delayed or impaired the initiation of the epithelial would repair. Also, the loss of 
the Fox n1 gene expression impairs the intraepithelial development of the thymus, so it is 
possible wound repair and regeneration responses in other epithelial tissues may experience 
impaired effects as well. These different explanations are also not necessarily mutually exclusive.  
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3.5.2 Discussion of the potential reasons why the treatment failed to promote tumor 
development in the athymic mice and in the Fox n1/J mice 
As discussed in section 1.5.5 and 2.1, the composition of the colonic microbiota can mitigate the 
adverse effects of the DSS treatment by increasing the animal’s tolerance for the DSS dose. This 
would mean that mice with certain colonic microbiota would require DSS treatments at higher 
doses to potentiate cancer development than other mice would require with different flora. This 
effect may even be strain independent. While the 2% DSS dose was clearly toxic to the athymic 
mice, the 1% DSS treatment did not induce a severe enough immune response to potentiate 
cancer development in either mouse strain. The small numbers of adenomas developing in the 
immune competent Fox n1/J mice supports this conclusion (Table 13). Based on their response 
to the 2% DSS treatment from the first trial, the Fox n1/J mice did not have a severe enough 
immune response to potentiate cancer development.  
3.5.3 Why did more adenocarcinomas develop in the Fox n1/J mice compared to the 
athymic mice after the third AOM+DSS treatment? 
While the tumor incidence and multiplicity were not significantly different between the Fox n1/J 
mice and athymic mice, significantly more adenocarcinomas developed in the Fox n1/J mice 
after treatment with AOM+DSS (Table 14). The role of the immune response in cancer 
development is expected to impede and inhibit cancer cell progression and pathology. However, 
the immune competent mice had more tumors progress to cancers than the immune compromised 
mice during the same timecourse. 
 145 
If the anti-bacterial innate immune response is resolved quickly, as the pro-inflammatory 
response is suppressed by Treg cells and Th2 cells, then tissue repair and regeneration can be 
initiated within a short duration from the onset of the DSS treatment. In the athymic mice, 
lacking immune suppressive α/β T-cells, the innate immune response against the bacteria may be 
prolonged in comparison to the Fox n1/J mice. This hypothesis would suggest that the cancer 
potentiating effect of inflammation is a part of the repair and regeneration of the colon 
epithelium. Therefore, the quicker the tissue repair can be initiated the more potent the cancer 
development will be. This would also suggest that a significant component the cancer 
potentiating effect of inflammation lies in the duration of the inflammatory response, specifically 
related to how rapidly the pro-inflammatory response can be ended and repair initiated. As 
discussed in section 3.5.1., the reasons the athymic mice experienced a greater toxicity to the 
DSS treatment, such as a potential delay in epithelial repair initiation, may have led to a latency 
in cancer development as well. 
3.5.4 Why were the WT mice sensitive to AOM+DSS treatment and the immune 
compromised TCRβ-/- mice and TCRβ-/-δ-/- mice resistant to AOM+DSS induced colon 
cancer by comparison? 
In the fourth carcinogenicity experiment the WT mice had a 60% tumor incidence, with the mice 
developing an equivalent number of adenomas and carcinomas (Table 15). Interestingly, in both 
the TCRβ-/- mice and the TCRβ-/-δ-/- mice only one animal developed one adenoma per group 
(Table 15). In the previous section 3.5.3., the suggestion was made that the cancer potentiating 
effect of the DSS treatment is enhanced by a rapid resolution of the anti-pathogenic immune 
response. This result also suggests that the more rapidly α/β T-cell signaling moves toward anti-
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inflammatory signaling, the stronger the tumor potentiating effect of DSS derived inflammation 
becomes. The duration of the anti-bacterial inflammatory response occurring in the WT mice 
would be considered normal, as the WT mice have immune suppressive Treg cells and Th2 cells 
to resolve the pro-inflammatory response. The TCRβ-/- mice and TCRβ-/-δ-/- mice are likely to 
have a dysregulated duration of an innate pro-inflammatory response, favoring an 
inappropriately long duration of an innate pro-inflammatory response and delaying the onset of 
tissue repair.  
Resolution of the pro-inflammatory response does not mean the end of immune cell 
signaling. As discussed in section 3.1, one of the outcomes of Treg and Th2 cell signaling is the 
modulation of monocyte differentiation. Through IL-10 signaling Tregs inhibit Th1 cells to drive 
down the expression of INFγ that polarizes monocytes into the M1 macrophage 
phenotype.(324)(325)(326)(327)(328) Th2 derived IL-4/IL-13 modulate infiltrating monocytes to adopt 
the tissue regenerative M2 macrophage phenotype (M2 cells).(305)(306)(307)(308)  M2 cells express an 
array of cytokines, such as VEGF and IGF-1, that support angiogenesis, lymphangiogenesis, and 
epithelial restitution.(229)(230)(231)(231)(233)(234)(235) M2 cells may even express NO· as an anti-
inflammatory extracellular signaling molecule.(157)(158)  
DSS exposure is particularly devastating to colonic epithelial macrophages and DCs. The 
onset of the DSS pathology initiates with the oncosis of macrophages as they phagocytize the 
dextran based molecule.(84)(85) The only functional macrophages would be newly derived from 
the influx of monocytes into the site of inflammation, although DSS also disrupts monocyte 
maturation.(89) Still, the WT mice would be more capable of polarizing monocytes into M2 cells 
than the α/β T-cell deficient mice as WT mice have Th2 cells. The presence of the M2 cells in 
the WT mice could lead to more rapid immune suppression and onset of epithelial repair than the 
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α/β T-cell deficient mice would experience. The fact that the WT mice are more susceptible to 
colon cancer induction with an AOM+DSS treatment suggests that α/β T-cell mediated 
modulation of the monocytes into M2 cells could be an important component of DSS mediated 
tumor promotion.   
The TCRδ-/- mice, which are γ/δ T-cell deficient, did not show a significant decrease in 
tumor incidence or multiplicity from the WT mice due to the small sample sizes of the animal 
treatment groups. However, no adenocarcinomas developed in these mice after the AOM+DSS 
treatment. As these mice are α/β T-cell competent the conclusions addressing the results of the 
AOM+DSS treatment on the TCRβ-/- B6 mice would not apply to this result.  
γ/δ T-cells comprise only a small percentage of the peripheral T-cell population, but are 
strong presence in the tissue resident IELs. TCRδ-/- mice have been shown to have delayed 
colonic epithelial repair after treatment with DSS in comparison to WT mice.(238) γ/δ IELs supply 
critical growth factors to the colonic epithelium.(236) Also, γ/δ IELs would be one of the very first 
immune cells activated by DSS induced damage, helping to shape the initial immune response 
before the influx of circulating immune cells.(221) The less potent effect of the AOM+DSS 
treatment on tumor induction in the TCRδ-/- mice in comparison to the WT mice could suggest a 
role for the γ/δ IEL subset in potentiating inflammation induce carcinogenesis, although this role 
is likely to be concomitant with the α/β T-cells.  
Interestingly, the restricted cancer development in the α/β T-cell deficient mice does not 
eliminate the possibility that innate cytolytic cells, NK cells and γ/δ T-cells, may have an 
increased efficacy of anti-tumor cell cytolysis in the absence of Tregs. It could be possible that 
the α/β T-cell deficient mice express less TGF-beta to inhibit innate cytolytic cells, as the pro-
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inflammatory response is also likely diminished without α/β T-cells.(241)(242) An absence of Tregs 
and reduced levels of TGF-beta expression would allow innate cytolytic cells to avoid the strong 
immunosuppressive restrictions they normally operate under.  
3.5.5 Why was the significant difference in cancer development observed between the WT 
mice and the TCRβ-/- mice after the fourth carcinogenicity experiment no longer observed 
in the WT mice and TCRβ-/- mice after the fifth carcinogenicity experiment? (Table 11) 
There was a very significant difference in carcinogenesis between the TCRβ-/- mice treated in the 
fourth carcinogenicity experiment and the TCRβ-/- mice treated in the fifth carcinogenicity 
experiments (Table 11). The increase in tumor incidence, multiplicity, adenomas, and 
carcinomas in the TCRβ-/- mice after the 10 mg/kg AOM + 2% DSS treatment used in 
Carcinogenicity Experiment 5 resulted in there being no significant difference in cancer 
development between the WT mice and TCRβ-/- mice in the fifth carcinogenicity experiment 
(Table 16). However, the WT mice did not have a significant change in cancer development 
between the fourth and the fifth carcinogenicity experiments (Table 11). It is interesting that the 
values of the cancer incidence, multiplicity, adenomas and carcinomas between the WT mice and 
the TCRβ-/- mice are very similar. Is it possible that the increased inflammation resulting from 
the higher DSS dose led to compensation for the deficient α/β T-cell mediated signaling? 
It can be concluded that α/β T-cell mediated signaling is not indispensable to 
inflammation potentiating cancer development. If compensatory signaling occurred that caused 
the α/β T-cell deficient mice to adopt a similar phenotype to the WT mice in a more severe 
inflammatory event, then which cells and signaling molecules could have been responsible for 
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this? It has already been suggested that RONS, such as NO·, can lead to anti-inflammatory 
signaling when RONS is generated in high concentrations.(157)(158) It has been reported that high 
concentrations of RONS signaling may also polarize monocyte differentiation into M2 cells.(358) 
If high RONS concentrations do polarize monocytes into M2 cells, then this could generate M2 
cells in the TCRβ-/- mice during a severe inflammatory insult. The M2 cells would then be able 
supply the normal levels of cytokines that potentiate epithelial wound repair. This would 
effectively be compensating for the loss of Th2 cell signaling in the TCRβ-/- mice that would 
normally polarize influxing monocytes into M2 cells, through the expression of IL-4/13. This 
compensation may help to resolve the pro-inflammatory response in a shorter duration, one that 
matches the WT mice thereby potentiating cancer development. In WT mice with normal Th2 
cell development and signaling, the impact of the RONS concentrations would be less significant 
to M2 cell polarization. This would partially explain why the WT mice did not have a significant 
change in cancer development between the fourth and fifth carcinogenicity experiments.  
 Il-10 represents an intriguing possibility as a compensatory signaling molecule. While 
Tregs are an important source of Il-10 expression, Il-10 is expressed by other cell types including 
M2 macrophages. IL-10 may also be expressed by enterocytes in response to insults, as was 
shown by a study using a human enterocyte cell culture line.(359) IL-10 must be expressed by 
cells other than α/β T-cells in the TCRβ-/- mice as these animals do not spontaneously develop 
colitis. IL-10-/- mice will spontaneously develop colitis, unless they are germ-free, and this 
spontaneous inflammation acts as a tumor promoter if the IL-10-/- mice are treated with 
AOM.(151)(152)  
Since there was so little difference in the carcinogenicity data between the WT mice and 
the TCRβ-/- mice with more severe inflammation, uninhibited innate cytolytic cell activity must 
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not have an impact on this result. In spite of the absence of Tregs, innate cytolytic cell activity 
did not lead to a reduction in the tumors in the TCRβ-/- mice. Understanding why innate anti-
tumor cells (NK cells and γ/δ T-cells) did not eliminate cancer cells, in an environment that 
should have left their cytolytic anti-tumor cell activity enhanced, could represent an important 
research question.    
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4.0  ARE MUTATIONS THE RATE LIMITNG COMPONENT OF 
CARCINOGENESIS? 
4.1 SCOPE AND SYNOPSIS 
The first section of Chapter 4 presents a summary of the mutagenesis data from Chapter 2 and its 
relationship to the carcinogenesis experimental data in Chapter 3. The following section 
discusses a possible explanation for the results.  
4.2 REUSLTS SUMMARY AND ANALYSIS OF THE MUTAGENESIS DATA 
(TABLE 1) AND CARCINOGENESIS DATA (TABLE 16) FOR THE WT MICE AND 
TCRβ-/- TREATED WITH 10 MG/KG AOM, 2% DSS AND 10 MG/KG AOM + 2% DSS  
One of the significant results of this study indicates that although mutagenesis is indispensable to 
carcinogenesis, mutations are not the sole determinate factor in cancer development. Also, 
mutagenesis is not the mechanism through which DSS induced inflammation potentiates cancer. 
What effects could inflammation have on a cell with an oncogenic mutation to drive it toward 
becoming a cancer cell? 
A significantly higher G6PD M.F. occurred in the WT mice than occurred in the TCRβ-/- 
mice after one treatment with AOM (Table 1). As G6PD mutations are a conservative marker for 
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somatic stem cell mutations, it is likely many different types of mutations were fixed in colonic 
stem cells that subsequently produced progeny cell populations harboring those mutations. 
However, in spite of the likely oncogenic mutations in certain stem cells, no tumors developed in 
the WT mice or the TCRβ-/- mice after one treatment with AOM (Table 16). This result would 
indicate that the mutations generated by the AOM treatment were not the primary driving force 
behind cancer development.  
It is generally assumed that RONS resulting from the DSS induced inflammation leads to 
a substantial increase in mutations. However, DSS did not cause somatic stem cell mutations in 
G6PD in either mouse strain (Table 1). No tumors developed in the WT mice or the TCRβ-/- 
mice after one treatment with DSS (Table 16). While it is possible that somatic stem cell 
mutations did occur as a result of RONS damage generated by the DSS treatment, these 
mutations did not lead to tumor development. The immune status of the mice did not impact the 
occurrence of G6PD mutant crypts after treatment with DSS, however, this result contrasts the 
AOM treatment where the immune status of the mice did impact the occurrence of G6PD crypts 
(Table 1). 
A significant cancer development resulted in both the WT mice and in the TCRβ-/- mice 
after one treatment with 10 mg/kg AOM + 2% DSS treatment (Table 16). Interestingly, the 
immune status of the mice did not impact the colon cancer development after the 10 mg/kg AOM 
+ 2% DSS treatment (Table 16). This is despite the fact that the G6PD M.F. was significantly 
higher in the WT mice in comparison to the TCRβ-/- mice (Table 1). This difference in the G6PD 
M.F was observed after both the AOM treatment and the AOM+DSS treatment. Conventional 
understanding says that mutations are the driving cause of carcinogenesis. However, in this work 
the G6PD M.F. did not correlate to tumor burden in either strain of mice.  
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4.3 IF MUTATIONS ARE NOT THE ONLY DETERMINATE FACTOR IN 
CARCINOGENESIS, THEN WHAT OTHER MECHANISMS WOULD POTENTIATE 
CANCER CELL DEVELOPMENT? 
It has been proposed that the pre-cancer cell population arises from a colonic epithelial stem cell 
with an oncogenic somatic mutation.(29) This process begins with a stem cell suffering DNA 
alkylation damage from treatment with AOM. This cell must successfully complete cell division 
with the unrepaired lesion leading to a mutation, and the cell harboring the mutation must remain 
a stem cell in the stem cell niche. Furthermore, the mutated stem cell must usurp the dominate 
position in the niche and begin to propagate cells. A mutated stem cell is more likely to dominate 
a niche if the mutation confers a selective advantage.(30)(31) So which gene, if mutated, is 
oncogenic and provides a selective advantage to stem cells? 
 Beta-catenin is a transcription factor that is strongly associated with colon cancer 
development.(212) Beta-catenin is regulated by a multiprotein phosphodestruction complex that 
phosphorylates specific amino-acids on beta-catenin targeting it for ubiquitin-proteasome 
degradation. The phosphodestruction complex itself can be regulated through extracellular Wnt 
signaling,(213) where the complex is transiently inactivated by Wnt binding to allow for beta-
catenin DNA binding and transcription. The phophodestruction complex is mutated, primarily in 
the APC protein,(31) in the vast majority of colon cancers in both mice and humans.(217) However, 
AOM treatments frequently induce beta-catenin mutations in mice that prevent the 
phosphorylation of beta-catenin by GSK-3, a protein of the phosphodestruction 
complex.(214)(215)(216) A somatic mutation in beta-catenin would confer a selective advantage to a 
stem cell, enhancing the likelihood it could usurp a stem cell niche and propagate a population of 
epithelial cells expressing a mutated beta-catenin resistant to phosphodegradation.(30)(31)  
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Yet, AOM treatments are not enough to cause colon cancer development in B6 
mice.(160)(161) Could B6 mice be resistant to AOM induced mutations? If that were the case then 
treatment with AOM followed by treatment with DSS would not create colon cancer 
susceptibility in the B6 mice.(164) Does treatment with DSS affect beta-catenin in a way that is 
unique in comparison to other oncogenes, one that leads to an enhancement of a mutated beta-
catenin protein’s activity?  
4.3.1 Beta-catenin activity is dysregulated by anti-inflammatory immune cell signaling 
during epithelial restitution 
Beta-catenin is a transcription factor that also combines with E-cadherin to form tight cell-cell 
adhesion junctions linking epithelial cells together and forming a barrier to the lumen of the 
colon.(217) Binding beta-catenin into the catenin binding domain of E-cadherin is essential for 
maintaining epithelial cell-cell adhesion junctions,(217) while also allowing beta-catenin to act as 
an intracellular signaling molecule in response to extracellular modulation of a cell’s plasma 
membrane. In fact, beta-catenin activity is regulated by forming cell-cell adhesion protein 
complexes as well as through beta-catenin phosphodegradation.(360)(361)(362)  
 Treatment with DSS disrupts the epithelial layer through dysregulating tight cell-cell 
junction complexes.(97)(98) In turn this would dysregulate beta-catenin by increasing the free 
intracellular concentration of the transcription factor. Cells with a normal form of beta-catenin 
may be able to compensate for an increase in free intracellular beta-catenin levels through 
phosphodegradation, but cells with a mutated beta-catenin that prevents phosphorylation may be 
forced to function with the higher than normal intracellular concentration of beta-catenin. These 
cells would then be vulnerable to enhanced beta-catenin activity driving the cells toward 
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carcinogenesis. It is important emphasize that increased intracellular beta-catenin levels are not 
the result of increased beta-catenin transcription and translation, but are resulting from a decrease 
in E-cadherin complex cell-cell junctions. 
Beta-catenin activity is dysregulated by anti-inflammatory immune cell signaling during 
epithelial restitution. Treatment with DSS causes epithelial cell death but so does treatment with 
AOM, bacterial and viral infections, wounds, etc… However, DSS treatment causes a loss of 
colonic crypt morphology and, depending on the severity of the DSS induced damage and 
inflammation, the disrupted colon architecture can persist for weeks after the DSS treatment 
ended.(85)(86)  Epithelial restitution is a physiological process where undamaged epithelial cells at 
the edge of a wound will migrate into the wound space to reconstitute the epithelial barrier.(235)  
To accomplish this epithelial cells, primarily enterocytes, can assume a motile non-columnar 
non-axial morphology by eliminating many E-cadherin cell-cell junctions among other 
significant changes.(234)(235) Epithelial cells in this form are considered to be partially 
dedifferentiated and are capable of undergoing mitotic cell division.(234)(235) 
Insulin-like growth factor 1 (IGF-1) is a mitogenic growth factor that induces the partial 
dedifferentiation of epithelial cells.(233)(234) IGF-1 is expressed by M2 cells, that are polarized 
from monocytes by Th2 cells through the expression of IL-4/13.(305)(306)(307)(308) If DSS treatment 
leads to polarizing M2 cells that express IGF-1, then epithelial cells are being induced into a 
partially dedifferentiated state that will contribute to the disrupted crypt architecture. If a stem 
cell with a somatic mutation in beta-catenin, which either prevents beta-catenin phosphorylation 
or inactivates the phosphodegradation complex, is generating progeny then those cells would be 
vulnerable to enhanced beta-catenin activity while they are in the dedifferentiated state. 
Therefore, the DSS treatment is effectively creating a window of opportunity for enhanced beta-
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catenin activity, which then potentiates carcinogenesis in epithelial cells with mutated beta-
catenin regulation.   
This window of beta-catenin dysregulation can be opened by rapidly resolving the pro-
inflammatory response, leading to M2 cells polarized form monocytes through anti-
inflammatory signaling. Anti-inflammatory and wound repair induced dysregulation of epithelial 
cell turnover will also prolong the window of beta-catenin dysregulation. An increased rate of 
stem cell division will provide more cells with mutated beta-catenin, while epithelial cells will be 
able to resist normal apoptotic induction in attempting to reconstitute the wounded epithelium 
and maintain a partially dedifferentiated state for a significant length of time.(11)(12) As DSS 
treatments can lead to a disrupted crypt morphology that persists for several weeks, the cells with 
the mutated beta-catenin could experience a significant length of time with beta-catenin having 
enhanced activity. This duration in a dedifferentiated state must be long enough to cause further 
changes in a few of these cells to progress into cancer cells. 
Treatment with AOM had to generate somatic beta-catenin mutations, as a single 
treatment with DSS did not lead to any detected G6PD mutations, but the mice that only received 
an AOM treatment did not develop cancer. So despite the likelihood of crypts with dominate 
stem cells harboring a somatic mutation in beta-catenin, these cell populations did not experience 
an additional level of beta-catenin dysregulation that potentiated cancer development without the 
DSS treatment. Whether a stem cell divides symmetrically or asymmetrically, both cell copies 
would rapidly assume there designated position in the normal crypt niche architecture. The 
newly divided cell would only transiently have a motile morphology, and once it relocates within 
the niche, would assume a normal columnar axial morphology with an identifiable apical-basal 
axis. The cells would then express the appropriate level of E-cadherin cell-cell junctions and 
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normalize the free intracellular beta-catenin levels. Regulating beta-catenin levels through E-
cadherin cell-cell junction complexes must be sufficient to prevent enhanced beta-catenin 
transcriptional activity in cells with a beta-catenin mutation that inhibits phosphodegradation. 
Also, nearly all stem cell divisions are asymmetrical so cells will progress to lineage 
differentiation and turnover before the mutated beta-catenin will have time to produce a 
deleterious carcinogenic effect.  
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5.0  CONCLUSIONS AND SIGNIFICANCE 
The work presented here generated several important basic scientific findings. While it will 
require more studies and time to gauge the overall impact of our results, they still provide several 
important observations. These observations challenge some long standing ideas and could force a 
reexamination of established dogma related to chemical carcinogenesis and the role of 
inflammation. 
1) The work herein indicates that a fully competent immune system enhances the survival 
and continued cell division of DNA alkylation damaged colonic stem cells. While α/β T-
cell deficient mice exhibited a reduction in the survival DNA alkylation damaged colonic 
stem cells. This result is significant in several ways. For the first time this result suggests 
that immune cells and the immune response, at least partially mediated by α/β T-cells, 
protects or enhances the survival of colonic stem cells with DNA alkylation damage. The 
increase in stem cell mutations in wild type vs. TCR null mice represents an entirely new 
functional capacity for immune cells that had previously not been elucidated. As α/β T-
cells already are components of a myriad of immune cell mediated functions it may not 
be surprising to see these cells implicated in a new capacity. The enhanced damaged stem 
cell survival may be an effect of the activity of multiple immune cells, and not solely a 
α/β T-cell mediated response. The significance to carcinogenesis may be even more 
profound, as it seems that involvement of the immune system in responding to 
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cytotoxicity resulting from DNA alkylation damage leads to the development of an 
expanded pre-cancer cell population. It would be interesting to know if the enhance 
survival of DNA alkylated stem cells is restricted to colonic stem cells or if any DNA 
alkylated cell would be protected from cell death.  
2) Our work demonstrated that DSS does not yield somatic stem cell mutations in either 
wild type of TCR null mice. This is a critical observation as inflammatory agents, such as 
DSS, have been associated with the generation of RONS and it is widely assumed that 
RONS leads to oxidative DNA lesions that cause an increase in the mutation rate. This is 
clearly incorrect in mice with a normal DNA repair capacity. This result forces the 
question of the actual function of the inflammatory agent, which is required for 
tumorigenesis. 
3) The DSS treatment following the AOM treatment actually reduced the number of somatic 
stem cell mutations in both the WT and α/β T-cell deficient mice. However, the cancer 
incidence, multiplicity and progression, was not significantly different between two 
strains of mice at the higher 2% DSS but lower dose of AOM, although the M.F. was 
significantly higher in the WT mice. The significance of this result confirms that the 
generation of somatic stem cell mutations does not correlate with colon cancer 
development. The generation of mutations in critical target cells appears to not be the 
rate-limiting step in cancer development. 
4) We calculated for the first time the in vivo conversion efficiency of an O6mG lesion into 
a somatic stem cell mutation based on the observed G6PD M.F. and the level of O6mG 
lesions in the colon. The value of 0.3% from the analysis demonstrates that measuring 
adduct levels does not necessarily correlate with mutations. Only a fraction of adducts are 
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converted in mutations, due to DNA repair, cell death, correct coding during 
polymerization. 
5) In this work, we demonstrated that α/β T-cell deficient mice had reduced colon cancer in 
comparison to WT mice after treatment with AOM+DSS at lower DSS concentrations. 
However, this insensitivity was lost when the concentration in DSS was increased. An 
increased concentration of DSS would cause the development of a more severe 
inflammation. The significance of this result is that the deficient α/β T-cell signaling in 
the TCRβ-/- mice could have been compensated for when the mice were exposed to a 
more severe inflammatory event. This finding could mean that α/β T-cell mediated 
signaling can potentiate colon cancer development.  
 
This work generated several significant questions. In Chapter 3, a potential role for α/β T-
cells supporting colon cancer development by polarizing M2 macrophages is discussed and 
this could be an important future research aim. In Chapter 4, a possible mechanism by which 
DSS, in a dose dependent manner may dysregulate cytoplasmic and nuclear beta-catenin 
levels by disrupting E-cadherin cell-cell junctions was introduced. This would release AOM 
mutated beta-catenin from the cell junction into the cytoplasm. This could be a very 
significant basic research question to pursue as it would explain why the concentration of 
DSS correlates better with carcinogenicity than the dose of AOM.    
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6.0    EXPERIMENTAL DESIGN 
6.1 ANIMAL HUSBANDRY 
The animals used in the work are both wild type (WT) and immunocompromised mice. All B6 
strains (WT, athymic, TCR β-/-, TCR δ-/-, TCR β-/-δ-/-) were housed in the University of 
Pittsburgh vivarium. The mice were housed ≤ 4 mice per cage, in plastic cages with filter covers 
that were specially designed to hold immunocompromised animals. A HEPA-Filtered Laminar 
Air Flow system provided air to the cages. This system prevents the introduction of potential 
pathogens to the cages by filtering 99.97% of air-borne pathogens 0.3 µm and larger.(366) All of 
the mice received irradiated chow and autoclaved water in autoclaveable water bottles designed 
to fit the cages. 
All animal injections were carried out in a clean room under a Class II Type A biological 
safety cabinet that was thoroughly sterilized before use. All water bottles containing DSS 
solution were prepared in the aforementioned animal facility’s clean room. Food and water 
consumption were not monitored during these studies. 
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6.2 AZOXYMETHANE DOSING 
 AOM was administered to the mice via intraperitoneal injection (i.p.).(45) AOM was acquired 
from Sigma-Aldrich (Sigma-Aldrich, St. Louis MO). AOM is a neat liquid with a density of 
0.991 g/ml in its native form. The AOM used in the initial experiments was a practical grade, (≥ 
90% by GC). The AOM used for the mutagenesis/carcinogenesis study was ≥ 98% pure. As 
previously reported, the practical grade AOM was discontinued, which is why the experiments 
were conducted with the higher purity material.  
A single stock solution of AOM (10 mg/kg or 15 mg/kg b.w.) was prepared in phosphate 
buffered saline (PBS) (Thermo Fisher Scientific Inc., Waltham MA) to ensure that all of the 
mice received the same AOM. The PBS was purchased sterilized by filtration through a 0.2 
Micron Filter. The PBS (pH 7.4) is comprised of 11.9 mM phosphate, 137 mM sodium chloride 
and 2.7 mM potassium chloride. As the PBS was at an initial 10X concentration, it was diluted 
using ultrapure water to a 1X concentration for the final AOM stock solution. The final amount 
of AOM and volume of PBS for each stock solution was determined by the number of mice 
receiving an AOM treatment in the experiment. One tuberculin syringe (26 gauge) (Thermo 
Fisher Scientific Inc., Waltham MA) was prepared for each mouse receiving an AOM dose. 
An example calculation for an experimental trial where 40 mice were dosed with AOM at 
10 mg/kg b.w. is as follows: 
 
 
 
Since the mice weight between 20-30 g at 6-8 weeks of age, with a few outliers above and below 
this range, the calculation is converted to mg/g b.w. 
10 mg AOM 
kg b.w. 
0.010 mg AOM 
g b.w. = 
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 A 200 µl volume of PBS was used per injection, which was adjusted for mice weighting 
less than 30 g. So a 30 g mouse would receive 0.30 mg AOM dose in 200 µl of PBS via i.p 
injection. The AOM stock solution is stable overnight at 4 oC in the dark. For trials with large 
numbers of mice, all of the syringes were prepare in advance and the mice were dosed the 
following day.  
6.3 DEXTRAN SULFATE SODIUM DOSING 
IUCAC requirements stated that mice needed to be provided with excess drinking water during 
an animal treatment involving a reagent administered ab libitum. It was determined that a 300 ml 
volume of DSS solution per cage would last for more than 7 days. As each mouse was expected 
to drink 6 to 7 ml of water per day and there were a maximum of 4 mice per cage. The daily 
consumption of DSS solution was not monitored since the individual consumption per mouse 
could not be determine. 
DSS (36-50 kDa) (MP grade colitis grade, white powder, MPBiomedicals LLC, Santa 
Ana CA) is a water soluble powder that goes into solution with moderate shaking and no heating 
at the concentrations used in these studies. The DSS solution was prepared in a biosafety hood 
where DSS powder was added to autoclaved water bottles. The bottles were resealed before 
being removed from the hood. Once in the animal facility, the DSS solutions were transferred 
into sterilized water bottles for the cages from the original containers.  
0.30 mg AOM 
30 g b.w. 
0.010 mg AOM 
g b.w. 
x 30 g b.w. 
30 g b.w. 
= 
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6.4 TISSUE HISTOLOGY 
6.4.1 Tissue Collection 
 All mice were euthanized by CO2 asphyxiation followed by cervical dislocation. The final 
weight of the animal was then recorded. Dissections were performed in the 
immunocompromised procedure rooms of the University of Pittsburgh animal facility. 
Dissections were carried out in the aforementioned sterilized biosafety hoods. The abdominal 
cavity was washed gently with sterile PBS to remove bedding dust, urine, and to prevent hairs 
from entering into the body cavity. The animal’s body was pinned with 18 G needles to a 
styrofoam cutting board and the abdominal cavity opened from just above the anus to the base of 
the sternum. The skin, body fat, and peritoneum were carefully removed from the open cavity. 
The seminal vesicle, urinary bladder, prostate, and perputial gland were excised. The small 
intestine that comprises most of the organ mass in lower body cavity, along with the liver, was 
moved out of the body cavity but not excised. The lower intestine was excised beginning just 
below the cecum. The point of excision is arbitrary as each animal’s lower intestine varied based 
on both the size and weight of the animal, and also on the treatment that the animal received 
(untreated, AOM, DSS and AOM+DSS). The lower intestine was excised down to the rectum. If 
the animal’s rectum had prolapsed, this tissue was recovered separately. The colons were then 
placed full length on a cutting board and carefully sliced along one side using the blade of a 
micro-dissection scissor. Feces were then removed and the colons quickly washed in clean sterile 
PBS. Tears in the tissue were infrequent and if they did occur were only in one location. The 
presence of the rectum allowed for proper tissue orientation to be retained if a tear did occur. The 
colon lengths were measured at this time. Other organs harvested were the liver and spleen. All 
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of the livers and spleens collected were weighted and immediately placed into 4% formalin and 
stored at 4 oC. 
6.4.2 Paraffin Embedding 
The excised lower intestines were placed in 4% formalin and stored at 4 oC overnight. The 
paraffin embedding of the colons was performed following a standard protocol with 
modifications.(367) The colon sections were Swiss-rolled after the 70% ethanol step of the 
protocol. The Swiss-roll was created by fully extending the flat colon and placing the end of the 
colon that was excised from the cecum on a matchstick or the thick edge of a pipet tip. The colon 
is then rolled over itself until all of the tissue is coiled around the stick ending at the rectum. It is 
common practice that the lumenal side of the colon face outward in the rolled shape. An example 
of an H+E stained section of mouse colon in the Swiss-roll shape in shown in Figure 15. 
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 Figure 15.       Mouse Colon Swiss-Roll 
(adopted from reference 43) 
 
 
 
 
 
 
 
 167 
 Formalin Fixation and Paraffin Embedding Protocol: 
 
1. 4% Formalin at stored at 4 oC overnight. 
2. 50% Ethanol for 3-4 hours at RT. 
3. 50% Ethanol for 3-4 hours at RT. 
4. 70% Ethanol at 4 oC overnight. 
5. Tissues are Swiss-rolled. 
6. 85% Ethanol ½ hour at RT. 
7. 90% Ethanol ½ hour at RT. 
8. 100% Ethanol for 1 hour at RT. 
9. 100% Ethanol for 1 hour at RT. 
10. Xylene for 1-2 hours at RT. 
11. Xylene for 1-2 hours at RT. 
12. Paraffin for 1-2 hours at 60 oC. 
13. Paraffin for 1-2 hours at 60 oC. 
14. Paraffin for overnight at 60 oC. 
15. Paraffin for 2-4 hours at 60 oC. 
 
The paraffin incubations are necessary to remove the xylene from the tissue. The paraffin blocks 
are then prepared by filling a tissue mold with melted paraffin (65 oC), immersing the Swiss-
rolled colon in the melted paraffin, and then waiting until the block solidifies completely as it 
cools at room temperature.   
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6.4.2.1 Hematoxylin and Eosin 
 Sections from each tissue were cut at 5 µm using a standard microtome. Sections for 
each colon were H+E stained using a standard protocol.(368) H+E staining was performed by the 
UPMC Pathology Department. Pathology findings were reported by Dr. Shi-Fan Kuan 
(Department of Pathology).  
6.4.3 Freezing Tissues for Sectioning 
After measuring their length, the excised colons were opened longitudinally to remove feces then 
immediately washed in clean sterile PBS, Swiss-rolled, and placed in a tissue mold. The colons 
were then completely immersed in OCT medium (Tissue-Tek® Optimal Cutting Temperature 
Compound, Ted Pella, Inc., Redding, CA). The mold was then placed in a bench-Dewar 
containing a small volume of liquid N2. The mold is held so that its plastic base was just in 
contact with the liquid N2 until the OCT medium had frozen completely solid. The frozen tissue 
block was then stored at -80 oC until tissue sections were generated. No fixative was used during 
this process, as that would inactivate the G6PD enzyme.  
6.4.3.1 Cutting frozen sections  
H+E analysis requires only one section of tissue from the Swiss-rolled colons, normally 
taken from the center of the tissue block. To determine the number of G6PD mutant crypts in a 
colon, multiple regions of the tissue need to be assessed. Frozen tissue sections were cut at a 
thickness of 7 µm using a fixed-blade cryostat at -25 oC. Two consecutive sections were placed 
on each slide. Two slides, or four consecutive sections, were cut to represent one level. The next 
region (level) was sectioned at a minimum distance of 50 µm from the last section of the 
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previous level. This distance ensured that the crypts assessed for each level did not duplicate one 
another. 
Generating optimal frozen sections using the cryostat requires controlling the room 
temperature and humidity using a dehumidifier. The cryostat chamber, where the tissue and 
blade sit, is extremely humid and the blade was frequently wiped with 100% ethanol to remove 
the OCT medium residue that accumulates during cutting. Before sectioning was resumed, the 
dry blade was also wiped with a normal dryer sheet to dissipate any accumulated static charge. 
This was performed to prevent sections from curling or floating off of the blade before they 
could be adhered to a slide. All of the slides with the frozen sections were stored at -80 oC.  
6.4.3.2 Hematoxylin and Eosin 
Each slide with a frozen section was fixed in 4% formalin for 3 hours before being H+E 
stained. Sections from each colon were H+E stained using a standard protocol(368) in the UPMC 
Pathology Department. Pathology findings were reported by Dr. Shi-Fan Kuan. 
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6.5 ENZYME HISTOCHEMISRTY 
6.5.1 Tissue Staining Reaction Mixture 
6.5.1.1  OCT Medium as the Alternative Enzyme Stabilizer 
The reaction mixture is a formulation modified from protocols described by Williams et 
al.,(205) and Van Noorden et. al.(369) The polyvinyl alcohol (PVA) used for in the original 
protocols was replaced by OCT medium. Some enzymes, such as G6PD, can diffuse out of the 
cells on an unfixed tissue section if the sections are placed in an aqueous solution. The PVA acts 
a stabilizer for these enzymes in the tissue sections to be analyzed.(370) The stabilizer in the 
reaction media does allow for the diffusion of small molecules, such as the reagents necessary 
for the G6PD enzymatic reaction. 
There were several reasons that the OCT medium was used to replace the PVA as the 
stabilizer in the reaction mixture. The PVA is acidic and quite viscous at the solution percentages 
(18% and greater) necessary to facilitate the enzyme histochemistry reaction while preventing the 
diffusion of the G6PD enzyme. Attempting to adjust the solution pH caused a decrease in the 
viscosity of the PVA solution and resulted in the diffusion of the G6PD enzyme into the reaction 
mix. Solubilizing PVA is difficult as it requires heating at very high temperatures for a long 
period of time. Even solubilizing the PVA in a pH adjusted phosphate buffer did not result to a 
consistently reproducible reaction mixture at the correct pH and viscosity. Also, ascertaining the 
pH of the PVA solution was impossible due to the viscosity of the reaction mixture. The high 
viscosity of the PVA solution prevented the reagents from distributing evenly, as the mixture 
could not be effectively shaken to homogenicity. These problems lead to poor and inconsistent 
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overall tissue staining in which different areas of the tissue sections stained with variable 
efficacy. 
The OCT medium, which is comprised of approximately 10% PVA, offered a solution to 
all of the aforementioned problems. The OCT medium could be pH adjusted with a minimal 
volume of aqueous phosphate buffer while retaining the necessary solution viscosity. The pH 
could be accurately determined with a least one type of pH paper (Hydrion Microfine Paper, 
Brooklyn NY). With only vigorous hand shaking, the mixture would become homogeneous. At 
pH 7.2-7.4 the OCT reaction mixture has a characteristic crystal clear deep red color after all of 
the reagents are in solution. 
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6.5.1.2 G6PD enzymatic reaction 
 G6PD  
G6P + NADP 
  
PG + NADPH + H+ 
 
NADPH + H+ 
  
NADP + (1-m-5-mPMS)·2H+ 
  
(1-m-5-mPMS)·2H+ + NBT 
  
(1-m-5-mPMS) + Formazan 
 
Figure 16.          G6PD Enzymatic Reaction 
          (adopted from reference 371) 
 
 
 
 
 
 
 
 
 
Detecting the presence or absence of G6PD activity is actually the result of cells 
acquiring, or staining, insoluble Formazan which has a dark blue color. G6P is oxidized into PG 
by G6PD releasing 2e- (electrons) which is an irreversible modification of the enzyme substrate. 
One hydrogen (H·) will transfer to NADP forming NADPH. As enzyme cofactors are only 
reversibly modified, the NADPH can be oxidized to NADP and facilitate the oxidation of 
Figure 16. G6PD oxidizes G6P and reduces NBT to insoluble Formazan 
The G6PD enzyme substrate is Glucose-6 phosphate (G6P). G6P is oxidized 
into phosphogluconate (PG). β-Nicotinamide adenine dinucleotide phosphate 
(NADP) is the cofactor. Magnesium chloride (MgCl) is utilized in the enzyme 
binding pocket when occupied by G6P. 1-methoxy-5-methylphenazinium 
methyl sulfate (1-m-5mPMS) acts as a transient electron carrier. Nitro Blue 
Tetrazolium (NBT) is reduced into Formazan. 
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another G6P molecule. 1-m-5mPMS transiently acquires 2 H· molecules and transfers them to 
NBT, reducing the NBT into the insoluble Formazan. As 1-m-5mPMS is also transiently 
modified, one molecule of 1-m-5mPMS can reduce many NBT molecules. Formazan is insoluble 
and diffuses out of solution, localizing where it is reduced, so the presence of the blue color in a 
cell indicates the G6PD enzyme is active.    
6.5.1.3  pH Adjustment of the OCT Medium 
The largest alteration from other previously reported G6PD staining protocols was 
replacing the PVA solution with the OCT medium. The OCT medium is approximately pH 6. 
However, the G6PD enzymatic reaction occurs optimally at pH 7.2-7.4 or the physiological pH.  
The pH of the OCT medium can be adjusted by adding an aqueous buffered solution, e.g., 
phosphate buffer (PB). A 200 mM concentration of PB (pH 7.4) allowed for the adjustment of 
the OCT medium pH while only minimally increasing the volume of solution. 2 ml of 200 mM 
PB was used to adjust 35 ml of OCT to pH 7.2-7.4. This additional volume did not reduce the 
viscosity of the OCT medium significantly and adversely impact the G6PD enzymatic reaction. 
6.5.1.4 Assembling the Reaction Mix 
The final volume of the reaction mixture was set at 40 ml. The mixture was prepared 
fresh for use on each day.(369) 35 ml of OCT medium was placed into a standard 50 ml centrifuge 
tube and 2 ml of 200 mM PB (pH 7.4) was added to the tube and shaken vigorously. This affords 
a characteristic effervescent mixture. To avoid diluting the viscosity of the OCT medium, the 
reaction reagents were solubilized in the minimum necessary volume of PB before they were 
added.  
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The final concentration of each reagent, following the method by Williams et al.,(205) was 
5 mM G6P (Sigma-Aldridge, St Louis MO); 2 mM NADP (AppliChem Inc., St. Louis MO), 5 
mM MgCl2 (Sigma-Aldridge, St Louis MO), 0.35 mM 1-m-5mPMS (Sigma-Aldridge, St Louis 
MO) and 0.8 mM NBT (Life Technologies, Grand Island NY), respectively. 1-m-5mPMS 
replaced the 5-methylphenazinium methyl sulfate used in the original method as the electron 
transfer mediator due to its superior stability and activity.(372)  
For each reagent the initial concentration was derived for a 40 ml final volume. Using the 
dilution equation (C)c(V)c=(C)d(V)d to determined the initial concentration for each reagent: 
 
G6P: (200 mM G6P)(1 ml)=(5 mM)(40 ml) 
Dissolve 60.8 mg G6P into (0.94 ml 200 mM PB) in a 2 ml microcentrifuge tube. 
NADP: (80 mM NADP)(1 ml)=(2 mM)(40 ml) 
Dissolve 61.2 mg NADP into (0.94 ml 200 mM PB) in a 2 ml microcentrifuge tube. 
MgCl2: (200 mM MgCl2)(1 ml)=(5 mM)(40 ml) 
Dissolve 40.66 mg MgCl2 into (0.96 ml 100 mM PB) in a 2ml microcentrifuge tube. 
1-m-5mPMS: (56 mM 1-m-5mPMS)(0.25 ml)=(0.35 mM)(40 ml) 
Dissolve 4.71 mg 1-methoxy-5-methylphenazinium into (0.25 ml 200 mM PB) in a 1 ml 
microcentrifuge tube. 
 
Once each reagent was fully dissolved into solution, the solution was then added to the pH 
adjusted OCT medium. The resulting reaction mixture was then shaken vigorously to form a 
deep crystal red homogenate. The pH was then checked at this step (pH 7.4) as a final 
confirmation the reaction mix was assembled correctly.  
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The solution should be highly effervescent and not appear cloudy. If the solution is 
cloudy, the pH is off and the mixture had to be discarded. The OCT medium is normally the 
source of this problem and that lot of OCT must be discarded and new OCT used. Since each 
reagent was solubilized in PB (pH 7.4), it further insulated the OCT medium from pH changes. 
This buffering is critical since both G6P and NADP are acidic in solution and, therefore, would 
lower the pH below 7.4. The tube containing the reaction mixture was wrapped in foil to 
minimize exposure to light. One of the purposes of using 1-m-5mPMS is to eliminate the light 
sensitivity of the reaction mixture.(372)  
 The reaction mixture was then stored at room temperature while the final component, 
NBT, was solubilized. NBT is highly insoluble and requires boiling in a solution mixture of N,N-
dimethylformamide (DMF) (N,N-Dimethylformamide Molecular Biology Reagent, Sigma-
Aldridge, St Louis MO) and 100% ethanol to solubilize the NBT:(369) 
 
NBT: (250 mM NBT)(0.8 ml) = (5 mM)(40 ml) 
0.4 ml DMF and 0.4 ml 100% EtOH were added to 163.53 mg NBT in a 2 ml microcentrifuge 
tube with an O-ring lid. The lid was loosely closed (not tightly sealed) and the solution brought 
to a vigorous boil in an oil bath until the NBT was in solution. This must be done in a room with 
low humidity. The DMF and 100% EtOH (1:1) volume was determined by Van Noorden et 
al.(369) to be 2% of the final reaction mixture’s volume.  
 
Once the NBT is solubilized and removed from the oil bath, it was allowed to cool to room 
temperature and then added to the OCT reaction mixture and shaken vigorously. This changes 
the reaction mixture to an orange-red colored solution. Unlike the other reagents, the NBT would 
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transiently fall out of solution when added to the reaction mixture but with continued shaking 
would quickly go back into solution. At this point, the reaction mixture was placed in a 37 oC 
warm room for 1 h.  
6.5.1.5   Staining Slides for G6PD Activity 
The enzyme histochemistry reaction was carried out in a 37 oC warm room to ensure that 
the temperature of all of the components was the same. The warm room also had high humidity 
that facilitated the reaction. Attempting the enzymatic reaction in an incubation oven or on a 
slide warmer led to poor and inconsistent staining efficacy. 
Tissue staining for G6PD activity was performed by building wells using two 1.5 cm x 
0.15 cm steel washers (interior diameter x height) that were sealed together using silicone grease. 
Parafilm was then cut to fit the base of the well with the center cut out and the well placed over 
the tissue section on the slide. The parafilm on the bottom of the washer created a seal between 
the slide and the washer that maintained the media on the tissue section by preventing diffusion. 
This construct gave a well with a 0.4-0.5 ml volume so that each tissue section in the study 
would receive approximately the same volume of the G6PD reaction mixture. 
The frozen slides were incubated at 37 oC in a warm room for 10 min to equilibrate the 
slide temperature. The OCT reaction mixture, at 37 oC, was then added to each tissue section (2 
sections per slide) for 45-50 min. After the incubation period the slides were removed from the 
warm room, the wells were carefully lifted off of the slides, and the slides were set on there long 
edge to allow the reaction medium to drain. The slides were then placed in 100 mM PB (pH 7.4) 
for 30-60 min to remove the OCT mixture from the tissue without disturbing the tissue staining. 
The slides were placed in distilled water for 5-10 min to remove PB salts and then sealed with 
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fluro-gel (Fluoro-gel with TRIS buffer Cat. # 17985-11, Electron Microscopy Sciences, Hatfield 
PA). 
6.5.2 G6PD Activity Analysis 
6.5.2.1  Assessing G6PD Mutant Crypts and Total Counts 
Slides were analyzed for mutant crypts under a Leitz Orthoplan-Pol light microscope. To 
assess the number of G6PD mutant crypts in the colons of the animals it was necessary to 
observe different regions of the colon. Generating tissue sections and levels was previously 
described in section 5.4.3.1. The reason that consecutive sections were generated was two-fold. 
First, it was to prevent losing data due to inadequate tissue sectioning or staining. It is impossible 
to evaluate the quality of each section at the time the sections are being cut. Tissue areas are 
vulnerable to folds, tears, or simply adhere poorly to the slide. Sections of the tissue that are cut 
closely together will duplicate the same crypts. Therefore, assessing consecutive sections 
improves the chances of properly evaluating a colon region.  
Second, G6PD mutant crypts will appear on consecutively cut sections. This presents an 
internal control for the proper identification of a G6PD mutant crypt. Certain crypts or clusters of 
crypts may also stain poorly and can produce false G6PD mutant crypts. A true G6PD mutant 
crypt can be correctly identified by appearing on two consecutive sections in the same location. 
The verification of a G6PD mutated crypt required two independent observers to identify the 
same crypt. Each G6PD mutant crypt was then imaged at 40x magnification and catalogued 
using a Mitocam 2500 5.0M Pixel camera (Motic, Hong Kong) and Motic Images Plus 2.0 
software.  
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To calculate the total number of observed crypts, one level was selected as representative 
of all of the levels assessed in that animal. As the tissue surface area varied between levels, a 
section from the level with the least amount of surface area was selected for total crypt 
quantification. The total surface area of this section was then imaged at 10x magnification and 
catalogued. The image files were then individually opened in ImageJ (NIH Free Software) and 
using the Cell Counter feature each crypt was flagged. The software recorded the total number of 
flags (crypts) per image. The final number of crypts for each image was then recorded.  
6.5.3 Total Counts and Mutation Frequency 
After all of the image files (>15 images per section) were analyzed, the total number of crypts in 
the level was determined by adding the final numbers from each image. This number was then 
multiplied by the number of levels assessed for each mouse. For example, a total count of 1,250 
crypts per level multiplied by 8 levels assessed would give a total count of 10,000 crypts 
assessed. A minimum of 10,000 crypts were assessed from each colon. 
 To determine the M.F. for each animal, the number of G6PD mutant crypts was divided 
by the total number of crypts counted. For example; 5 G6PD mutant crypts divided by 12,386 
total crypts would give a M.F. of 4.04x10-4. Once the M.F. was calculated for each animal, an 
average M.F. could be determined for each treatment group. 
 
 
 179 
6.6 STATISTICAL ANALYSIS 
6.6.1 Student’s T-test 
The unpaired t-test compares the means of two unmatched groups, comparing the effect of a 
treatment and a strain, assuming that the values follow a Gaussian distribution. The normality 
test was utilized to show that the values of the data sets followed a Gaussian distribution. The F-
test determined the equality of variances between the data sets being compared. The unpaired t-
test and normality test were conducted with Prism 4 (GraphPad Software, Inc., La Jolla, CA) and 
the F-test for Two Data Sets was conducted with XLSTAT (Addinsoft, New York NY).  
 
6.6.2 Fisher’s Exact Test 
The Fisher’s Exact Test is a contingency table test used to derive an exact p-value for assessing 
the difference between two categorical data sets.(356) Categorical data sets represent data sets that 
have no intrinsic values assigned to them.(355) The Fisher’s Exact Test is best utilized for small 
sample sizes.(357) The Fisher’s Exact Test was conducted using  GraphPad QuickCals Analyze a 
2x2 contingency table online: http://graphpad.com/quickcalcs/contingency1/ 
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APPENDIX A 
LIST OF ABBREVIATIONS 
ACS = American Cancer Society  MMR = Mismatched DNA repair  
ADH = Aldehyde Dehydrogenase M.F. = Mutation Frequency  
AOM = Azoxymethane   NO· = Nitric Oxide 
APC = Adenomatous Polyposis Coli  O6mG = O6-methylguanine 
B6 = C57Bl/6     OCT medium = Optimal Cutting Temperature 
BER = Base Excision Repair   PVA = Polyvinyl Alcohol 
CRC = Colorectal cancer   RONS = Reactive Oxygen and Nitrogen Species 
DSS = Dextran Sulfate Sodium 
FAP = Familial Adenomatous Polyposis 
G6PD = Glucose-6 Phosphate Dehydrogenase 
H2O2 = Hydrogen Peroxide  
IBD = Inflammatory bowel disease 
IEL = Intraepithelial lymphocytes 
MAM = methylazoxymethanol 
MGMT = O6-methylguanine-DNA methyltransferase  
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